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Abstract
ETIOLOGICAL CONTRIBUTIONS OF GENETIC AND ENVIROMENTAL FACTORS TO
NONMEDICAL USE OF PRESCRITPION DRUGS AMONG YOUNG ADULTS
By Cassie Overstreet, MS
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctorate of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2019.
Major Director: Ananda Amstadter, Ph.D.
Affiliate Associate Professor of Psychology
Associate Professor of Psychiatry & Human and Molecular Genetics
Key variables such as trauma exposure (TE) and internalizing symptoms (e.g., posttraumatic stress
disorder [PTSD]) have been shown to correlate with non-medical use of prescription drugs
(NMUPD); however, the temporal associations between these phenotypes remain poorly
understood. Moreover, there is a paucity of research that incorporates the influence of genetic
factors in the etiology of NMUPD. Although it has been demonstrated that drug use disorders are
moderately heritable, research aimed at identifying the specific genes conferring risk is virtually
non-existent for NMUPD. Therefore, determining the contribution of genetic and environmental
factors associated with risk is critical to understanding NMUPD. To this end, the aims of the
present study included a) examination of the prevalence and longitudinal relationships between
TE, probable-PTSD, and NMUPD (experimental lifetime use [E] and repeated use of 6 or more
occasions [R]) via crosslag autoregressive models; and b) identification of genetic variation
associated with NMUPD and PTSD via genome wide analyses (i.e., genome wide complex trait
analysis [GCTA], and genome wide association analysis [GWAS]) within a sample consisting of
7,579 college students (61.1% female; Mage at baseline=18.53, SD=.65). Follow-up analyses were
additionally conducted focused on interpersonal violence.

The findings from the present study lends support to the extant literature suggesting that the high
risk model (i.e., substance use precedes TE/PTSD) plays an important role in the longitudinal
associations between NMUPD (-E, -R) and TE/probable-PTSD (prior NMUPD associated with
heightened risk of TE/probable-PTSD at later time points). The h2SNP estimate derived from the
meta-analysis of GCTA results for NMUPD-E was .15 (SE = .01) and for NMUPD-R was .22 (SE
= .01). The h2SNP estimate for TE was .02 (SE = .01). Due to concerns regarding power, GWAS
were conducted only with NMUPD-E, probable-PTSD, and IPV phenotypes. Genetic variants
associated with NMUPD-E (rs73241778, rs138647543, rs142738451, rs74901044, and
rs9578774) and suggestive variants associated with probable-PTSD (rs10024355) were identified
following GWAS analyses. Overall, although the model suggesting that TE/PTSD precedes
substance use and the role of genetic factors received limited support within the present study, it
is critical to note that each of these pathways is likely important yet partially dependent on a
multitude of other factors including developmental period and class of NMUPD substance being
examined. Moreover, continued efforts within better powered samples are warranted to better
understand the contribution of genetic factors.

Etiological Contributions of Genetic and Environmental Factors to Nonmedical Use of
Prescription Drugs among Young Adults
Introduction
Young adulthood is a critical period associated with high risk of trauma exposure (TE),
posttraumatic stress disorder (PTSD), and substance use behaviors, including aberrant use of
prescription drugs (i.e., non-medical use of prescription drugs [NMUPD]). The following section
begins with an overview of the prevalence of NMUPD and negative correlates associated with use.
Next, concerns regarding definitional variability and delineating NMUPD from other forms of
substance use are reviewed. Following, demographic (sex, ethnicity/race, age) and environmental
factors (i.e., TE) are discussed prior to describing models of comorbidity between TE, PTSD, and
NMUPD and the extant longitudinal literature regarding these phenotypes. Genetic factors
associated with NMUPD, TE, and PTSD are then reviewed within the domains of behavioral (i.e.,
family and twin studies) and molecular genetic studies (i.e., candidate gene studies and genome
wide association studies [GWAS]). Moreover, more novel molecular approaches with be discussed
(i.e., genome-wide complex trait analysis [GCTA]) prior to review of the aims of the present study.
Non Medical Use of Prescriptions Drugs (NMUPD)
NMUPD is defined by the National Survey on Drug Use and Health (NSDUH) as using a
prescription drug “even once, that was not prescribed to you, or that you took only for the
experience or the feeling it caused” (Substance Abuse and Mental Health Services Administration
[SAMHSA], 2013) and is an umbrella term frequently applied to the most commonly misused
categories of prescription medications: stimulants, sedatives, and opioids (Volkow, 2005). In 2015,
18.9 million individuals (7.1%) reported NMUPD within the past year (SAMHSA, 2016).
Prevalence of NMUPD has been rising since the 1990’s and NMUPD is the second most common
illicit substance of misuse after marijuana (SAMHSA; 2010). Rates of such misuse have been
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shown to vary significantly by prescription medication type with rates of past year opioid misuse
being the highest (4.7%) followed by stimulants (2%) and sedatives (.6%; SAMHSA, 2016).
Misuse also differs by developmental period assessed with young adults (18 to 25 years of age)
being more likely to report past year misuse (15.3%) relative to youths (12 to 17 years of age;
5.9%) and adults (26 years of age or older; 5.8%; SAMHSA, 2016).
Aberrant prescription drug use has been associated with a number of negative
psychological and physical outcomes (e.g., depression, anxiety [Cai, Crane, Poneleit, & Paulozzi,
2010], emergency room visits [Warner, Chen, & Makuc, 2009], and overdose deaths, [Becker,
Sullivan, Tetrault, Desai, & Fiellin, 2008]). A four-fold increase in opioid misuse was noted
between 1998 and 2008 among treatment admissions (2.2% to 9.8%; Mental Health Services
Administration, 2008). Moreover, in 2008, opioid overdose surpassed automobile accidents as the
leading cause of accidental death with the majority of overdoses being associated with prescription
opioid misuse (18,893 prescription opioid related deaths compared to 10,574 heroin related deaths;
Center for Disease Control and Prevention, 2015). Given growing use and potential negative
correlates, NMUPD has been cited as a growing public health concern and significant economic
burden with approximately $50 billion in estimated economic loss associated with health care,
legal, and workplace costs (Birnbaum et al., 2011; for review: Oderda, Lake, Rüdell, Roland, &
Masters, 2015).
NMUPD definitional and assessment variability. As NUMPD has received increased
attention, researchers have noted a number of methodological concerns within the burgeoning
literature (Boyd & McCabe, 2008). NMUPD is a blanket term, and there is significant
heterogeneity in how individual research studies operationalize it. The variability in how
investigators define NMUPD, as well as differences in assessment of NMUPD are of significant
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concern. The formal definition provided by SAMHSA in the 2013 NSDUH stated the any use
within an individual’s lifetime could be considered NMUPD (SAMHSA, 2013). Not only does the
focus on lifetime misuse with the SAMHSA definition complicate our understanding of temporal
relationships between NMUPD and other variables, but “any use” may not capture problematic
use worthy of clinical attention. For instance, as identified with other substances, a pattern of
experimental use may not be as relevant to the aforementioned negative correlates as a pattern of
repeated substance use (Young et al., 2002). On the opposite end of the misuse continuum, DSMIV-TR criteria for abuse and dependence are thought to more accurately identify those with
problematic use (American Psychiatric Association [APA], 2000). Although DSM-IV-TR may
better capture clinically significant misuse, the use of strict diagnostic criteria as a means of
determining NMUPD may not aid in identification of individuals exhibiting problematic but
subthreshold use. Much less empirical attention has been placed on misuse existing between these
two extremes. However, the DSM-5 has embraced this consideration of continuous symptoms with
the transition to drug use disorders and classifications of mild, moderate, and severe substance use
(APA, 2013) but few studies have yet to implement these criteria in the assessment of NMUPD.
Given the potential for variability in correlates associated with this continuum of use, additional
examination of both experimental and repeated aberrant use of prescription medications is
necessary.
In addition to concerns raised regarding “any use”, the portion of the definition referencing
use for “the feeling it may cause” was considered problematic given that some individuals may
indeed be using the medication for its intended purpose (e.g., pain relief; Huang et al., 2006). Thus,
such use may not be necessarily problematic. Given the definitional concerns surrounding
NMUPD, SAMHSA (2016) has attempted to refine the definition by shifting from “non-medical
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use” to “misuse.” Moreover, the definition has shifted to defining “misuse” as using a prescription
medication “any way that a doctor did not direct you to use them, including (1) use without a
prescription of the respondent's own; (2) use in greater amounts, more often, or longer than the
respondent was told to take them; or (3) use in any other way a doctor did not direct the respondent
to use them.” However, it remains unclear whether this alteration in definition is associated with
more refined assessment or has potentially created more complexities with regard to identifying
individuals that may be using for intended purpose (e.g., pain relief) albeit without a doctor’s
guidance (e.g., may be using for intended purpose [pain relief]; however, if they do not have a
medical background it may be less likely that they would be able to correctly gauge appropriate
medication/dose for the pain experienced). Given that the extant literature frequently utilizes the
term “non-medical use of prescription drugs” which also encompasses use of a medication for the
feeling it may cause, discussion of this form of substance use will be referred to as NMUPD
throughout the present manuscript.
Many of the aforementioned concerns regarding the operationalization of NMUPD within
the literature has been reviewed in detail by Barrett and colleagues (2008). Although SAMHSA
has undergone attempts to refine the definition, differing views on what constitutes NMUPD
remain and this lack of consistency within the literature creates challenges in interpretation across
studies. As this literature continues to rapidly evolve, continued efforts to view findings within
the context of these differing definitions will be necessary.
Delineating NMUPD from other forms of substance use. Despite rising concerns
regarding NMUPD and the consequences associated with use, a paucity of research exits
examining NMUPD independently relative to other substances (e.g., alcohol).

NMUPD is

frequently binned with other forms of illicit drug use although some evidence suggests that
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examinations of these substances independently is critical. Given the binning, it remains unclear
as to whether specific substances are driving the associations with risk correlates and outcomes.
Limited attempts have been made at delineating NMUPD from other forms of substance misuse
(particularly other forms of illicit drug use); however, the extant literature suggests that different
risk correlates and outcomes may be affiliated with NMUPD specifically (Bohnert et al., 2012).
However, given the binning, it remains unclear as to whether specific substances are driving the
associations with risk correlates and outcomes. For example, depression and anxiety symptoms
were shown to be more strongly associated with overdose via medication relative to other
substances (alcohol and illicit drugs; Bohnert et al., 2012). Moreover, Ford & Arrastia (2008)
demonstrated differential associations between sex, race, marital status, sexual activity, marijuana
use, and social bonding based on form of substance use (NMUPD versus other forms of illicit
substance use). The authors suggest that given these differences, NMUPD may be a unique form
of substance use; however, they strongly encourage additional research regarding differential
associations based on substance type (Ford & Arrastia, 2008).
Reasons for engaging in NMUPD rather than other substance types may be associated with
differing means of access and misperceptions regarding safety. Prescription drugs are frequently
considered “soft” drugs in comparison to “hard” drugs like heroin (Quintero, Peterson, & Young,
2006). In viewing prescription medications as “soft” drugs, the consequences associated with use
are frequently minimized. Moreover, prescription medications may be viewed as safer than other
illicit drugs and easier to obtain from friends and relatives (Friedman, 2006). Arria and colleagues
(2008) noted that low perceived risk was significantly associated with misuse when controlling for
demographic characteristics and sensation-seeking.
Aggressive marketing by pharmaceutical companies has also been linked with heightened
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misuse, particularly opioids (Van Zee, 2009; Maxwell, 2011). The increased exposure may also
contribute to the evolving misperceptions of safety and social acceptability of NMUPD (Quintero
et al., 2006). This marks a complex issue, given the benefits of direct to consumer marketing (e.g.,
greater awareness of potential medication options; Ventola, 2011). Thus, attempting to achieve a
balance whereby increased access to information is available while the potential influence on
misuse is minimized marks a critical area in need of additional attention.
In sum, although NMUPD falls broadly under the category of substance misuse, the risk
correlates of misuse (i.e., motivations, misperceptions regarding safety, perceived social
acceptability) may differ substantially from those identified for other substances. Given these
putative constellation of differences, it is critical to consider etiological factors and correlates that
may be unique to NMUPD. The extant literature on other substance use phenotypes is quite
developed, and in comparison, the etiologic literature on NMUPD is in its infancy. Thus, the
independent examination of NMUPD will only serve to further refine the field’s understanding of
this particular category of misuse and provide greater opportunities to create targeted prevention
and intervention programs that may prove more effective than more broadband approaches to
reduce substance use.
Demographic correlates of NMUPD. Due to the heightened concern regarding NMUPD,
recent focus has been placed on identifying putative risk and protective factors.

On the

demographic level, previous research has identified sex, race/ethnicity, and age as key variables
associated with variability in NMUPD. For example, men are more likely to report NMUPD
overall (i.e., clustered across drug classes) relative to women (McCabe et al., 2006; Johnston,
O’Malley, Bachman, & Schulenberg, 2005).

However, differential associations have been

identified among men and women when the broad NMUPD classification of misuse is parsed into
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independent categories (i.e., opioids, stimulants, sedatives) with women reporting greater
nonmedical use of opioids relative to men (SAMHSA, 2011). However, more recent research
suggests that prevalence of misuse is greater among men for each category with the exception of
sedatives (SAMHSA, 2016).

NMUPD patterns have also been examined for racial/ethnic

differences. Overall, the highest rates of use were among non-Hispanic individuals reporting two
or more races (11.7%; SAMHSA, 2016). Similar rates were identified among non-Hispanic White,
American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, and Hispanic
individuals (SAMHSA, 2016). The lowest prevalence rates were identified among non-Hispanic
Blacks or African Americans and Asians (SAMHSA, 2016).
NMUPD among college students.

In addition to the aforementioned demographic

variables, age has been linked with NMUPD variability. Prescription misuse is particularly
prevalent among young adults with approximately 4.4% of individuals within the 18-25 age group
reporting current NMUPD (i.e., past 30 days; SAMHSA, 2014) in comparison with the 12-17 age
group and 25+ age group which endorse 2.6% and 2.1% current use, respectively. Moreover, a
growing literature suggests that college aged students may be a particularly vulnerable population
for NMUPD (McCabe, West, & Wechsler, 2007; Tapscott, B. E., & Schepis, 2013). NMUPD is
more prevalent among young adults relative to other age groups and is particularly prevalent
among college students (SAMHSA, 2016). Additional research also suggests that stimulants use
is the most common form of NMUPD among college students (less expensive and more readily
available on campuses), followed by benzodiazepines and opioids (Parks et al., 2015). For
example, previous research suggests that college students relative to their non-collegiate peers
report greater Ritalin misuse (Johnston et al., 2005).
Several potential factors may contribute to the elevated risk of substance misuse present
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within this time period including heightened stress associated with the period of transition,
increased access, and lower levels of parental monitoring (Gfroerer, Greenblatt, & Wright, 1997).
Additionally, college students have been found to overestimate the prevalence of NMUPD among
peers (McCabe, 2008) which may influence perceived norms and potentially increase misuse
behavior (McCabe, West, & Wechsler, 2007). Moreover, permissive views on use among students
and overestimation of peer misuse have been linked with increased risk of misuse (Perkins, 2012).
Thus, college students may be a particularly at-risk group relative to non-collegiate same age peers,
making them a fitting group for further study.
Environmental Factors (i.e., Trauma Exposure) Associated with NMUPD
In identifying demographic variables associated with heightened risk, the ability to
implement intervention efforts may be improved. In addition to demographic factors, a growing
literature suggests that TE and PTSD may confer increased risk of aberrant prescription drug use
(Walsh et al., 2014; Ham et al., 2016) thereby potentially representing an important modifiable
risk factor. If individuals with histories of TE/PTSD are at heightened risk for NMUPD, targeted
interventions aimed at TE/PTSD may reduce the risk of NMUPD.
TE is a common occurrence with approximately 70% of individuals being exposed to at
least one traumatic event within their lifetimes (Benjet et al., 2016). Although TE is prevalent,
trajectories of symptoms experienced post trauma are frequently characterized by resilience
(Bonanno et al., 2012). However, an estimated 6.1% of Americans meet lifetime diagnostic criteria
for DSM-5 PTSD which pertains to a constellation of symptoms (i.e., intrusion, avoidance,
negative alterations in cognitions and mood, alterations in arousal and reactivity) that may occur
post trauma (APA, 2013) and 4.7% meet past year criteria (Goldstein et al., 2016) although
estimates can vary greatly depending on sample characteristics and method of assessment (Breslau,
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2001). TE is particularly relevant among young adults (16 to 20 years of age; Breslau et al., 1998).
This age group is additionally at heightened risk of experiencing exposure to interpersonal violence
(IPV; e.g., physical assault, sexual assault; Breslau et al., 1998). This has become a growing focus
of concern across college campuses with such violence being identified as particularly prevalent
(Azimi & Diagle, 2017).
Correlates of TE and PTSD. Previous research has identified several demographic
variables which may influence the association between TE and PTSD. Although men report
greater exposure to any traumatic event, the prevalence of IPV is higher among women (Tolin &
Foa, 2006; Cromer, & Smyth, 2010). Women additionally have higher rates of PTSD relative to
men (Breslau, 2001). In regard to other demographic variables of race/ethnicity, previous research
suggests that the lifetime prevalence of PTSD was highest among African Americans relative to
other racial groups (Roberts et al., 2001; Breslau, Davis, & Andreski, 1995). However, rates of
TE varied by event with African Americans being exposed to trauma more interpersonal in nature
(e.g., child maltreatment, witnessing domestic abuse; Roberts et al., 2001). Other studies have
identified mixed results regarding prevalence of TE by race/ethnicity (Breslau et al., 1991; Hanson
et al., 1993; Kilpatrick et al., 1997). Age has also been identified as a critical variable to be
considered when examining the associated between TE and PTSD. Specifically, college represents
a time in which the likelihood of TE is at its peak (i.e., college students represent the age range at
highest risk for trauma exposure [Breslau, et al., 1998]).
Aspects of the trauma itself, including trauma type, have also shown differential
associations with PTSD. Specifically, IPV has been associated with increased post exposure
psychopathology relative to trauma considered more accidental or non-assaultive (e.g., natural
disasters, transportation accidents; Breslau et al., 1991). Moreover, IPV has been frequently
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associated with problematic substance use (Ouimette, Kimerling, Shaw, & Moos, 2000; Back et
al., 2001; Hedtke et al., 2008). Few studies have thoroughly examined the NMUPD risk affiliated
with TE type, but the extant research indicates that witnessing violence and sexual assault are
significantly related to past year NMUPD (McCauley et al., 2010, 2011). Given these findings,
the potential influence of trauma type when examining the associations between TE/PTSD and
NMUPD is a critical consideration.
Associations between PTSD and NMUPD.

Although extensive literature exists

regarding the relationship between PTSD and other forms of substance use (Hawkins, Catalano,
& Miller, 1992; Newcomb & Felix-Ortiz, 1992), examination of the associations between PTSD
and NMUPD remains in a relatively nascent stage. However, within the extant literature a
significant association between PTSD and NMUPD is typically found (Cochran et al., 2015;
McCauley et al, 2009; Rhoades & Wenzel, 2013; Saha et al., 2016; White et al., 2009; Smith et
al., 2016; Bohnert et al., 2012; Liebschutz et al., 2010; McCauley et al., 2010; Mackesy-Amiti et
al., 2015) although not consistently (Kennedy et al., 2015; Wilsey et al., 2008; Hall et al., 2016;
Berenson & Rahman, 2011; Becker et al., 2008). Several factors may contribute to the lack of
significant findings between PTSD and NMUPD.

Kennedy and colleagues, 2015 did not

demonstrate a significant association between PTSD and stimulant misuse. The authors did not
provide detailed information regarding PTSD assessment and created a dichotomous “mental
health” variable, although a large proportion included participants diagnosed with PTSD. Thus,
poor reporting regarding PTSD measurement and the binning of several mental health disorders
into a single dichotomous variable make it difficult to discern the association between PTSD
specifically and NMUPD. Wilsey et al., 2008 examined the relationship between PTSD and opioid
misuse within a chronic pain sample but did not control for pain in the final model. Moreover,
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state anxiety was included in the final model which may have accounted for the variance in
NMUPD associated with PTSD (e.g. potential multicollinearity issues). Hall et al., 2016 also
focused on a very specific population, examining a traumatized sample of women on probation or
parole which limits generalizability. Moreover, although a fairly comprehensive list of covariates
(i.e., pain, substance use, mental health disorders) were included, trauma load/type was not
controlled for. The other two studies that did not demonstrate associations between PTSD and
NMUPD included several important covariates, however, had limitations in regard to assessment
of each variable (Berenson & Rahman, 2011; Becker et al., 2008 adapting items from the NSDUH
survey and DSM-IV-TR, respectively). Lack of standardized assessment may have influenced the
findings.
Although biases were present in each of the studies that did not suggest a significant
association, it is critical to note that many of these same limitations and additional problematic
sources of bias are also present in the studies that did identify an association. For example,
McCauley and colleagues (2010) did not correct for multiple testing, thus, although a significant
finding was identified, it would unlikely remain significant upon application of corrections. Thus,
it is difficult to determine the true relationship between PTSD and NMUPD and to quantify
whether the biases within the five studies were more or less problematic than those identified
within the other studies. However, the pervasiveness of these conceptual and methodological
issues warrant considerable attention.
NMUPD and TE/PTSD models of comorbidity. Although associations have been noted
between TE, PTSD, and NMUPD, the causal relationship among these phenotypes is unknown.
However, multiple models of comorbidity have been hypothesized including the self-medication
model (i.e., TE/PTSD precedes NMUPD which is used as a method of coping with PTSD
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symptoms), substance use increasing risk of TE and thus PTSD (i.e., individuals misusing
prescription medications may engage in behaviors putting them at heightened risk for trauma [e.g.,
transportation accident] and post trauma symptoms), and shared risk liability to both disorders
(i.e., a third factor [e.g., genetic factors] contributes to comorbidity).
The self-medication hypothesis is frequently used to describe the mechanism potentially
underlying the association between post-trauma distress and substance use broadly which has been
conceptualized under negative reinforcement models of comorbidity (Keane & Kaloupek, 1997).
This hypothesis posits that the psychoactive effects of substances aid in alleviating distress
following trauma, at least for a short period of time (Miranda, Meyerson, Long, Marx, & Simpson,
2002). The numbing effect or altered state created by substances thereby serves as a negative
reinforcer (i.e., removes psychological distress) and acts as an effective short term strategy for
reducing distress. However, although reinforcing in the short term, it does not allow the individual
to recognize that they are indeed capable of experiencing and tolerating distress without the use of
substances and can contribute to the development of substance abuse/dependence.

The

relationship between PTSD and misuse as a means of self-medication has been noted among
several forms of substance use (Ouimette et al., 2010; Hawkins et al., 1992; Newcomb et al., 1992).
Although the association between PTSD and substance use is often explained by the selfmedication hypothesis, alternative models regarding the relationship between traumatic stress and
substance use also exist. It has been hypothesized that substance use may increase risk of trauma
exposure and PTSD (e.g., lowered inhibitions could increase participation in risky behaviors
and/or unsafe situations; Cottler, Compton, Mager, Spitznagel, & Janca, 1992). The high-risk
hypothesis suggests that misuse of substances may be related to a broader cluster of other high risk
behaviors which could heighten risk for TE and thus, indirectly, PTSD (Chilsoat & Breslau, 1998).
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Although this model is less frequently referenced within the literature, there is some research that
suggests that substance use increases IPV risk and IPV in turn confers heightened risk of substance
use thereby creating a “vicious cycle” (Kilpatrick et al., 1997)
Additionally, a shared etiological factor (e.g., genetic influences) may increase
vulnerability to both PTSD and substance use (Sartor, McCutcheon, Pommer, Nelson, & Grant,
2011). Multiple genetically informed studies suggest that substance use and PTSD are influenced
by common genetic contributions (Xian et al., 2000; Sartor et al., 2011; Wolf et al., 2010).
However, the shared liability hypothesis has not received as much empirical attention as the selfmedication hypothesis and the lack of temporal assessment within the NMUPD and PTSD
literature further diminishes the field’s understanding of how each of these variables may influence
one another.
Longitudinal examination of NMUPD, TE, and PTSD. The research examining the
relationship between TE and NMUPD has been predominately cross-sectional in nature thereby
reducing the ability to determine causal influences. Although a longitudinal study design was not
utilized, Sturza & Campbell (2005) noted that a large proportion of rape victims reporting misuse
stated they were using the medication “to deal with” their rape experience. Given the theorized
perceived safety and social acceptability of NMUPD, individuals may be at increased risk of
NMUPD as a means of coping with PTSD. Another pathway by which these TE/PTSD may
increase risk of NMUPD includes access to prescription medications following a potentially
traumatic experiences. Fortuna and colleagues (2010) noted increasing trends in prescribing of
opioids for non-injury and injury related visits since 1994. In instances of pain management
following an injury, an individual may be prescribed an opioid. The opioid may serve dual
purposes in that the patient could use the medication for both pain management and perhaps to aid
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in PTSD symptom reduction post injury. This may also be further complicated by psuedoaddcition.
Psuedoaddiction refers to the misuse of medications for treatment of underlying undiagnosed
physical pain rather than emotional distress associated with traumatic experiences (Passik, Kirsh,
& Webster, 2011). This is a complex concern, particularly among veterans. Many returning
veterans report pain symptoms and are also at heightened risk of PTSD given the risk of trauma
exposure while deployed. Therefore, an important balance must be achieved whereby the pain is
being treated adequately while also considering the potential impact of PTSD on risk of misuse.
The confluence of these aforementioned factors may contribute to heightened risk of
NMUPD rather than other forms of substance misuse when experiencing PTSD. Although it is
assumed that NMUPD is used to cope with TE/PTSD (Miranda et al., 2002), it remains merely an
assumption given the scarcity of data to validate this claim. The relationship between TE/PTSD
and NMUPD is likely bidirectional in nature; however, the relative risk associated with TE/PTSD
and NMUPD across time has not been investigated. Thus, there is a need for large-scale
longitudinal studies to examine the relationships between TE/PTSD and NMUPD at a phenotypic
level. Elucidating the causal association among these variables is critical given the clinical
implications. If TE/PTSD influences NMUPD it could prove to be a beneficial assessment point.
Moreover, TE/PTSD prevention efforts could effectively reduce NMUPD. However, this may be
a misguided effort if the reverse is the case and NMUPD increases risk of TE/PTSD.
Genetic Factors Associated with NMUPD
Although environmental factors (i.e., TE) are thought to confer risk for NMUPD,
understanding of the etiology of NMUPD would be incomplete without consideration of genetic
factors. Thus, a model that would most appropriately capture the associations among these
variables would integrate both environmental factors and the underlying genetic risk that may
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impact each phenotype. Previous research within the PTSD and alcohol use disorder literature
suggests a ~55% overlap in the genes contributing to each disorder (Sartor et al., 2011; Xian et al.,
2000). Shared genetic effects have also been identified between PTSD and other forms of
substance use including nicotine dependence (63%; Koenen et al., 2005) and drug use disorders
(i.e., meeting DSM-III-R criteria for marijuana, sedatives, stimulants, heroin/opioids,
PCP/psychedelics; Xian et al., 2000). These findings lend support for a shared liability model of
comorbidity characterized by a third factor (e.g., genetics) that may explain the aforementioned
documented associations between PTSD and NMUPD.
Behavioral genetics studies.
Family and twin studies of NMUPD. Several methods exist to examine the potential
genetic influences associated with TE/PTSD and NMUPD. Early behavioral genetics studies
consisted of family studies and derivatives (i.e., adoption studies; Plomin et al., 2013). Family
studies determine the inter-generational transmission of traits by examining familial aggregation
(i.e., a higher rate of the trait among family members when compared to the general population;
Gelenter & Kranzler, 2010). Family studies regarding the transmission of substance use have
shown that it runs in families (Merikangas et al., 1998). Previous literature has examined illicit
substance use more broadly (Agrawal & Lynskey, 2008); however, family studies of NMUPD
independently have not been conducted.
Family studies provide an opportunity to determine if a particular trait runs in families,
usually by demonstrating that there is a higher incidence of the trait the closer in relation
individuals are to the proband (i.e., affective individual). However, determining the genetic
influences alone can become difficult, especially as multiple factors could be contributing to the
trait in question (i.e., genetic influences, shared environment). Thus, twin studies have emerged
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as a method to determine heritability or the proportion of phenotypic variance that can be attributed
to genetic factors. Twin models provide an opportunity to partition the variance of the trait
according to: additive genetic factors (A), common environment (C), and unique environment (E).
Additive genetic effects (A) refer to the “sum of the average effects of the individual alleles
(variant form of a gene)” (Neale & Maes, 2004). Common environment (C) refers to the shared
environment that is assumed to be the same for all family members (e.g., happens to both twins
such as socioeconomic status; Jang, 2005). Unique or non-shared environment (E) refers to unique
experiences that one twin may experience while the other may not (e.g., trauma exposure) (Jang,
2005).

Measurement error in twin models is also captured under the umbrella of unique

environmental component. The ability to partition the variance and covariance between twins into
A, C, and E rests on the fact that monozygotic twins share 100% of their genes while dizygotic
twins share on average 50%. Thus, if intra pair correlations among MZ twins are more than twice
the size of DZ intra correlations, additive genetic effects play a role in the trait of interest. It is
critical to note that estimates of heritability derived from twin studies are to be viewed on a
population level rather than an individual level (i.e., would not be appropriate to claim that 60%
of a particular trait within an individual is attributable to genetic factors as heritability is referring
to differences among individuals and averages). By estimating heritability, previous twin models
have highlighted the relative influence of genetics and laid a foundation for specific investigation
of genes exerting a potential influence. Thus, as Afifi et al. (2010) stated, twin studies serve as a
guide for future molecular genetics research.
Similar to family studies, relatively few twin studies have treated NMUPD as an
independent phenotype. Rather, previous studies have clustered NMUPD with other forms of illicit
drug use and/or not made the explicit distinction as to whether these substances were used against
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a doctor’s order (Agrawal et al., 2005; Lynskey et al., 2012). However, one twin study that did
examine NMUPD independently identified a modest heritability estimate for stimulants (23%) and
much smaller estimates for sedatives (6%) and opioids (3%); however, the authors report that this
is likely due to low sample (499 MZ pairs and 327 DZ pairs; Karkowski et al., 2000). Another
twin study examining a common genetic factor associated with various types of substance use
suggests that a common genetic pathway may be shared across several forms of use, including
NMUPD, rather than substance specific (Kendler et al., 2003).
Twin studies have been more extensively used in the examination of other forms of
substance use and have identified moderate to strong heritability estimates for alcohol use
disorders (Verhulst et al., 2015), licit substance use (e.g., nicotine dependence, Vink et al., 2005),
and illicit substance use (e.g., cocaine, opioid dependence, Gelertner et al., 2010). Rates of
heritability vary greatly depending on sample assessed, form of illicit substance use being
examined, and severity of use. McGue and colleagues (2000) identified a heritability estimate of
25% among a sample of adolescent twin pairs for illicit substance use (e.g., marijuana,
amphetamines). Moreover, just as some evidence suggests that common genetic influences may
be associated with various forms of substance misuse (Young et al., 2006; Kendler et al., 2006;
Palmer et al., 2015), shared genetic factors may also influence other forms of psychopathology.
Xian and colleagues (2000) findings suggest that genetic influences associated with alcohol and
substance use account for approximately 40% of the variance identified in PTSD, highlighting the
genetic overlap across disorders. However, additional examination is warranted specifically with
regard to NMUPD.
Family and twin Studies of TE and PTSD. Family studies regarding TE and PTSD have
additionally demonstrated that PTSD runs in families with biological relatives of individuals with
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PTSD having high rates of PTSD, relative to other trauma exposed individuals (Yehuda et al.,
2001; Nugent et al., 2008).

Moreover, despite views of TE as an entirely environmental

phenomenon, twin studies examining the heritability of trauma exposure have identified a
moderate genetic influences (Sartor et al., 2012). For example, genetic effects have been found to
account for 35-47% of the variance in exposure to combat related trauma (Lyons et al., 2003).
Moreover, exposure to TE (i.e., assaultive) has been linked to certain individual (e.g., history of
depression) and familial (e.g., maternal depression) level factors (Koenen et al., 2002). However,
the literature regarding the influence of genetic factors associated with non-assaultive forms of TE
is mixed. The majority of twin studies have not identified a genetic contribution to non-assaultive
forms of TE (e.g., natural disaster; Afifi et al., 2010) while one study noted a genetic impact on
“low risk traumas” which could be attributable to methodological differences (e.g., inclusion of
both twins and siblings rather than twins alone, Sartor et al., 2012). Gene by environment
correlation (rGE), which refers to the influence of genes on environment (e.g., genotype influences
selection and interaction with one’s environment), has also been identified as a factor contributing
TE. Specifically, personality may influence selection of environments that may be associated with
heightened risk of TE exposure (Nadar, 2016).
Genetic influence additionally appears to influence PTSD development following TE.
Approximately 24-72% of the variance in PTSD has been accounted for by genetic factors (for
review see Afifi et al., 2010; Lyons et al., 1993; Sartor et al., 2012; Stein et al., 2002). Moreover,
the moderate heritability of PTSD symptoms has been identified among both male and female
samples (Sartor et al., 2012). Given the genetic contribution to TE in addition to PTSD and that
TE is a necessary, but not sufficient, component contributing to risk to PTSD, it is necessary to
account for this when attempting to determine the heritably of the PTSD. Even while controlling
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for the genetic influences associated with TE, the literature examining the heritability of PTSD has
continued to find moderate estimates of heritability (True et al., 1993).
Twin studies have determined that the genetics effects associated with PTSD symptoms
overlap with several forms of substance use including alcohol consumption (McLeod et al., 2001),
alcohol dependence, cannabis dependence, and tobacco dependence (Koenen et al., 2003). The
genetic liability to PTSD post-TE appears to be shared with the liability for substance use
disorders. Stated another way, some of the covariation between these disorders appear to be
attributable to the same underlying genetic liability (Sherrer et al., 2008).
Molecular genetics studies. Given the identified heritability of these phenotypes, growing
effort has been placed into identifying specific genetic variants associated with risk. Although
twin studies provide an opportunity to determine the degree of heritability associated with specific
traits, advances within the past thirty years have allowed us to investigate the contribution of
genetic variants, mostly commonly in the form of specific single nucleotide polymorphisms
(SNPs), to complex traits (McCarthy et al., 2008). Molecular studies examine how specific
variants in the genome are associated with risk for various phenotypes.

Although such

examination began with linkage studies, which were useful in the identification of areas of specific
chromosomes that may be associated with the phenotype of interest; Lander & Schork, 2004),
growing emphasis has been placed in determining if certain polymorphisms are associated with
cases vs. controls (i.e., those that have the disorder [PTSD] vs. those that do not) or degree of
association based on a quantitative trait. Candidate gene studies, which test theorized genes of
influence in an association with a specific variable of interest, have demonstrated inconsistent
results within the literature (Tabor, Risch, & Myers, 2002). Thus, growing emphasis has been
placed in utilizing more agnostic approaches to examining the molecular genetic influences
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including genome wide association studies (GWAS; Wilkening, Chen, Bermejo, & Canzian,
2009). Moreover, growing emphasis has been placed on the polygenetic contribution to complex
phenotypes such as mental health disorders (Hirshorn & Daly, 2005). Candidate gene studies do
not take into account the small contribution of many genes to the trait of interest. Moreover, given
our limited knowledge regarding the relationship between specific genes and certain traits, it may
be overly ambitious to narrow in on a single trait before associations within the genome have been
established (Nussbaum et al., 2007). Additional disadvantages of candidate gene studies include
lack of adjustment for population stratification (i.e., differences in allele frequencies based on
ancestry), less coverage relative to genome-wide studies, and frequent use of smaller sample sizes
which results in less power to detect effects and increases the likelihood of false positives if an
effect is found (Zhu & Zhao, 2007; Hirshhorm & Daly, 2005). Thus, testing for genome wide
associations without a priori assumptions is a more powerful method of identifying variants
associated with a specific trait. This is not to say that use of candidate gene studies are not fruitful
(particularly given the the potential utility in validating GWAS findings via candidate gene
studies); however, following evidence of association present in GWAS and an understanding
regarding biological pathways contributing to risk may better position researchers in examining
genes of significance (Amos et al., 2010).
Given the interest in identifying genes associated with specific traits with a more unbiased
approach, GWAS have become more frequently used. GWAS determine if certain SNPs occur
more frequently based on case status or severity of the trait in question (Risch & Marikangas,
1996). These analyses are completed by taking into account linkage disequilibrium (LD), which
refers broadly to the non-random association of alleles at different loci, within a given population
(Reich et al., 2001). After generations of assortative mating, linkage equilibrium will occur
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whereby each allele is independent. However, those linked together are considered to be in LD.
Some groups have lower LD such as African ancestral groups because there have had more
opportunities for recombination over the passage of time. Other groups such as Europeans and
Asians have higher LD because of factors including founder effects. The concept of LD is
important given that most chips use “tag” SNPs that are in high LD with other SNPs, thus thereby
allowing for the examination of neighboring alleles (Need & Goldstein, 2006). LD is also
important to consider, since molecular studies can be confounded by population stratification,
which occurs when there is a systematic difference in allele frequencies between subpopulations
within a population (Price et al., 2010). An additional benefit includes the capability to examine
the overlap between two constructs whereby certain SNPs may be relevant in both phenotypes
(e.g., TE and NMUPD).
GWAS test the “common disease, common variant” hypothesis which suggests that
common diseases are attributable to common variation occurring within at least 1-5% of the
population (Wessel, 2013). But to date, there is a discrepancy between the amount of variance
that SNPs identified as associated with a certain traits account for via GWAS and those suggested
by twin studies although this gap is closing as samples sizes increase (Gratten et al., 2012). This
discrepancy likely reflects the multifactorial contribution of many SNPs to complex traits and
given the small contribution across many variants, large sample sizes are necessary to have enough
power to detect an effect (Psychiatric GWAS Consortium Coordinating Committee, 2009). The
discrepancy regarding heritability estimates identified in twin studies and the amount of variance
in a trait accounted for by additive contribution of SNPs identified via GWAS could also be due
to other factors including: rare variants (those occurring in <1% of the population), epistasis (gene
by gene interaction), and gene-by-environment interactions (Korte & Farlow, 2013). The progress
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of GWAS in accounting for more of the variance as suggested by twin studies and the growing
interest in other methods which may address some of the shortcomings associated with behavioral
genetic methods and GWAS demonstrate further promise.
Molecular studies of NMUPD. To date, no molecular studies exist explicitly examined
NMUPD. Hundreds of candidate gene studies have been conducted with regard to substance use
disorders both licit and illicit (please see reviews: Dick & Foround, 2003; Agrawal & Lynskey,
2009; Bousman et al., 2009). Broadly, findings have consistently identified associations between
genes associated with alcohol metabolism (ADH and ALDH; Dick & Agrawal, 2008) and alcohol
use. Moreover, dopamine receptor genes (DRD2, DRD3, DRD4) have demonstrated associations
with both licit and illicit substance (Du et al., 2011). Additionally, several candidate genes have
been linked with variation in opioid use variation. The most consistently identified genes include
DRD2, OPRM1, OPRD1, and BDNF which are thought to play a role in encoding receptors and
signaling molecules (for review please see Mistry et al., 2014). Although several candidate genes
of interest have shown associations with substance use phenotypes, no candidate gene studies to
date have examined NMUPD specifically.
Similar to the paucity of candidate gene studies, no GWAS of NMUPD has been
conducted; however, there have been GWAS of other forms of illicit substance use. GWAS for
opioid dependence have identified multiple loci of potential influence including a genome-wide
significant SNPs in NCK2 (rs2377339; protein associated with growth factor receptors; Liu et al.,
2013), KCNG2 (rs62103177), and KCNC1 (rs60349741; both potassium voltage-gated channel
genes; Gelertner et al., 2014). Gelertner and colleagues (2014) additionally identified associations
between the APBB2 (rs115368721) and PARVA (rs73411566) genes and opioid dependence
symptom count. A GWAS conducted by Nelson et al. (2016) additionally noted an association
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between CNIH3 (rs10799590) in opioid dependent individuals. With regard to other illicit
substances, a recent GWAS also identified a SNP in FAM53B (rs2629540), which is potentially
associated with regulating cell proliferation, associated with cocaine dependence (Gelernter et al.,
2014). Uhl and colleagues (2008) identified two markers CDH13 and CSMD1 that almost reached
genome-wide significant for methamphetamine dependence. Despite molecular studies of licit and
illicit substances, continued molecular examination of these phenotypes is needed to identify
additional variants and replicate previous findings. Moreover, given that there has yet to be a
GWAS of NMUPD, a large gap within the literature remains present.
Molecular studies of TE and PTSD.

Over 100 candidate gene studies have been

conducted specifically targeting SNPs in over 52 different genes and their associations with PTSD
(Sheerin et al., 2017). Given the large number of candidate gene studies, meta-analyses have been
conducted and have identified multiple significant findings including DRD2 (rs1800497), SLC6A3
(three prime untranslated region variable number tandem repeat; both in the dopaminergic system;
Li et al., 2016) and the BDNF (rs6265) gene (when sample is limited to TE individuals; Bruenig
et al., 2016).
To date, ten GWAS have been conducted and multiple novel loci have reached genomewide significance. Logue and colleagues (2013), in the first PTSD GWAS, identified the retinoidrelated orphan receptor alpha (RORA [rs8042149]; involved in neuroprotection) as associated with
PTSD. Additional PTSD GWAS have also identified novel loci including a genome-wide
significant SNP on chromosome 7p12 (rs406001; associated with protein expression in the
hippocampus; Xie et al., 2013) and lincRNA AC068718.1 (rs1611133; potentially a non-coding
RNA gene with regulatory function; Guffanti et al., 2013). Xie and colleagues (2013) additionally
identified a nominally significant hit in the Tolloid-Like 1 gene (rs6812849). This particular gene
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is thought to be associated with protein expression in the hippocampus and may be influenced by
stress hormones (Xie et al., 2013). Genome-wide significant variants have also been identified at
chromosome 4p15 (rs717947), which the authors suggest may be associated with methylation
(Almli et al., 2015), and ANKRD55 (rs159572; associated with autoimmune and inflammatory
disorders) and ZNF626 (rs11085374; potentially involved in RNA transcription regulation) in two
separate samples (Stein et al., 2016). A meta analyses across four ancestral groups conducted by
Nievergelt et al., 2015 identified a novel variant in the PRTFDC1 gene (rs6482463; putative
tumor-suppressor gene), a finding which was also replicated in another independent sample.
Powers and colleagues (2016) identified a significant variant in the IL2RA gene (rs6602398; a proinflammatory cytokine associated with inflammatory response) associated with PTSD diagnosis.
However, this finding was only present among males and no genome-wide significant hits were
identified among females (Powers et al., 2016). Another study demonstrated a significant
association between a novel variant in the NLGN1 gene (rs6779753; encodes the protein
neurologin 1) and PTSD diagnostic status among a civilian population (Kilaru et al., 2016). Two
studies (Wolf et al., 2014; Ashley-Koch et al., 2015) were unable to find genome-wide significant
variants which is likely due to low sample size (<2,000 participants). Recognizing low power as
a difficulty within the field and interest in improving gene finding efforts, Duncan and colleagues
meta-analyzed data from Freeze 1 of the Psychiatric Genetics Consortium – PTSD which included
20,070 participants. No variant reached genome-wide significance with the exception of a variant
in the KLHL1 gene (rs139558732) within the African ancestral group. However, it is critical to
note that this finding is likely spurious in nature given that, when meta-analyzed with results from
another sample, genome-wide significance for that variant decreased (Duncan et al., 2018).
Recognizing limitations associated with low sample size, Freeze 2 of the Psychiatric Genetics
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Consortium – PTSD increased the sample significantly by including 206,655 participants
(Nievergelt et al., 2018). Six loci were identified as being associated with PTSD at a genomewide level, including rs34517852, rs9364611, rs148757321, rs571848662, rs115539978, and
rs142174523. The identification of these variants upon inclusion of significantly greater number
of participants (ten times the amount of previous work), highlight the importance of power in
determining the impact of influence of genetic factors in PTSD (Nievergelt et al., 2018).
Aggregate molecular genetic methods. Although family and twin studies have been
historically used as methods of partitioning sources of variance associated with genes. Growing
popularity has been placed on utilizing genome wide complex trait analysis (GCTA) which is a
SNP based method of estimating the heritability of a particular trait among unrelated individuals.
This is accomplished by creating a genetic relatedness matrix whereby correlations are created
among individuals and then regressed on the phenotype of interest (Yang et al., 2011). Similar to
other genetic methods, GCTA has limitations with regard to not accounting for rare variants and
also being sample dependent. However, there are advantages in that a smaller sample size can be
utilized relative to other genetic methods. Bivariate analyses can also be conducted to examine
the covariance between two traits, thereby, aiding in determining if the genetic influences
associated with one trait are shared with the other (Lee et al., 2012).
SNP based heritability of substance dependence/drug problems ranges from approximately
25 to 36% (Palmer et al., 2015). Moreover, the authors suggested that the SNPs across various
forms of substance use are likely common given the high correlation identified (Palmer et al.,
2015). Another study examining the SNP based heritability of cannabis use disorder identified an
estimate of 21%; however, this finding was not significant (Agrawal et al., 2014) while a
significant finding with regard to age of cannabis initiation was identified by Minica et al., 2015

25

(25% heritability estimate). GCTAs conducted by Vrieze and colleagues (2013) identified
aggregate heritability estimates ranging from 10-30% for drug use, alcohol consumption, alcohol
dependence, nicotine use, and nicotine dependence. Taken together, these findings suggest that
this novel molecular approach may provide another method of determining heritability estimates
of substance use among unrelated individuals. Limited examinations of the SNP based heritability
regarding TE and PTSD have been conducted. However, the extant literature suggests a moderate
heritability of IPV (47%; Palmer et al., 2016). Palmer and colleagues (2016) additionally noted
that the genetic effects associated with IPV was also shared with drug dependence which supports
previous research suggesting a potential common liability to both disorders. With regard to the
heritability of PTSD, a recent GCTA conducted by Stein et al., (2016) do not identify a significant
heritability estimate. However, in the recent PGC-PTSD freeze (Freeze 2), SNP-based heritability
estimates largely fell within the 10-20% range across ancestries and studies (Nievergelt et al.,
2018). Moreover, Duncan and colleagues (2017) identified a significant SNP based heritability
estimate for European-American females (29%) although a significant heritability estimate was
not identified among European-American males within the sample.
Summary of literature regarding environmental and genetic factors associated with
NMUPD. The NSDUH reports that 7.1% of individuals 12 years or older in the United States have
engaged in NMUPD within the past 12 months (SAMHSA, 2016) and college aged students may
be a population that is particularly at risk for NMUPD (McCabe et al., 2006). College also
represents a time in which the likelihood of TE an important risk factor for NMUPD (McCauley
et al., 2011), is at its peak (Breslau, et al., 1998). Further, TE confers risk for internalizing
psychopathology (e.g., PTSD) which may increase risk for NMUPD (Young et al., 2012), perhaps
via a self-medication pathway (Walsh et al., 2014). Thus, there is a need for large-scale studies of
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college students to examine the relationships between TE/PTSD and NMUPD at a phenotypic
level to help inform prevention and intervention programming (e.g., enhance our ability to deliver
targeted prevention/intervention efforts in the wake of trauma that may prevent/decrease NMUPD
and PTSD development).
Moreover, despite the demonstrated high prevalence of this problematic form of substance use,
the genetic contributions of NMUPD remain unclear. This is in contrast to phenotypes like alcohol
dependence, where numerous quantitative genetic studies and gene finding efforts have been
conducted (Treutlein et al., 2009; Yan et al., 2014). Environmental factors including TE and PTSD
may influence aberrant prescription drug use; however, limited research to date has thoroughly
examined this putative association although it is well established within the broader substance use
literature as a while (Ouimette, Read, Wade, & Tirone, 2010). Thus, there is a critical gap in the
literature needing to be filled. In contrast to the paucity of genetically informative research on
NMUPD, quantitative genetic studies have demonstrated a heritable influence on TE and
subsequent internalizing symptoms (i.e., PTSD) and substance use (Stein et al., 2002, True et al.,
1993, Lyons et al., 1993; Xian et al., 2000). In fact, previous research suggests that the genetic
contribution to risk for TE/PTSD and substance use is overlapping (Sartor et al., 2011; Xian et al.,
2000).

Although some literature suggests that TE/PTSD are associated with NMUPD on a

phenotypic level and both phenotypes are likely genetically influenced, to date, there have not
been any efforts to examine the genetic underpinnings of these conditions concurrently to
determine the degree to which they overlap or are distinct.
Aims of the Present Study
The aims of the present study were divided broadly into phenotypic and genotypic aims and
will be discussed in turn.
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Phenotypic aims. The first phenotypic aim was to determine the prevalence of TE/probablePTSD and NMUPD (experimental and repeated use, which will be referred to as NMUPD-E and
NMUPD-R, respectively, throughout the remaining manuscript) in a large representative sample
of undergraduate students (N = 7,579). The second aim was to investigate the longitudinal
relationship between TE and NMUPD (-E, -R) in an attempt to clarify specific associations across
time (e.g., does TE before college increase risk of NMUPD later in college [self-medication
model], or conversely does NMUPD before college increase risk of TE in college [high risk
model]). A supplementary aim included examining the longitudinal relationship between
probable-PTSD and NMUPD to further elucidate whether it is the distress rather than the
experience of TE that contributes to NMUPD. In accordance with existing literature regarding the
self-medication model (Leeies, Pagura, Sareen, & Bolton, 2010), it was expected that TE would
significantly prospectively predict NMUPD (-E, -R). Finally, also in line with the self-medication
hypothesis, it was hypothesized that probable-PTSD would predict NMUPD (-E, -R) over time.
Genotypic aims. The genotypic aims were three fold and included conducting genome wide
analyses, specifically GCTA and GWAS, to establish SNP-based heritability and identify genetic
variation, respectively, associated with: (a) TE, and (b) NMUPD (-E, -R). This set of analyses was
additionally conducted to estimate SNP-based heritability and identify specific genetic variation
associated with probable-PTSD. It was hypothesized that each phenotype would be modestly
heritable (lower than those identified within the twin literature for these phenotypes) and it was
also expected that some unique variants would be identified within each phenotype.
Methods
The present study included data from the first three cohorts of Spit for Science (S4S; N =
7,579). The first three cohorts were included in the present analyses given that they had been
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genotyped and were enrolled in the study across all three time points (prior to college, freshman
year, and sophomore year) at the time the present study was proposed. From 2011-2014, all
incoming freshman age 18 or older were invited to participate in a university-wide research study
on college behavioral health, which included an online survey of a variety of factors including
childhood experiences, personality, and college experiences. First year students who did not
participate in the fall were sent additional e-mail invitations in the spring, thereby providing
another opportunity to complete the baseline survey and become part of the study. Participants
who were enrolled in the fall completed follow-up surveys in each spring beginning their first year
while those enrolled in the spring completed follow-up surveys beginning spring of their
sophomore semester. The new spring survey asked participants to retrospectively report on the
items from the fall survey. The present study includes data collected during the first three time
points (i.e., survey conducted fall of freshman year [pre college], survey conducted spring of
freshman year [freshman year], and survey conducted spring of sophomore year [sophomore
year]). The pre-college survey pertained to events occurring prior to college, the freshman year
survey assessed events occurring since beginning college, and the sophomore year survey assessed
events occurring within the past 12 months (i.e., time period since freshman spring survey).
Participants received $10 and a t-shirt for their involvement. Additional detailed information
concerning recruitment can be found in Dick et al., 2014.
Invitations were sent to 11,328 individuals, with a 67% response rate. Participants were
representative of the broader university student population in terms of sex and race/ethnicity. The
university Institutional Review Board approved all study procedures; informed consent was
obtained from all study participants. Study data were collected and managed using REDCap
(Research Electronic Data Capture), hosted at the university (Harris et al., 2009). REDCap is a
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secure, web-based application designed to support data capture for research studies, providing 1)
an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and
export procedures; 3) automated export procedures for seamless data downloads to statistical
packages; and 4) procedures for importing data from external sources.
Sample Characteristics
The sample was comprised of 7,579 participants (cohort 1: n = 2,707, cohort 2: n = 2,481,
cohort 3: n = 2,391, across cohorts: 61.1% female; Mage at baseline=18.53, SD=.65). With regard to
demographic variables, self-identified race of those that responded to the item (n = 7,458) was as
follows: White (50.3%), Black (19.6%), Asian (16.3%), and Other (13.9%) which included
American Indian/Native Alaskan (.5%), Hispanic/Latino (6%), Native Hawaiian/Other Pacific
Islander (.7%), more than one race (6.3%), and unknown (.4%).
Phenotypic Assessment (Appendices I-III)
NMUPD-E. Participants were asked “Have you ever used any of the following drugs for
non-medical use? Non-medical use means on your own, without a doctor's prescription, in greater
amounts than prescribed, or for reasons other than your doctor recommended.” Participants
reported as “yes” or “no” to each substance category: opioids (heroin, opium, other), sedatives
(Ativan, Dalmane, Klonopin, Rivotril, Librium, Serax, Valium, Xanax, other), and stimulants
(ecstasy, amphetamines, crystal meth, other). A response of “yes” to any category was used as
indication of experimental NMUPD.
NMUPD-R (6+ Use[s]). An additional item was used to distinguish between experimental
and repeated use. Participants answered “yes” or “no” within each drug class (i.e., opioids,
sedatives, stimulants) to the question “Have you used 6 or more times in your life?” and a positive
response to this item was used as an indicator of repeated use.
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TE. TE was assessed via an abbreviated version of the Life Events Checklist (Blake et al.,
1995; Gray et al., 2004). Participants reported on the occurrence of five different TE events:
transportation accident, natural disaster, physical assault, sexual assault, and other unwanted or
uncomfortable sexual experience. Participants completing the survey in the fall or retrospectively
in the spring of their first year were given the response options of “yes” or “no” to items regarding
whether each stressful event occurred “before the past 12 months”, “during the past 12 months”,
or “never happened to me”. Participants completing the survey retrospectively in the spring were
given the response options of “yes” or “no” to items regarding each stressful event occurred “since
starting VCU”, “before starting college”, or “never happened to me”. Follow-up surveys conducted
in the spring of freshman year and sophomore year included a single item asking participants
whether they had experienced an TE event since college or within the past 12 months, respectively
(“yes” or “no” response options). A positive response to any TE event prior to college (“before the
past 12 months”, “during the past 12 months”) was considered a report of TE at the fall time point.
If a participant retrospectively completed the survey in the spring of their freshmen year and
reported any TE prior to college (“before starting VCU”) it was also considered a report of TE at
the fall time point. A positive response to any TE event “since starting VCU” or within the past 12
months at the freshman and sophomore time points, respectively, was considered a report of TE.
The same aforementioned method was used to create the interpersonal violence (IPV) variable,
only restricted to report of sexual assault, physical assault, and other unwanted and/or
uncomfortable sexual experience.
Probable-PTSD. If a participant reported TE at any time point they were asked to respond
to a probable-PTSD screener item. The probable-PTSD screener item was derived from the
Primary Care PTSD Screen (PC-PTSD), which has previously been used in screening of PTSD
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symptoms in primary care settings (Prins et al., 2004). The item asked whether the participant had
experienced “nightmares, attempts to avoid thoughts or reminders of the potentially traumatic
experience, hypervigilence, and feelings of detachment.” Endorsement of this item was used as
indication of a positive report of probable-PTSD. The same item was utilized at freshman and
spring follow-up time points and a positive endorsement of probable-PTSD prior to college
(“before the past 12 months”, “during the past 12 months, “since starting VCU”), and within the
past 12 months, depending on time point, was also used as an indication of a positive report of
probable-PTSD.
Genotypic Procedures
DNA was collected via an Oragene kit and isolated via standard procedures. 6,534 samples
passing DNA and initial genotyping quality control (QC) were genotyped on the Axiom BioBank
Array, Catalog Version 2 at the Rutgers University Cell and DNA Repository (RUCDR). The array
is designed to assay 653K SNPs and InDels including a) 296K common variants that serve as grid
for imputation and genome wide association studies (GWAS) and b) 357K likely functional
variants from exome studies including non-synonymous, loss of function, known disease, splice
altering, eQTL, and pharmacogenetics-related loci. Many of the ‘functional’ variants are low allele
frequency. Therefore, the array allows testing of both common and rare variants.
Given that the present study utilizes data from a large university grant funded resources, a
project specific pipeline was created to process all samples (please see Webb et al., 2017 for full
description). The present study used the established pipeline for genetic analyses. Rigorous quality
control measures (e.g., missing genotype rates, deviations from Hardy-Weinberg equilibrium
(HWE), inbreeding, cryptic relatedness), analyses of ancestry, and suggested best practices for
genetic analyses have been implemented.

Per protocol set forth by the Psychiatric Genomics
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Consortium (PGC), off target variants identified via SNPolisher, SNPs missing >5% of genotypes,
samples missing >2% of genotypes, and SNPs missing >2% of genotypes post sample filtering
were removed, thus, resulting in a pre-imputation sample of 6,325. Imputation was then conducted
using the following programs SHAPEIT2 and IMPUTE2 and the 1000 genomes reference panel
(phase 3; n = 2,504). Variants within the 1000 Genomes Project (1KGP, phase 3) found to be in
common with the filtered S4S genotypes were merged together. Following exclusion of regions
with high LD and pruning (r2 < .1) via PLINK 1.9, 109,259 variants were identified for ancestry
analyses.
Principle components analyses (PCA) was then conducted within the 1KGP phase 3
reference panel to establish SNP weights for each eigenvector and projected onto the S4S data to
create 10 principle components. Participants were assigned to 1KGP based ancestry super
populations based on Mahalanobis distance (Mahalanobis, 1936) identified between each sample
and each 1KGP population. Participants were assigned to the 1KGP population with the minimum
Malahanobis distance.

Finally, each participant was classified into their respective super

population resulting in five ancestral groups African descent (AFR), American descent (AMR),
East Asian descent (EAS), European descent (EUR), and South Asian descent (SAS). To adjust
for potential fine structure within each super population, within ancestry group PCA was
conducted. Again, EIGENSOFT and smartPCA were used to perform PCA for each super
population. Ten distinct within ancestral group PCs were generated for each super population.
Additional filtering by HWE, minor allele frequency, and relatedness was conducted within each
super population. As a result, 274 samples were also excluded, resulting in 6,239 as the final
sample for genotypic analyses.

33

Additional filtering based on ancestry specific HWE and sample size based MAFs was
conducted following each GWAS. Minimum observed minor allele count (MAC) was used instead
of a MAF threshold based on the recommendation of existing literature (Bigdeli, Neale, & Neale).
GWAS results were then meta-analyzed using METAL (Willer, Li, & Abecases, 2010), which
uses a fixed effect model and inverse variance weighting based on sample size. Genomic inflation
(λ and λ1000) was determined within each ancestral group GWAS and meta-analyses, which were
performed in R 3.5.0. False Discovery Rate (FDR) analysis was performed using the “q-value”
package (https://github/jdstorey/qvalue) using Bioconductor 3.221.
Data Analytic Plan
Phenotypic analyses. To address aim 1 of the phenotypic aims regarding the prevalence
of TE, probable-PTSD, and NMUPD (-E, -R) descriptive statistics were computed for each time
point. Additionally, given the extant literature suggesting that sex and cohort may be confounding
variables when examining substance/trauma related variables (McCabe et al., 2006, Cromer, &
Smyth, 2010) and more broadly in studies utilizing cohort design (Prentice, 1995), chi-square
analyses were conducted to examine associations between each phenotype and both sex and
cohort. To address aim 2 regarding the temporal association between TE and NMUPD, cross lag
autoregressive models were utilized to estimate the association between TE and NMUPD across
time. Autoregressive path weights account for stability within each measure across time and the
correlations among both measures were also estimated. This model provides the opportunity to
estimate the effect of TE on NMUPD-E across time and alternatively the influence of NMUPD-E
on TE across time. Two sets of models were conducted: (1) a model examining longitudinal
associations between NMUPD-E and TE, and (2) a model examining the longitudinal associations
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between NMUPD-R and TE. A detailed description of the analyses is provided below only for the
NMUPD-E model, as the same analytic framework was used for both substance use variables.
To examine the longitudinal associations between NMUPD-E and TE, first a saturated
model including all paths was established (Model 1; Figure 1) and two additional models were
compared to the saturated model to determine the best fitting longitudinal model examining
NMUPD-E and TE. The fit of each model was evaluated by the Akaike information criterion (AIC)
and change in -2 log likelihood compared to the saturated model. The two models compared to the
saturated model examined the self-medication and the high risk models (i.e., Longitudinal Effects
Models). In Model 2, cross lag paths from TE to NMUPD-E across time points (h, l, and k paths)
were constrained to zero to test the self-medication model across time (i.e., TE serves as a
significant predictor of future NMUPD-E). In Model 3, cross lag paths from NMUPD-E to TE
across time points (i, j, and m paths) were constrained to zero to test the high risk model across
time (i.e., NMUPD-E serves as a significant predictor of future TE).
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Figure 1: Saturated autoregressive cross lag model examining the longitudinal association between trauma exposure and experimental
non-medical use of prescription drugs controlling for sex and cohort.
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Note: TE = trauma exposure, NMUPD-E = experimental non-medical use of prescription drugs, Y1F = prior to college, Y1S = freshman year, Y2S = sophomore
year. Double headed arrows indicate correlation and single headed arrows indicate regression.
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In order to determine if the associations above held when considering distress experienced
(e.g., probable-PTSD) rather than exposure to a TE itself, two additional sets of models were
conducted to examine the temporal association between probable-PTSD and NMUPD (i.e., -E, R). First a saturated model was established (Model 1; Figure 1). Next, cross lag autoregressive
models were utilized to examine the influence of probable-PTSD on NMUPD (-E, -R) across time
(Model 2, self-medication model). Conversely, this model also provides the opportunity to
examine the influence of NMUPD (-E, -R) on probable-PTSD longitudinally (Model 3, high risk
model).
Thus, in total, four sets of two cross lag autoregressive models (i.e., Longitudinal Effects
Models) were conducted examining the longitudinal relations among (a) TE and NMUPD-E, (b)
TE and NMUPD-R, (c) probable-PTSD and NMUPD-E, and (d) probable-PTSD and NMUPD-R.
Genotypic analyses. Genetic analyses were conducted separately within homogenous
ancestral subgroups and then meta-analyzed to increase statistical power, which is the “best
practice” that has been implemented by the Psychiatric Genetics Consortium (PGC;
https://github.com/Nealelab/ricopili). Super population PCs (African descent [AFR], American
descent [AMR], East Asian descent [EAS], European descent [EUR], South Asian descent [SAS],
sex, and cohort were included as covariates in all genetic analyses. First, in order to establish the
heritability of NMUPD (-E, -R) and TE independently, a univariate GCTA was conducted for each
phenotype. GCTA estimates the heritability of a trait based off of the additive effect of all SNPs.
This method creates a genetic relationship matrix (GRM) based on SNPs for all individuals in the
sample. The GRM is then used to predict phenotypic relatedness in an estimate of the variance in
the trait that is due to each phenotype independently. Following, three GWAS analyses (one for
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variants associated with each phenotype. The genomic inflation factor λ was estimated and the
quantile-quantile (QQ) plots were used to determine and adjust for bulk inflation and excess false
positives. False discovery rate (FDR) were used to adjust for multiple testing in all analyses and
to determine what p-values are significant or suggestive. An additional set of exploratory analyses
(GCTA, GWAS) were conducted to establish the SNP-based heritability and to identify specific
variants associated with probable-PTSD and IPV.
Results
Phenotypic Results
Prevalence of phenotypes of interest. The prevalence of NMUPD (-E, -R), TE, and
probable-PTSD are presented in Table 1. Approximately 16% of participants reported NMUPDE prior to college and 7% reported NMUPD-R during that same time frame. Rates of NMUPD (E, -R) remained relatively stable over the three time points (Table 1). Moreover, when collapsed
across all time points, 25.2% (1890/7500) of the sample reported NMUPD-E and 12.4%
(933/7502) reported NMUPD-R. Stimulants were the most frequently reported substance used
non-medically, followed by sedatives, and then opioids. This pattern applied to both experimental
and repeated use forms of NMUPD at each time point. Across all time points and each form of
NMUPD, males had significantly higher report of use relative to females (Table 1).
TE was prevalent with 83.3% of participants reporting at least one lifetime exposure prior
to college. Freshman and sophomore year prevalence of TE were lower than prevalence identified
prior to college and prevalence of probable-PTSD ranged from 26.6% to 37.5% across the time
points (Table 1). Prevalence of TE types and probable-PTSD differed significantly by sex.
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Overall, probable-PTSD was more prevalent among females, as were multiple forms of TE
including sexual assault and any other unwanted and/or uncomfortable sexual experience.
However, physical assault was more prevalent among males. Transportation accidents and natural
disaster prevalence did not significantly differ by sex with the exception of transportation accident
during sophomore year with females reporting more accidents relative to males (Table 1). Across
all of the assessment periods, 85.5% (6405/7489) of the sample reported at least one TE, 44.6%
(3323/7452) reported IPV (sexual assault, physical assault, other unwanted and/or uncomfortable
sexual experience), and 39.1% (2476/6336) reported probable-PTSD.
Outcome variables of interest (NMUPD-E, NMUPD-R, TE, and probable-PTSD) across
each time point also consistently differed by cohort (with the exception of NMUPD-E and
NMUPD-R during sophomore year [ps = .24, .07, respectively], Table 2). Broadly, cohorts 2 and
3 reported greater NMUPD (-E, -R) with the exception of cohort 3 during sophomore year which
exhibited lower prevalence of NMUPD-R relative to cohorts 1 and 2. With regard to TE,
prevalence was highest among cohort 1 across time. However, prevalence of PTSD was highest
in cohort 3.
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Table 1. Prevalence of non-medical use of prescription drugs (experimental, repeated use,
sedatives, stimulants, and opioids), trauma exposure, and probable posttraumatic stress disorder
across time points by sex.
Prior to College (Y1F)
% (n)
X2(p)

Freshman Year (Y1S)
% (n)
X2(p)

Sophomore Year (Y2S)
% (n)
X2(p)

16.5
(947/5743)
14.4
(520/3515)
20.0
(418/2089)
5.7
(327/5713)
4.8
(174/3599)
7.1
(147/2075)
14.3
(817/5713)
12.4
(439/3541)
18.2
(368/2027)
3.7
(209/5648)
2.5
(91/3576)
5.7
(115/2033)
7.2
(412/5745)
5.8
(210/3616)
9.4
(197/2090)
2.4
(140/5715)
2.1
(74/3599)
3.1
(64/2078)
5.9
(333/5602)
4.3
(159/3741)
6.8
(148/2183)

17.9
(655/3653)
15.8
(381/2417)
22.1
(268/1212)
5.3
(194/3631)
4.6
(111/2405)
6.8
(82/1202)
15.8
(570/3617)
13.7
(329/2396)
19.7
(236/1197)
4.3
(155/3635)
3.0
(73/2409)
6.7
(80/1202)
8.8
(320/3657)
7.4
(179/2420)
11.2
(136/1213)
1.9
(68/3655)
1.8
(42/2400)
2.2
(26/1200)
7.4
(268/3613)
6.4
(154/2394)
9.2
(110/1195)

NMUPD
NMUPD-E
Females
Males
Sedatives
Females
Males
Stimulants
Females
Males
Opioids
Females
Males
NMUPD-R
Females
Males
Sedatives
Females
Males
Stimulants
Females
Males

16.7
(1238/7424)
15.2
(690/4552)
19.1
(542/2841)
8.2
(606/7400)
7.0
(317/4538)
10.1
(286/2831)
13.5
(980/72691)
12.1
(540/4473)
15.7
(435/2768)
5.6
(409/7367)
4.1
(186/4531)
7.9
(221/2807)
7.0
(523/7429)
6.1
(279/4555)
8.4
(239/2843)
2.6
(191/7291)
2.5
(111/4488)
2.8
(78/2772)
5.6
(405/7263)
4.7
(209/4471)
6.9
(191/2764)

19.35***
22.54***
19.47***
46.98***
13.99***
.78
16.35***
-
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30.49***
12.48***
34.48***
35.48***
26.18***
5.82*
17.95***
-

22.16***
7.71*
21.57***
25.97***
14.85***
.39
8.99**
-

Opioids
Females
Males
Any TE
Females
Males
Sexual Assault
Females
Males
Any other
unwanted/uncomfortable
sexual experience

1.9
(138/7360)
1.3
(58/4529)
2.8
(79/2802)
83.3
(5802/6963)
84.8
(3631/4283)
81.0
(2146/2651)
9.8
(583/5922)
13.0
(478/3667)
4.4
(99/2230)
24.4
(1477/6059)

22.35***
17.25***
116.07***
285.30***

1.1
(61/5643)
.8
(27/3574)
1.6
(33/2030)
50.0
(2826/5723)
52.4
(1882/3592)
45.8
(960/2095)
3.8
(219/5714)
4.9
(175/3592)
2.1
(44/2084)
13.5
(768/5693)

9.25**
22.85***
27.10***
95.84***

1.5
(54/3641)
1.0
(25/2411)
2.3
(28/1206)
37.8
(1364/3613)
39.6
(951/2400)
34.1
(405/1189)
4.2
(152/3619)
5.1
(122/2397)
2.4
(29/1198)
14.2
(513/3615)

9.19**
10.45***
14.14***
50.21***

31.6
16.9
17.1
(1193/3781)
(605/3581)
(410/2395)
12.3
7.7
8.4
Males
(276/2252)
(159/2075)
(100/1196)
28.4
7.8
7.8
Physical Assault
63.26***
12.16***
6.27*
(1764/6210)
(446/5736)
(282/3625)
24.8
6.8
7.0
Females
(941/3800)
(245/3605)
(169/2401)
34.1
9.4
9.4
Males
(814/2385)
(196/2095)
(113/1200)
48
11.9
13.7
Transportation Accident
.11
1.19
7.14*
(3119/6496)
(683/5729)
(496/3630)
47.8
11.5
14.8
Females
(1917/4013
(416/3605)
(355/2406)
48.2
12.5
11.5
Males
(1184/2457)
(261/2086)
(138/1199)
67.8
38.3
18.3
Natural Disaster
1.10
6.79
.04
(4567/6732)
(2199/5747)
(664/3622)
68.3
39.6*
18.4
Females
(2840/4158)
(1430/3612)
(442/2402)
67.1
36.1
18.1
Males
(1709/2548)
(758/2099)
(217/1196)
36.0
26.6
37.5
Probable-PTSD
168.12***
70.45***
46.72***
(1683/4671)
(920/3459)
(503/1341)
42.9
31.2
43.5
Females
(1269/2959)
(699/2243)
(405/932)
23.9
17.9
23.7
Males
(405/1693)
(214/1196)
(95/401)
Note: NMUPD-E = experimental non-medical use of prescription drugs, NMUPD-R = repeated use non-medical use
of prescription drugs, TE = trauma exposure, probable-PTSD = probable posttraumatic stress disorder, Y1F = fall
assessment period in reference to NMUPD, TE, and probable-PTSD prior to college, Y1S = spring assessment period
in reference to NMUPD, TE, and probable-PTSD freshman year, Y2S = spring assessment period in reference to
NMUPD, TE, and probable-PTSD sophomore year.
Females
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Table 2. Prevalence of non-medical use of prescription drugs (experimental, repeated use,
sedatives, stimulants, and opioids), trauma exposure, and probable posttraumatic stress disorder
across time points by cohort.
Prior to College (Y1F)
% (n)
X2(p)

Freshman Year (Y1S)
% (n)
X2(p)

Sophomore Year (Y2S)
% (n)
X2(p)

NMUPD
16.7
16.5
17.9
24.26 ***
6.54 *
2.89
(1238/7424)
(947/5743)
(655/3653)
13.8
15.6
18.1
Cohort 1
(367/2635)
(336/2147)
(237/1307)
18.5
15.7
19.1
Cohort 2
(446/2407)
(297/1891)
(225/1175)
18.0
18.4
16.5
Cohort 3
(425/2364)
(314/1705)
(193/1171)
7.0
7.2
8.8
NMUPD-R
6.70 *
11.17 **
5.42
(523/7429)
(412/5745)
(320/3657)
6.0
6.7
9.0
Cohort 1
(160/2661)
(143/2147)
(118/1307)
7.6
6.2
9.9
Cohort 2
(182/2405)
(117/1889)
(117/1179)
7.7
8.9
7.3
Cohort 3
(181/2363)
(152/1709)
(85/1171)
83.3
50.0
37.8
Any TE
100.66 ***
668.45 ***
88.74 ***
(5802/6963)
(2826/5723)
(1364/3613)
89.2
69.9
47.9
Cohort 1
(2189/2453)
(1497/2141)
(620/1294)
81.4
47.0
31.7
Cohort 2
(1842/2263)
(883/1877)
(370/1168)
78.8
28.3
32.5
Cohort 3
(1771/2247)
(482/1705)
(374/1151)
36.0
26.6
37.5
Probable-PTSD
8.32 *
47.86 ***
14.04 **
(1683/4671)
(920/3459)
(503/1341)
36.1
22.5
32.2
Cohort 1
(601/1664)
(377/1678)
(196/609)
33.5
26.8
40.6
Cohort 2
(509/1520)
(292/1089)
(147/362)
38.5
36.3
43.2
Cohort 3
(573/1487)
(251/692)
(160/370)
Note: NMUPD-E = experimental non-medical use of prescription drugs, NMUPD-R = repeated use non-medical use
of prescription drugs, TE = trauma exposure, probable-PTSD = probable posttraumatic stress disorder, Y1F = fall
assessment period in reference to NMUPD, TE, and probable-PTSD prior to college, Y1S = spring assessment period
in reference to NMUPD, TE, and probable-PTSD freshman year, Y2S = spring assessment period in reference to
NMUPD, TE, and probable-PTSD sophomore year.
NMUPD-E
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Longitudinal associations between TE and NMUPD-E. To examine the longitudinal
associations between TE and NMUPD-E, autoregressive cross lag models were conducted with
sex and cohort included as covariates. The first (saturated) model, serving as the basis for
comparison, included all potential paths (Figure 1 [see page 36; Model 1.1 in Table 3).
For parsimony, Figure 2 presents a simplified figure wherein the covariates, sex and cohort,
are not included pictorially (but are included in the modeling). Figure 2 also provides path
notations which will be referenced throughout the results section.

Figure 2. Simplified autoregressive cross lag model examining the longitudinal association
between trauma exposure and experimental non-medical use of prescription drugs.
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Note: TE = trauma exposure, NMUPD-E = experimental non-medical use of prescription drugs, Y1F = fall assessment
period in reference to the time period prior to college, Y1S = spring assessment period in reference to freshman year,
Y2S = spring assessment period in reference to sophomore year. Double headed arrows indicate correlation and single
headed arrows indicate regression. Sex and cohort excluded from figure included in analyses.

Model comparisons: TE and NMUPD-E. Next, a series of sub-models were fitted by
constraining paths. The fit statistics (AIC and change in -2 log likelihood) from each sub-model
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were compared to the saturated model (Model 1.1, Table 3). Two models examining the selfmedication and the high risk hypotheses (i.e., Longitudinal Effects Models in Table 3) were
compared to the saturated model. In Model 2.1 (Table 3), cross lag paths from TE to NMUPD-E
across time points (h, k, and l paths) were constrained to zero to test the self-medication model
across time. This model was not significantly different from the saturated model (p = .44)
indicating that these paths could be dropped without significantly effecting the fit. In Model 3.1
(Table 3), cross lag paths from NMUPD-E to TE across time points (i, j, and m paths) were
constrained to zero to test the high risk model across time. This model was significantly different
from the saturated model (p < .001) suggesting that dropping these paths would result in worse fit
with the data. In short, the results of the model fitting procedures provide support for the high risk
hypothesis (i.e., prior NMUPD-E is associated with heightened risk for TE).
TE and NMUPD-E best fitting model results. Following comparisons between the
Longitudinal Effects Models (Table 3, Models 2.1 [self-medication model] and 3.1 [high risk
model]) to the saturated model (Table 3, Model 1.1), the fit indices from Model 2.1 indicate that
paths from TE to NMUPD-E across time can be constrained to zero without significantly
impacting model fit. Path estimates with these paths dropped are reported in Table 4.
The covariates of cohort and sex were consistently significantly associated with NMUPDE and TE (with female sex being associated with greater report of TE but lower NMUPD-E and
cohort being positively associated with NMUPD-E at baseline but negatively associated
sophomore year, ps < .05) with the exception of sex not being a significant predictor of NMUPDE during sophomore year and cohort not being a significant predictor of NMUPD-E occurring
freshman year. When examining TE and NMUPD-E, prior TE and NMUPD-E were significant
predictors of future TE and NMUPD-E, respectively. Specifically, TE prior to college was
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associated with TE freshman year (B = .12, p < .001 [path a]) and TE in freshman year was
significantly associated with TE sophomore year (B = .22, p < .001 [path b]). NMUPD-E prior to
college was associated with freshman year NMUPD-E (B = 1.16, p < .001 [path c]) and freshman
year NMUPD-E was also significantly associated with sophomore year NMUPD-E (B = .57, p <
.001 [path d]). Potential long term associations between TE and NMUPD-E occurring prior to
college and TE and NMUPD-E, respectively, occurring in sophomore year were also examined.
TE prior to college was associated with TE sophomore year (B = .15, p = .001 [path n) and
NMUPD-E prior to college was also significantly associated with NMUPD-E sophomore year (B
= .54, p = .001 [path o]).
Given that model fitting results suggested that TE was not a significant predictor of
NMUPD-E across time, these paths were not included in the final model and thus only the cross
paths between NMUPD-E and TE across time are presented. NMUPD-E prior to college served
as a significant predictor of TE freshman year (B = .06, p = .04); however, NMUPD-E during
freshman year did not serve as a significant predictor of TE sophomore year (B = .10, p = .05).
NMUPD-E prior to college did not serve as a significant predictor of TE sophomore year (B = .01,
p = .96). To summarize, the results of the model fitting procedures provide support for the high
risk hypothesis (i.e., prior NMUPD-E is associated with heightened risk for TE).
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Table 3. Model fitting results of autoregressive cross lag models between trauma exposure and experimental non-medical use of
prescription drugs.
-2LL
df
Saturated Model

Model

Changes

-2LL

df

AIC

1.1

a

57773.13

48193

-38612.87

--

--

p
--

Longitudinal Effects Models
2.1

b

57775.84

48196

-38616.16

2.71

3

0.44

3.1

c

57799.89

48196

-38592.11

26.77

3

<.001

Note: a = model includes all paths; b = paths ‘pre college TE to freshman NMUPD-E’, ‘freshman TE to sophomore NMUPD-E’, and ‘pre college TE to
sophomore NMUPD-E’ constrained to zero; c = paths ‘pre college NMUPD-E to freshman TE’, ‘freshman NMUPD-E to sophomore TE’, and ‘pre college
NMUPD-E to sophomore TE’ constrained to zero.
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Figure 3. Visual representation of path significance for the best-fitting cross lag autoregressive
model examining the longitudinal associations between trauma exposure and experimental nonmedical use of prescription drugs.
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Note: Significant paths are represented with black lines while grey lines represent non significant estimates. TE =
trauma exposure, NMUPD-E = experimental non-medical use of prescription drugs, Y1F = prior to college, Y1S =
freshman year, Y2S = sophomore year.

47

Table 4. Path estimates, p values, and standard errors for the best-fitting trauma exposure and
experimental non-medical use of prescription drugs autoregressive cross lag model.

Path
Correlations
TE Y1F
NMUPD-E Y1F (e)
TE Y1S
NMUPD-E Y1S (f)
TE Y2S
NMUPD-E Y2S (g)
Sex
TE Y1F
Sex
NMUPD-E Y1F
Cohort
TE Y1F
Cohort
NMUPD-E Y1F
Regressions
Controlling for sex and cohort
Sex
TE Y1S
Sex
NMUPD-E Y1S
Sex
NMUPD-E Y2S
Sex
TE Y2S
Cohort
TE Y1S
Cohort
NMUPD-E Y1S
Cohort
NMUPD-E Y2S
Cohort
TE Y2S
Autoregressive paths 1
TE Y1F
TE Y1S (a)
TE Y1S
TE Y2S (b)
Experimental NMUPD Y1F
NMUPD-E Y1S (c)
NMUPD-E Y1S
NMUPD-E Y2S (d)
Autoregressive paths 2
TE Y1F
TE Y2S (n)
NMUPD-E Y1F
NMUPD-E Y2S (o)
Cross lag paths 1
TE Y1F
NMUPD-E Y1S (h)
TE Y1S
NMUPD-E Y2S (k)
NMUPD-E Y1F
TE Y1S (i)
NMUPD-E Y1S
TE Y2S (j)
Cross lag paths 2
TE Y1F
NMUPD-E Y2S (l)
NMUPD-E Y1F
TE Y2S (m)

Estimate

p value

SE

.12
.17
.10
.10
-.10
-.19
.07

<.001
<.001
.04
<.001
<.001
<.001
<.001

.03
.04
.05
.02
.02
.02
.02

.13
-.10
-.05
.09
-.52
-.04
-.12
-.06

<.001
.004
.24
.007
<.001
.23
.003
.10

.02
.03
.05
.03
.02
.03
.04
.03

.12
.22
1.16
.57

<.001
<.001
<.001
<.001

.03
.04
.05
.07

.15
.54

.001
.001

.03
.09

.06
.10

.04
.05

.03
.07

.01

.96

.10

Note: TE = trauma exposure, NMUPD-E = experimental non-medical use of prescription drugs, Y1F = prior to college,
Y1S = freshman year, Y2S = sophomore year. - = best fitting model (Table 3) indicated that these paths could be
dropped.
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Longitudinal Associations between TE and NMUPD-R. To examine the longitudinal
associations between TE and NMUPD-R, a similar set of autoregressive cross lag models as
described above for NMUPD-E were also conducted with sex and cohort as covariates. The first
(saturated) model, serving as the basis for comparison, is presented in Figure 1 (Model 1.2 in Table
5). Figure 4 presents a simplified figure with path notations wherein the covariates, sex and cohort,
are not included pictorially (but are included in the modeling).
Model comparisons:

TE and NMUPD-R.

A series of sub-models were fitted by

constraining paths. The fit statistics (AIC and change in -2 log likelihood) from each sub-model
were compared to the saturated model (Model 1.2, Table 5). Two models examining the selfmedication and the high risk hypotheses (i.e., Longitudinal Effects Models in Table 5) were
compared to the saturated model. In Model 2.2 (Table 5), cross lag paths from TE to NMUPD-R
across time points (h, k, and l paths) were constrained to zero to test the self-medication model
across time. This model was not significantly different from the saturated model (p = .11)
indicating that these paths could be dropped without significantly effecting the fit. In Model 3.2
(Table 5), cross lag paths from NMUPD-R to TE across time points (i, j, and m paths) were
constrained to zero to test the high risk model across time. This model was significantly different
from the saturated model (p < .001) suggesting that dropping these paths would result in worse fit
with the data. In short, the results of the model fitting procedures provide support for the high risk
hypothesis (i.e., prior NMUPD-R is associated with heightened risk for TE).
TE and NMUPD-R best fitting model results. Following comparisons between the
Longitudinal Effects Models (Table 5, Models 2.2 [self-medication model] and 3.2 [high risk
model]) to the saturated model (Table 5, Model 1.2), the fit indices from Model 2.2 indicate that
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paths from TE to NMUPD-R across time can be constrained to zero. Path estimates with these
paths dropped are located in Table 6.
The covariates of cohort and sex were consistently significantly associated with NMUPDR and TE (with female sex being associated with greater report of TE but lower report of NMUPDR, and cohort being negatively associated NMUPD-R, ps < .05) with the exception of sex not
being a significant predictor of NMUPD-R during sophomore year and cohort not being a
significant predictor of NMUPD-R occurring freshman year. When examining TE and NMUPDR, prior TE and NMUPD-R were significant predictors of future TE and NMUPD-R, respectively.
Specifically, TE prior to college was associated with TE freshman year (B = .12, p < .001 [path a])
and TE in freshman year was significantly associated with TE sophomore year (B = .21, p < .001
[path b]). Repeated use NMUPD-R prior to college was associated with freshman year NMUPDR (B = 1.10, p < .001 [path c]) and freshman year NMUPD-R was also significantly associated
with sophomore year NMUPD-R (B = .45, p < .001 [path d]). Potential long term associations
between TE and NMUPD-R occurring prior to college and TE and NMUPD-R, respectively,
occurring in sophomore year were also examined. TE prior to college was associated with TE
sophomore year (B = .16, p < .001 [path n) and NMUPD-R prior to college was also significantly
associated with NMUPD sophomore year (B = .55, p < .001 [path o]).
Given that model fitting results suggested that TE was not a significant predictor or
NMUPD-R across time, these paths were not included in the final model and thus only the cross
paths between NMUPD-R and TE across time are presented. NMUPD-R prior to college served
as a significant predictor of TE freshman year (B = .10, p = .002) and NMUPD-R during freshman
year also served as a significant predictor of TE sophomore year (B = .19, p = .005). NMUPD-R
prior to college did not serve as a significant predictor of TE sophomore year (B = -.08, p = .36).
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In summary, the results of the model fitting procedures provide support for the high risk hypothesis
(i.e., prior NMUPD-R heightens risk for TE).
The high risk hypothesis was found to be the best fitting model across both forms of
NMUPD (-E, -R) when comparing the Longitudinal Effects Models to the saturated model. When
examining the best-fitting model for each form of NMUPD, NMUPD (-E, -R) prior to college was
significantly associated with TE freshman year. However, significant associations between
NMUPD freshman year and TE sophomore year were only identified when examining NMUPDR. This path was not significant when examining the association between NMUPD-E freshman
year and TE sophomore year. Thus, although the high risk hypothesis best fits the data in both
models examining TE and NMUPD (-E, -R), NMUPD serving as a significant predictor across
each time point is inconsistent.
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Table 5. Model fitting results of autoregressive cross lag models between trauma exposure and repeated use non-medical use of
prescription drugs.

Model

Changes

-2LL

df

AIC
Saturated Model

1.2

a

52528.67

48204

-43879.33

-2LL

df

p

--

--

--

Longitudinal Effects Models
2.2

b

52534.65

48207

-43879.35

5.98

3

0.11

3.2

c

52572.34

48207

-43841.66

43.66

3

< .001

Note: a = model includes all paths; b = paths ‘pre college TE to freshman NMUPD-R’, ‘freshman TE to sophomore NMUPD-R’, and ‘pre college TE to
sophomore NMUPD-R’ constrained to zero; c = paths ‘pre college NMUPD-R to freshman TE’, ‘freshman NMUPD-R to sophomore TE’, and ‘pre college
NMUPD-R to sophomore TE’ constrained to zero.
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Figure 4. Visual representation of path significance for the best-fitting cross lag autoregressive
model examining the longitudinal associations between trauma exposure and repeated use nonmedical use of prescription drugs.
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Note: Significant paths are represented with black lines while grey lines represent non significant estimates. TE =
trauma exposure, NMUPD-R = repeated use non-medical use of prescription drugs, Y1F = prior to college, Y1S =
freshman year, Y2S = sophomore year.
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Table 6. Path estimates, p values, and standard errors for the best-fitting trauma exposure and
repeated use non-medical use of prescription drugs autoregressive cross lag model.

Path
Correlations
TE Y1F
NMUPD-R Y1F (e)
TE Y1S
NMUPD-R Y1S (f)
TE Y2S
NMUPD-R Y2S (g)
Sex
TE Y1F
Sex
NMUPD-R Y1F
Cohort
TE Y1F
Cohort
NMUPD-R Y1F
Regressions
Controlling for sex and cohort
Sex
TE Y1S
Sex
NMUPD-R Y1S
Sex
NMUPD-R Y2S
Sex
TE Y2S
Cohort
TE Y1S
Cohort
NMUPD-R Y1S
Cohort
NMUPD-R Y2S
Cohort
TE Y2S
Autoregressive paths 1
TE Y1F
TE Y1S (a)
TE Y1S
TE Y2S (b)
NMUPD-R Y1F
NMUPD-R Y1S (c)
NMUPD-R Y1S
NMUPD-R Y2S (d)
Autoregressive paths 2
TE Y1F
TE Y2S (n)
NMUPD-R Y1F
NMUPD-R Y2S (o)
Cross lag paths 1
TE Y1F
NMUPD-R Y1S (h)
TE Y1S
NMUPD-R Y2S (k)
NMUPD-R Y1F TE Y1S (i)
NMUPD-R Y1S
TE Y2S (j)
Cross lag paths 2
TE Y1F
NMUPD-R Y2S (l)
NMUPD-R Y1F
TE Y2S (m)

Estimate p value

SE

.09
.14
.06
.10
-.11
.05
-.19

.004
.001
.27
<.001
<.001
<.001
.04

.03
.05
.15
.02
.03
.03
.02

.14
-.12
-.04
.10
-.53
.04
-.12
-.07

<.001
.002
.50
.01
<.001
.30
.01
.01

.02
.05
.11
.03
.02
.05
.06
.04

.12
.21
1.10
.45

<.001
<.001
<.001
<.001

.03
.03
.12
.12

.16
.55

<.001
<.001

.04
.09

.10
.19

.002
.005

.04
.06

-.08

.36

.06

Note: TE = trauma exposure, NMUPD-R = repeated use non-medical use of prescription drugs, Y1F = prior to college,
Y1S = freshman year, Y2S = sophomore year. - = best fitting model (Table 5) indicated that these paths could be
dropped.

54

Follow-up Phenotypic Analyses
Given that posttraumatic distress following TE may be more relevant to substance misuse
than the exposure alone and in an effort to further refine the phenotypic analyses, follow-up
analyses were conducted examining longitudinal associations between probable-PTSD and
NMUPD (-E, -R).
Longitudinal associations between probable-PTSD and NMUPD-E. To examine the
longitudinal associations between probable-PTSD and NMUPD-E, autoregressive cross lag
models were conducted with sex and cohort as covariates, via the same steps as described above
for the primary analyses using TE in association with NMUPD (-E, -R). The first (saturated)
model, serving as the basis for comparison, included all potential paths and is presented in Figure
1 (Model 1.3 in Table 7). Figure 5 presents a simplified figure with path notations wherein the
covariates, sex and cohort, is not included pictorially (but is included in the modeling).
Model comparisons: probable-PTSD and NMUPD-E. A series of sub-models were fitted
by constraining paths. The fit statistics (AIC and change in -2 log likelihood) from each sub-model
were compared to the saturated model (Model 1.3, Table 7). Two models examining the selfmedication and the high risk hypotheses (i.e., Longitudinal Effects Models in Table 7) were
compared to the saturated model. In Model 2.3 (Table 7), cross lag paths from probable-PTSD to
NMUPD across time points (h, k, and l paths) were constrained to zero to test the self-medication
model across time. This model was not significantly different from the saturated model (p = .46)
indicating that these paths could be dropped without significantly effecting the fit. In Model 3.3
(Table 7), cross lag paths from NMUPD to probable-PTSD across time points (i, j, and m
paths) were constrained to zero to test the high risk model across time.

This model was

significantly different from the saturated model (p < .001) suggesting that dropping these paths
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would result in worse fit with the data. In short, the results of the model fitting procedures provide
support for the high risk hypothesis (i.e., prior NMUPD-E is associated with heightened risk for
probable-PTSD).
Probable-PTSD and NMUPD-E best fitting model results. Following comparisons
between the Longitudinal Effects Models (Table 7, Models 2.3 [self-medication model] and 3.3
[high risk model]) to the saturated model (Table 7, Model 1), the fit indices from Model 2.3
indicate that paths from probable-PTSD to NMUPD-E across time can be constrained to zero. Path
estimates with these paths dropped are located in Table 8.
The covariates of cohort and sex were consistently significantly associated with NMUPDE and probable-PTSD (with female sex being associated with greater report of probable-PTSD and
lower report of NMUPD-E and cohort being positively associated with probable-PTSD at baseline
but negatively associated sophomore year, ps < .05) with the exception of sex not being a
significant predictor of NMUPD-E during sophomore year and cohort not being a significant
predictor of NMUPD-E occurring freshman year. Moreover, cohort and probable-PTSD were not
significantly correlated at baseline. When examining probable-PTSD and NMUPD-E, prior
probable-PTSD and NMUPD-E were significant predictors of future probable-PTSD and
NMUPD-E, respectively. Specifically, probable-PTSD prior to college was associated with
probable-PTSD freshman year (B = .50, p < .001 [path a]) and probable-PTSD in freshman year
was significantly associated with probable-PTSD sophomore year (B = .40, p < .001 [path b]).
NMUPD-E prior to college was associated with freshman year NMUPD-E (B = 1.17, p < .001
[path c]) and freshman year NMUPD-E was also significantly associated with sophomore year
NMUPD-E (B = .57, p < .001 [path d]). Potential long term associations between probable-PTSD
and NMUPD occurring prior to college and probable-PTSD and NMUPD, respectively, occurring
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in sophomore year were also examined. probable-PTSD prior to college was associated with
probable-PTSD sophomore year (B = .28, p < .001 [path n) and NMUPD prior to college was
associated with NMUPD sophomore year (B = .54, p < .001 [path o]).
Given that model fitting results suggested that TE was not a significant predictor or
NMUPD-E across time, these paths were not included in the final model and thus only the cross
paths between NMUPD-E and TE across time are presented. NMUPD-E prior college served as
a significant predictor of probable-PTSD freshman year (B = .17, p < .001); however, NMUPD-E
during freshman year did not serve as a significant predictor of probable-PTSD sophomore year
(B = -.04, p = .62). Moreover, NMUPD-E prior to college did not serve as a significant predictor
of probable-PTSD sophomore year (B = .05, p = .67). To summarize, the results of the model
fitting procedures provide support for the high risk hypothesis (i.e., prior NMUPD-E is associated
with heightened risk for probable-PTSD).
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Table 7. Model fitting results of autoregressive cross lag models between probable posttraumatic stress disorder and experimental nonmedical use of prescription drugs.

Model

Changes

-2LL

df

AIC
Saturated Model

-2LL

df

p

1.3

a

51041.51

41365

-31688.49

--

--

--

Longitudinal Effects Models
2.3

b

51044.08

41368

-31691.92

2.57

3

0.46

3.3

c

51058.23

41368

-31677.77

16.72

3

.001

Note: a = model includes all paths; b = paths ‘pre college PTSD to freshman NMUPD-E’, ‘freshman PTSD to sophomore NMUPD-E’, and ‘pre college PTSD
to sophomore NMUPD-E’ constrained to zero; c = paths ‘pre college NMUPD-E to freshman PTSD’, ‘pre college NMUPD-E to sophomore PTSD’, and
‘freshman NMUPD-E to sophomore experimental PTSD’ constrained to zero.
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Figure 5. Visual representation of path significance for the best-fitting cross lag autoregressive
model examining the longitudinal associations between probable posttraumatic stress disorder and
experimental non-medical use of prescription drugs.
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Note: Significant paths are represented with black lines while grey lines represent non significant estimates. probablePTSD = probable posttraumatic stress disorder, NMUPD-E = experimental non-medical use of prescription drugs,
Y1F = prior to college, Y1S = freshman year, Y2S = sophomore year.
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Table 8. Path estimates, p values, and standard errors for the best-fitting probable posttraumatic
stress disorder and experimental non-medical use of prescription drugs autoregressive cross lag
model.
Path
Correlations
Probable-PTSD Y1F
NMUPD-E Y1F (e)
Probable-PTSD Y1S
NMUPD-E Y1S (f)
Probable-PTSD Y2S
NMUPD-E Y2S (g)
Sex
Probable-PTSD Y1F
Sex
NMUPD-E Y1F
Cohort
Probable-PTSD Y1F
Cohort
NMUPD-E Y1F
Regressions
Controlling for sex and cohort
Sex
Probable-PTSD Y1S
Sex
NMUPD-E Y1S
Sex
NMUPD-E Y2S
Sex
Probable-PTSD Y2S
Cohort
Probable-PTSD Y1S
Cohort
NMUPD-E Y1S
Cohort
NMUPD-E Y2S
Cohort
Probable-PTSD Y2S
Autoregressive paths 1
Probable-PTSD Y1F
Probable-PTSD Y1S (a)
Probable-PTSD Y1S
Probable-PTSD Y2S (b)
NMUPD-E Y1F
NMUPD-E Y1S (c)
NMUPD-E Y1S
NMUPD-E Y2S (d)
Autoregressive paths 2
Probable-PTSD Y1F
Probable-PTSD Y2S (n)
NMUPD-E Y1F
NMUPD-E Y2S (o)
Cross lag paths 1
Probable-PTSD Y1F
NMUPD-E Y1S (h)
Probable-PTSD Y1S
NMUPD-E Y2S (k)
NMUPD-E Y1F Probable-PTSD Y1S (i)
NMUPD-E Y1S
Probable-PTSD Y2S (j)
Cross lag paths 2
Probable-PTSD Y1F
NMUPD-E Y2S (l)
NMUPD-E Y1F
Probable-PTSD Y2S (m)

Estimate p value

SE

.21
.04
.16
.32
-.11
.01
.08

<.001
.44
.04
<.001
<.001
.71
<.001

.02
.03
.07
.02
.02
.02
.02

.16
-.09
-.05
.20
.16
-.03
-.12
.05

<.001
.007
.28
.002
<.001
.32
.002
.27

.05
.03
.04
.07
.04
.03
.04
.05

.50
.40
1.17
.57

<.001
<.001
<.001
<.001

.05
.07
.04
.05

.28
.54

<.001
<.001

.08
.07

.17
-.04

<.001
.62

.04
.09

.05

.67

.15

Note: probable-PTSD = probable posttraumatic stress disorder, NMUPD-E = experimental non-medical use of
prescription drugs, Y1F = prior to college, Y1S = freshman year, Y2S = sophomore year. - = best fitting model
indicated that these paths could be dropped.
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Longitudinal associations between probable-PTSD and NMUPD-R. To examine the
longitudinal associations between probable-PTSD and NMUPD-R, autoregressive cross lag
models were conducted with sex and cohort as covariates. The first (saturated) model, serving as
the basis for comparison, is presented in Figure 1 (Model 1.4 in Table 9). Figure 6 presents a
simplified figure wherein the covariates, sex and cohort, are not included pictorially (but are
included in the modeling).
Model comparisons: probable-PTSD and NMUPD-R. The fit statistics (AIC and change
in -2 log likelihood) from each sub-model were compared to the saturated model (Model 1.4, Table
9). Two models examining the self-medication and the high risk hypotheses (i.e., Longitudinal
Effects Models in Table 9) were compared to the saturated model. In Model 2.4 (Table 9), cross
lag paths from probable-PTSD to NMUPD across time points (h, k, and l paths) were constrained
to zero to test the self-medication model across time. This model was not significantly different
from the saturated model (p = .29) indicating that these paths could be dropped without
significantly effecting the fit. In Model 3.4 (Table 9), cross lag paths from NMUPD to probablePTSD across time points (i, j, and m paths) were constrained to zero to test the high risk model
across time. This model was significantly different from the saturated model (p = .02) suggesting
that dropping these paths would result in worse fit with the data. In summary, the results of the
model fitting procedures provide support for the high risk hypothesis (i.e., prior NMUPD-R is
associated with heightened risk for probable-PTSD).
Probable-PTSD and NMUPD-R best fitting model. Following comparisons between the
Longitudinal Effects Models to the saturated model (Table 9, Model 1.4), the fit indices from
Model 2.4 indicate that paths from TE to NMUPD-R across time can be constrained to zero. Path
estimates with these paths dropped are located in Table 10.
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The covariates of cohort and sex were consistently significantly associated with NMUPDR and probable-PTSD (ps < .05), with female sex being associated with greater report of probablePTSD but lower report of NMUPD-E and cohort being positively associated with NMUPD-R at
baseline but negatively associated sophomore year, with the exception of sex not being a
significant predictor of NMUPD-R during sophomore year and cohort not being a significant
predictor of NMUPD-R occurring freshman year. Moreover, cohort and probable-PTSD were not
significantly correlated at baseline. When examining probable-PTSD and NMUPD-R, prior
probable-PTSD and NMUPD-R were significant predictors of future probable-PTSD and
NMUPD-R, respectively. Specifically, probable-PTSD prior to college was associated with
probable-PTSD freshman year (B = .49, p < .001 [path a]) and probable-PTSD in freshman year
was significantly associated with TE sophomore year (B = .40, p < .001 [path b]). Repeated use
NMUPD prior to college was associated with freshman year NMUPD-R (B = 1.12, p < .001 [path
c]) and freshman year NMUPD-R was also significantly associated with sophomore year
NMUPD-R (B = .45, p < .001 [path d]). Potential long term associations between probable-PTSD
and NMUPD occurring prior to college and probable-PTSD and NMUPD, respectively, occurring
in sophomore year were also examined. probable-PTSD prior to college was associated with
probable-PTSD sophomore year (B = .27, p < .001 [path n) and NMUPD prior to college was also
associated with NMUPD sophomore year (B = .56, p < .001 [path o]).
Given that model fitting results suggested that TE was not a significant predictor or
NMUPD-R across time, these paths were not included in the final model and thus only the cross
paths between NMUPD-R and probable-PTSD across time are presented. Repeated use NMUPD
prior college served as a significant predictor of probable-PTSD freshman year (B = .16, p = .002);
however, NMUPD-R during freshman year did not serve as a significant predictor of probable-
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PTSD sophomore year (B = -.03, p = .83). Moreover, NMUPD-R prior to college did not serve as
a significant predictor of probable-PTSD sophomore year (B = .09, p = .62). In short, the results
of the model fitting procedures provide support for the high risk hypothesis (i.e., prior NMUPDR is associated with heightened risk for probable-PTSD).
The high risk hypothesis was found to be the best fitting model across both forms of
NMUPD (-E, -R) when comparing the Longitudinal Effects Models to the saturated model. When
examining the best-fitting model for each form of NMUPD, NMUPD (-E, -R) prior to college was
significantly associated with probable-PTSD freshman year. However, significant associations
between NMUPD freshman year and probable-PTSD sophomore year were only identified when
examining NMUPD-R. This path was not significant when examining the association between
NMUPD-E freshman year and probable-PTSD sophomore year. Thus, although the high risk
model best fits the data in both models examining probable-PTSD and NMUPD (-E, -R), NMUPD
serving as a significant predictor across each time point is inconsistent.
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Table 9. Model fitting results of autoregressive cross lag models between probable posttraumatic stress disorder and repeated use nonmedical use of prescription drugs.
Model

Changes

-2LL

df

AIC
Saturated Model

1.4

a

45801.39

41376

-36950.61

-2LL

df

p

--

--

--

Longitudinal Effects Models
2.4

b

45811.22

41379

-36952.82

3.79

3

0.29

3.4

c

45811.22

41379

-36946.78

9.83

3

0.02

Note: a = model includes all paths; b = paths ‘pre college probable-PTSD to freshman NMUPD-R’, ‘freshman probable-PTSD to sophomore NMUPD-R’, and
‘pre college probable-PTSD to sophomore NMUPD-R’ constrained to zero; c = paths ‘pre college NMUPD-R to freshman probable-PTSD’, ‘freshman NMUPDR to sophomore probable-PTSD’, and ‘pre college NMUPD-R to sophomore probable-PTSD’ constrained to zero.
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Figure 6. Visual representation of path significance for the best-fitting cross lag autoregressive
model examining the longitudinal associations between probable posttraumatic stress disorder and
repeated use non-medical use of prescription drugs.
n
ProbablePTSD
Y1F

ProbablePTSD
Y2S

b

a

ProbablePTSD Y1S

l
f

h

j

e

g
i

NMUPD-R
Y1F

k
m
c

NMUPD-R
Y1S

d

NMUPD-R
Y2S

o
Note: Significant paths are represented with black lines while grey lines represent non significant estimates.
probable-PTSD = posttraumatic stress disorder, NMUPD-E = experimental non-medical use of prescription drugs,
Y1F = prior to college, Y1S = freshman year, Y2S = sophomore year.
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Table 10. Path estimates, p values, and standard errors for the best-fitting probable posttraumatic
stress disorder and repeated use non-medical use of prescription drugs autoregressive cross lag
model.
Path
Correlations
Probable-PTSD Y1F
NMUPD-R Y1F (e)
Probable-PTSD Y1S
NMUPD-R Y1S (f)
Probable-PTSD Y2S
NMUPD-R Y2S (g)
Sex
TE Y1F
Sex
NMUPD-R Y1F
Cohort
TE Y1F
Cohort
NMUPD-R Y1F
Regressions
Controlling for sex and cohort
Sex
Probable-PTSD Y1S
Sex
NMUPD-R Y1S
Sex
NMUPD-R Y2S
Sex
Probable-PTSD Y2S
Cohort
Probable-PTSD Y1S
Cohort
NMUPD-R Y1S
Cohort
NMUPD-R Y2S
Cohort
Probable-PTSD Y2S
Autoregressive paths 1
Probable-PTSD Y1F
Probable-PTSD Y1S (a)
Probable-PTSD Y1S
Probable-PTSD Y2S (b)
NMUPD-R Y1F
NMUPD-R Y1S (c)
NMUPD-R Y1S
NMUPD-R Y2S (d)
Autoregressive paths 2
Probable-PTSD Y1F
Probable-PTSD Y2S (n)
NMUPD-R Y1F
NMUPD-R Y2S (o)
Cross lag paths 1
Probable-PTSD Y1F
NMUPD-R Y1S (h)
Probable-PTSD Y1S
NMUPD-R Y2S (k)
NMUPD Y1F Repeated Probable-PTSD Y1S (j)
NMUPD Y1S
Repeated Probable-PTSD Y2S (j)
Cross lag paths 2
Probable-PTSD Y1F
NMUPD-R Y2S (l)
NMUPD Y1F
Probable-PTSD Y2S (m)

Estimate

p
value

SE

.21
.06
.09
.32
-.11
.01
.05

<.001
.36
.31
<.001
<.001
.68
.03

.03
.06
.09
.02
.03
.02
.02

.16
-.12
-.02
.22
.18
.05
-.13
.05

<.001
.03
.68
.001
<.001
.24
.006
.23

.04
.04
.05
.07
.03
.04
.04
.05

.49
.40
1.12
.45

<.001
<.001
<.001
<.001

.05
.07
.08
.07

.27
.56

<.001 .08
<.001 .10

.16
-.03

.002
.83

.05
.13

.09

.62

.19

Note: probable-PTSD = probable posttraumatic stress disorder, NMUPD-R = repeated non-medical use of prescription
drugs, Y1F = prior to college, Y1S = freshman year, Y2S = sophomore year. - = best fitting model indicated that these
paths could be dropped.
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Longitudinal Associations Summary
Within each longitudinal model, prior TE, probable-PTSD, and NMUPD (-E, -R) served
as a significant predictor of future TE, probable-PTSD, and NMUPD (-E, -R) across time,
respectively, as indicated by the significant autoregressive paths identified in each model. In the
examination of longitudinal relationships between TE and NMUPD (-E, -R) similar patterns
emerged. When comparing each of the two models to the saturated model, (Longitudinal Effects
Models representing the self-medication hypothesis and high risk hypothesis), the model
representing the self-medication hypotheses, (which dropped cross lag paths from TE to NMUPD
[-E, -R] across time) was consistently not significantly different from the saturated model which
included all potential paths. Thus, the findings overall, do not lend support for the self-medication
hypothesis which posits that NMUPD may serve as a method of coping post trauma exposure.
Rather, the overall findings from each of the models suggests that NMUPD (-E, -R) heightens risk
for TE over time. This pattern was additionally demonstrated within the follow-up analyses
(examining the longitudinal associations between probable-PTSD and both forms of NMUPD)
which also suggested that the high risk model may best capture the associations between NMUPD
(-E, -R) and probable-PTSD across time within this sample1.
Aim 2: Genotypic Results
Determining molecular heritability of NMUPD (experimental and repeated use) and
TE. To determine the SNP-based heritability (h2SNP) of each variable of interest, univariate
GCTAs were conducted within each ancestral group. As reviewed in the QC portion of the

1

When the analyses were further refined to examine the longitudinal associations between IPV and
both forms of NMUPD, the same pattern emerged (Appendix II). However, this pattern did not
hold when the analyses were restricted to natural disaster (Appendix III). Please see Appendices
for results for each of these models.
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Methods section of the present document, each participant was classified into their respective super
population resulting in five ancestral groups: AFR (n = 1,339), AMR (n = 582), EAS (n = 557),
EUR (n = 3,018), and SAS (n = 455). It is important to note that the ns within each ancestral group
vary by phenotype (i.e., all participants may not have responded to every item); thereby resulting
in different ancestral group ns in each set of analyses.
Prior to conducting these analyses, power calculations were performed for each phenotype
(NMUPD-E, NMUPD-R, and TE) within each ancestral group (Table 11). Power analyses suggest
that overall, there is limited power to detect effects (with the exception of GCTAs conducted within
the EUR ancestry group for phenotypes with high heritability [h2SNP = 0.50]). When examining
the h2SNP of each phenotype by super population, most of the findings were not significant, as
confidence intervals for estimates frequently included 0 (Table 12). Some of the SNP-based
heritability estimates were significant; however, interpretation is problematic given the unusually
high estimates identified (e.g., h2SNP estimate of .99 within EAS super population for NMUPD-E).
In

accordance

with

standard

practice

set

forth

by

the

PGC

(https://github.com/Nealelab/ricopili), results were also meta-analyzed across ancestry groups.
The h2SNP estimate derived from the meta-analysis for NMUPD-E was .15 (SE = .01, CI = .12-.17)
and for NMUPD-R was .22 (SE = .01, CI = .19-.24). The h2SNP estimates identified for NMUPDE was significantly lower than that derived for NMUPD-R (F = 2.10, p < .001). The h2SNP estimate
for TE was .02 (SE = .01, CI = .001-.04). Despite the h2SNP estimates for NMUPD-E and NMUPDR being within a range reasonably consistent with the broader substance use literature (with a
higher estimate identified for the more refined NMUPD-R phenotype, compared to the NMUPDE phenotype), these findings should be interpreted cautiously.

Although the meta-analytic

approach increases the power to detect effects, the estimates produced are likely influenced by low
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prevalence rates (limited number of cases) for NMUPD (-E, -R) and limited number of controls
within the TE phenotype. Moreover, interpretability is limited given the heterogeneity present
within each of the phenotypes. Specifically, NMUPD (-E, -R) can capture a range of use
presentations (e.g., a single experiential use, problematic use) and the TE phenotype consists of a
broad range of potentially traumatic events (e.g., motor vehicle accidents, sexual assault) collapsed
into a single binary variable.
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Table 11. Power calculations within each phenotype (nonmedical use of prescription drugs
[experimental and repeated use] and trauma exposure) by ancestral group.
Power
Phenotypic
Outcome

Experimental
NMUPD

Repeated Use
NMUPD

2

h SNP
= 0.50
.14
.08
.07
.79
.06

h2SNP
= 0.20
.06
.06
.05
.20
.05

h2SNP =
0.10
.05
.05
.05
.09
.05

61
67
36
530

.07
.06
.06
.58

.05
.05
.05
.14

.05
.05
.05
.07

29

.05

.05

.05

Ancestry
Group
AFR
AMR
EAS
EUR
SAS

N
1325
573
545
2956
442

Prevalence
14%
27%
15%
34%
16%

Controls
1144
417
462
1963
371

Cases
181
156
83
993
71

AFR
AMR
EAS
EUR

1325
574
546
2957

5%
12%
7%
18%

1264
507
510
2427

SAS

442

7%

413

AFR
1322
87%
176
1146
.13
.06
.05
AMR
570
86%
79
491
.07
.05
.05
TE
EAS
546
81%
105
441
.07
.05
.05
EUR
2953
87%
375
2578
.44
.11
.06
SAS
442
82%
81
361
.06
.05
.05
Note: NMUPD = non-medical use of prescription drugs, TE = trauma exposure, AMF = African ancestry, AMR =
Americas ancestry, EAS = East Asian ancestry, EUR = European ancestry, AMF = South Asian ancestry, h2SNP = SNPbased heritability.
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Table 12. Estimates of SNP-based heritability for non-medical use of prescription drugs
(experimental and repeated use) and trauma exposure phenotypes (controlling for population
stratification, sex, and cohort) generated from genome-wide complex trait analyses.
Super population

Covariates

AFR
AMR
EAS
EUR
SAS

PCs, cohort, sex
PCs, cohort, sex
PCs, cohort, sex
PCs, cohort, sex
PCs, cohort, sex

AFR
AMR
EAS
EUR
SAS

PCs, cohort, sex
PCs, cohort, sex
PCs, cohort, sex
PCs, cohort, sex
PCs, cohort, sex

AFR
AMR
EAS
EUR
SAS

PCs, cohort, sex
PCs, cohort, sex
PCs, cohort, sex
PCs, cohort, sex
PCs, cohort, sex

Sample Prevalence
NMUPD-E
14%
27%
15%
34%
16%
NMUPD-R
5%
12%
7%
18%
7%
TE
87%
86%
81%
87%
82%

h2SNP

SE

p-value

.11
.33
.99
.08
.85

.26
.45
.63
.13
.72

.30
.20
.05
.30
.10

.71
.52
1.00
.06
< .001

.28
.49
.61
.13
.74

.01
.20
.01
.30
.50

.14
.01
<.001
<.001
< .001

.26
.42
.61
.13
.74

.30
.50
.50
.50
.50

Note: NMUPD-E = experimental non-medical use of prescription drugs, NMUPD-R = repeated use non-medical use
of prescription drugs, h2SNP = SNP-based heritability estimate, PCs = principle components, AMF = African ancestry,
AMR = Americas ancestry, EAS = East Asian ancestry, EUR = European ancestry, AMF = South Asian ancestry.

Follow-up analyses. Given concerns regarding the univariate GCTAs conducted for
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NMUPD (-E, -R) and TE associated with imbalance between cases and controls and with
interpretability, univariate GCTAs were also conducted for probable-PTSD within each ancestral
group in an effort to derive h2SNP estimates for a more refined phenotype. Again, prior to these
analyses, power calculations were conducted for probable-PTSD within each ancestry group
(Table 13). Results from the power analyses suggest that there is limited power to detect effects.
Determining the SNP-based heritability of probable-PTSD. No significant findings were
identified for univariate GCTAs for probable-PTSD, as confidence intervals for estimates
frequently included 0 (Table 14). Results were meta-analyzed across ancestry groups. However,
difficulties associated with limited power resulted in the inability to calculate the h2SNP for the
probable-PTSD phenotype.

Table 13. Power calculations within the probable posttraumatic stress disorder phenotype by
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ancestral group.

2

h
Phenotypic
Outcome
ProbablePTSD

Ancestry
Group
N
Prevalence
AFR
1139
39%
AMR
488
43%
EAS
435
32%
EUR
2548
42%
SAS
355
32%

Controls
691
278
295
1481
241

Cases
448
210
140
1067
114

SNP

=
0.50
.20
.08
.07
.71
.06

Power
h2SNP
=
0.20
.07
.05
.05
.17
.05

h2SNP
= 0.10
.05
.05
.05
.08
.05

Note: Probable-PTSD = posttraumatic stress disorder, AMF = African ancestry, AMR = Americas ancestry, EAS =
East Asian ancestry, EUR = European ancestry, AMF = South Asian ancestry, h2SNP = SNP-based heritability estimate.

Table 14. Estimates of SNP-based heritability for probable posttraumatic stress disorder phenotype
(controlling for population stratification, sex, cohort) generated from genome-wide complex trait
analyses.
Super population
AFR
AMR
EAS
EUR
SAS

Covariates

PCs, cohort, sex
PCs, cohort, sex
PCs, cohort, sex
PCs, cohort, sex
PCs, cohort, sex

Sample Prevalence
Probable-PTSD
39%
43%
32%
42%
32%

h2SNP

SE

p-value

<.001
<.001
<.001
<.001
< .001

.29
.45
.81
.15
.90

.50
.50
.50
.50
.50

Note: Probable-PTSD = probable posttraumatic stress disorder, h2SNP = SNP based heritability estimate, Ca = cases,
Co = controls, PCs = principle components, AMF = African ancestry, AMR = Americas ancestry, EAS = East Asian
ancestry, EUR = European ancestry, AMF = South Asian ancestry.

SNP-based heritability results summary. Overall, the findings from the meta-analyses
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resulted in significant h2SNP estimates for NMUPD-E and NMUPD-R. However, meta-analyses
for TE and probable-PTSD did not reveal significant h2SNP estimates. Moreover, additional
attempts to refine the analyses resulted in mixed findings (significant h2SNP estimate identified for
IPV [h2SNP = .05, SE = .01, CI = .03-.07] but not NMUPD-E when the covariates of TE and
probable-PTSD were included)2. The lack of significant results among the TE and probable-PTSD
phenotypes is likely attributable to limited statistical power to detect effects and limitations
associated with phenotypic assessment, which will be reviewed in detail within the discussion.
Despite the limited evidence of aggregate molecular influence provided by h2SNP for some of the
phenotypes, GWAS analyses were conducted to examine the potential influence of individual
variants in relation to study constructs. Justification for conducting GWAS despite the lack of
significant h2SNP estimates identified is reviewed within the discussion.
Identifying Genetic Variants Associated with Phenotypes of Interest.
Phenotype selection justification for GWAS. Prior to conducting these GWAS, power
analyses

were

completed

using

the

Genetic

Association

Study

Power

Calculator

(http://csg.sph.umich.edu/abecasis/cats/gas_power_calculator/index.html). Power was calculated
for several MAFs (i.e., .05, .25, .50) and genotype relative risks (i.e., 1.05, 1.10, 1.15, 1.20). As
demonstrated in the table below, the NMUPD-R phenotype were underpowered for GWAS.
Power calculations for the TE phenotype was also attempted; however, the calculations could not
be calculated likely due to the imbalance between cases and controls. Given the limited power to
detect effects for NMUPD-R and TE, likely associated with lack of balance between cases and

2

These attempts to refine the analyses included (1) conducting a GCTA on the more nuanced
phenotype of IPV, and (2) conducting a GCTA on NMUPD-E incorporating TE and probablePTSD as covariates in the most highly powered subsample (European ancestral group). Please see
Appendices VI and VII for results of these refined analyses.
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controls (low prevalence of cases in NMUPD-R and low prevalence of controls in TE), GWAS
were not performed for these phenotypes. Although not ideal, NMUPD-E was selected for GWAS
given the greater power to detect significant genetic effects (MAF > .25%, genotype relative risk
> 1.20, prevalence of 25%) and better balance with regard to case/control status relative to the
NMUPD-R and TE phenotypes (Table 15).
In addition to NMUPD-E, GWAS were conducted for probable-PTSD and IPV. There was
adequate power to detect common variants at MAF >.50% and genotype relative risk > 1.15 and
MAF >.25% and genotype relative risk > 1.20 for the probable-PTSD phenotype (prevalence of
40%) and to detect common variants at MAF > .25% and genotype relative risk > 1.15 (prevalence
of 46%).
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Table 15. Power to detect variants in GWAS across phenotypes.
NMUPD-E (1890 cases and 5610 controls)
MAF
1.05
.05
0
.25
0
.50
0
NMUPD-R (933 cases and 6569 controls)

Genotype Relative Risk
1.10
1.15
.01
.01
.06
.44
.13
.68

Genotype Relative Risk
MAF
1.05
1.10
1.15
.05
0
0
0
.25
0
0
.04
.50
0
.01
.10
Probable-PTSD (1979 cases and 2986 controls)
Genotype Relative Risk
MAF
1.05
1.10
1.15
.05
0
0
.03
.25
0
.14
.71
.50
.01
.27
.88
IPV (2673 cases and 3141 controls)
Genotype Relative Risk
MAF
1.05
1.10
1.15
.05
0
.01
.10
.25
.01
.38
.96
.50
.02
.60
.99

1.20
.06
.88
.98

1.20
0
.20
.38

1.20
.14
.98
1.00

1.20
.40
1.00
1.00

Note: NMUPD-E = experimental non-medical use of prescriptions drugs, NMUPD-R = repeated non-medical use of
prescription drugs, probable-PTSD = probable posttraumatic stress disorder, IPV = interpersonal violence, MAF =
minor allele frequency.

GWAS results overview.

GWAS for NMUPD-E, probable-PTSD, and IPV were

conducted with each phenotype treated as a binary variable (case/control). Moreover, GWAS were
conducted separately by ancestry (i.e., AFR, AMR, EAS, EUR, SAS) with PCs, sex, and cohort
included as covariates and then meta-analyzed using METAL (Willer, Li, & Abecases, 2010),
which uses a fixed effect model and inverse variance weighting based on sample size. Results
(sample size, number of markers, lambdas [λ and λ1000]) for each phenotype are presented in
Table 16. Manhattan plots and Q-Q plots are also presented for NMUPD-E (Figures 7 and 8,
respectively), probable-PTSD (Figures 9 and 10, respectively), and IPV (Figures 11 and 12,
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respectively).
GWAS results for NMUPD-E. No evidence of genomic inflation was identified (λ =
1.006, concern regarding potential bias associated with population stratification arises when λ is
greater than 1.1; Winkler et al., 2014), thus, no adjustments were made. Eight genomic bins
contained at least one SNP with a p-value that reached genome-wide significance (5x10-8) for
NMUPD-E; however, only five genomic bins passed the FDR correction (method of controlling
for Type 1 errors while maximizing power compared to standard Bonferroni type corrections;
Benjamini & Hochberg, 1995) threshold of .05 (Table 17). Information regarding the significant
SNPs identified for NMUPD-E is provided in Table 20. Moreover, Figures 13-17 present regional
association plots, which visually displays the strength of association between the SNP of interest
and other nearby markers within the region (+/- 200 kb [kilobase; one kb is equal to 1000 base
pairs of DNA]), for each of the five genomic bins with at least one genome wide significant SNP
passing FDR correction.
The SNPs with the lowest p-values passing FDR correction for NMUPD-E meta analyzed
across super populations were located on chromosome 20, chromosome 16, chromosome 13,
chromosome 11, and chromosome 3. The SNP located on chromosome 20 (rs73241778) mapped
onto the PAK7, a protein coding gene, while the SNP located on chromosome 16 (rs138647543)
mapped onto LINC00922, a noncoding RNA gene. The remaining three SNPs (rs142738451,
rs74901044, rs9578774) did not map onto any specific gene although they were close (within 5000
bp) to multiple genes including ATP12A, RNF17, AK095081, and LOC283177. The direction of
effect was similar across SNPs (minor allele [allele 1, listed at A1 in tables] being negatively
associated with NMUPD-E case status) with the exception of rs73241778 which was positively
associated with NMUPD-E case status. Each SNP was also a rare variant (MAF < .05) with the
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exception of rs73241778 which is considered common (MAF = .10). The regional association
plots (Figures 13-17) revealed that rs142738451, rs73241778, rs9578774, and rs74901044 are lone
SNPs or in weak LD with surrounding markers. However, rs138647543 is in strong LD with other
nearby markers suggesting that multiple SNPs within the region may be associated with NMUPDE. It could also suggest that the identified SNP is not the true casual variant but may be in LD
with the causal variant.
GWAS results for probable-PTSD. No evidence of genomic inflation was identified for
the probable-PTSD phenotype (λ = 1.011), thus, no adjustments were made. No SNPs had pvalues that reached genome-wide significance for the probable-PTSD phenotype meta analyzed
across super populations (Table 18). Although no SNPs reached genome wide significance for
these phenotypes, suggestive markers with p-values below 5x10-5 were identified (Table 18 and
19). The majority of genomic bins with SNPs possessing the lowest p-values were located on
chromosome 4 (rs10024355). The SNP with the lowest p-value for probable-PTSD is considered
common and were within or near KCNIP, which is a protein coding gene. The direction of effect
for rs10024355 with a minor allele of ‘a’ was negative for the probable-PTSD phenotype. The
regional association plots (Figure 18) revealed that rs10024355 was in strong LD with surrounding
markers for probable-PTSD.
GWAS results for IPV. No evidence of genomic inflation was identified for the IPV
phenotype (λ = 1.013), thus, no adjustments were made. No SNPs had p-values that reached
genome-wide significance for the IPV phenotype (Table 19). The majority of genomic bins with
SNPs possessing the lowest p-values were located on chromosome 6 (rs2764203). The SNPs with
the lowest p-value for IPV were also considered common and were within or near the two protein
coding genes of SNRPC and UHRF1BP1 (other surrounding genes included C6orf106, 1BP,
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ANKS1A, and TAF1). The direction of effect for rs2764203 with a minor allele of ‘a’ was positive
for the IPV phenotype. The regional association plots (Figure 19) revealed that rs2764203 was in
strong LD with nearby SNPs for IPV.
GWAS results summary. Two phenotypes (NMUPD-R, TE) were not examined due to
limited power to detect genetic effects; however, GWAS were conducted for the phenotypes of
NMUPD-E, probable-PTSD, and IPV. Five genomic bins containing at least one genome wide
significant SNP passing FDR correction were identified for NMUPD-E. Significant SNPs were
within or nearby PAK7 and LINC00922. The majority of significant SNPs possessed the minor
allele (‘t’ rather than ‘c’ for rs142738451 and rs73241778; ‘a’ rather than ‘g’ for rs9578774,
rs138647543, and rs74901044) that was negatively associated with NMUPD-E case status and are
considered rare; however, one SNP possessed a minor allele (‘a’ rather than ‘g’) that was positively
associated with case status and considered a common variant. Inspection of regional association
plots revealed that only one SNP (rs138647543) was in high LD with surrounding markers,
indicating that multiple other SNPs within this region may be associated with the NMUPD-E
phenotype or the actual causal variant. Although genome wide significant SNPs were identified
for the NMUPD-E phenotype, no genome wide significant SNPs were identified for probablePTSD or IPV phenotypes.

However, suggestive SNPs within the KCNIP4 gene for probable-

PTSD and SNRPC and UHRF1BP1 genes (other surrounding genes included C6orf106, 1BP,
ANKS1A, and TAF1) for IPV were identified.
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Table 16. Sample sizes, number of markers, lambdas, and lambda 1000 information for GWAS
results of experimental non-medical use of prescription drugs, probable posttraumatic stress
disorder, and interpersonal violence phenotypes.

N

AFR

AMR

EAS

EUR

SAS

Metal

1325

573

545

2956

442

>1000

14443339

8022304

6807786

10327163

7311043

16591911

1.018

1.032

1.003

1.014

1.006

n
NMUPD-E

markers
λ

1.003

λ1000

1.001

1.003

1.005

1.001

1.002

1.000

N

1139

488

435

2548

355

>1000

13865404

7699002

6526178

10123812

6924055

16257569

λ

1.002

1.017

1.020

.999

1.006

1.011

λ1000

1.000

1.003

1.004

1.000

1.001

1.000

N

1314

568

542

2949

441

>1000

14430840

8009501

6813103

10328147

7311426

16908762

λ

1.010

1.022

1.015

1.002

1.014

1.013

λ1000

1.002

1.003

1.003

1.001

1.002

1.000

n
Probablemarkers
PTSD

n
IPV

markers

Note: NMUPD-E = experimental non-medical use of prescription drugs, probable-PTSD = probable posttraumatic
stress disorder, IPV = interpersonal violence.
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Figure 7: Q-Q plot of experimental non-medical use of prescription drugs results within each super
population and meta-analyzed across super populations.

Note: The expected distribution of p-values is shown on the x-axis, while the observed distribution of p-values from
GWAS of experimental non-medical use of prescription drugs is shown on the y-axis. All p-values are represented as
–log10(P). The red lines to the sides represent 95% confidence intervals.
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Figure 8.

Manhattan plot for meta-analyzed results of experimental non-medical use of

prescription drugs.

Note: This figure plots the –log10(p) values of associations for experimental non-medical use of prescription drugs
by chromosome. The red line represents genome-wide significance (p = 5x10E-08), while the blue line indicates
nominal significance (p = 10-5).
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Figure 9: Q-Q plot of probable posttraumatic stress disorder meta-analyzed results within each
super population and meta-analyzed across super populations.

Note: The expected distribution of p-values is shown on the x-axis, while the observed distribution of p-values from
GWAS of probable posttraumatic stress disorder is shown on the y-axis. All p-values are represented as –log10(P).
The red lines to the sides represent 95% confidence intervals.
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Figure 10. Manhattan plot for meta-analyzed results of probable posttraumatic stress disorder.

Note: This figure plots the –log10(p) values of associations for probable posttraumatic stress disorder by chromosome.
The red line represents genome-wide significance (p = 5x10E-08), while the blue line indicates nominal significance
(p = 10-5).
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Figure 11: Q-Q plot of interpersonal violence results within each super population and metaanalyzed across super populations.

Note: The expected distribution of p-values is shown on the x-axis, while the observed distribution of p-values from
GWAS of interpersonal violence is shown on the y-axis. All p-values are represented as –log10(P). The red lines to
the sides represent 95% confidence intervals.
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Figure 12. Manhattan plot for meta-analyzed results of interpersonal violence.

Note: This figure plots the –log10(p) values of associations for interpersonal violence by chromosome. The red line
represents genome-wide significance (p = 5x10E-08), while the blue line indicates nominal significance (p = 10-5).
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Table 17. Annotated top 20 clusters of SNPs for experimental non-medical use of prescription
drugs phenotype using results from meta-analyses.
Chr

Start BP

End BP

Min P

Min Q

Genes

Local genes

22753786
9541486

# of
SNPs
1
1

3
20

22753786
9541486

6.13E-09
7.12E-09

0.03
0.03

None
PAK7

25301501

25313166

3

1.02E-08

0.03

None

16

65445551

65463312

3

1.02E-08

0.03

LINC00922

11
20
8
20
15

134390129
9552989
125229715
9521828
69953475

134392003
9557791
125230709
9527903
69956198

2
2
2
5
3

1.53E-08
2.57E-08
3.10E-08
4.38E-08
7.64E-08

0.04
0.05
0.05
0.07
0.08

None
PAK7
None
PAK7
None

16

65424997

65434757

3

8.18E-08

0.08

LINC00922

8
12
16
8

125171598
66130101
65474561
55755894

125195866
66143059
65540007
55755894

18
3
22
1

9.10E-08
1.69E-07
1.78E-07
1.88E-07

0.08
0.11
0.11
0.11

AK057332
None
LINC00922
None

1
9
8

1390226
104478986
2174033

1396458
104500980
2175104

2
5
4

2.89E-07
2.23E-07
2.40E-07

0.11
0.11
0.11

ATAD3C
GRIN3A
None

None
LAMP5,PAK7
ATP12A,RNF1
7
JB153694,LIN
C00922
AK095081,LO
C283177
LAMP5,PAK7
AK057332
LAMP5,PAK7
AK097902
JB153694,LIN
C00922
AK057332,FE
R1L6
RPSAP52
None
None
ANKRD65,AT
AD3B,ATAD3
C,MRPL20,TM
EM88B,VWA1
None
AX747124

13

9

134478679

134479696

3

3.16E-07

0.11

RAPGEF1

11

458441

540005

80

3.25E-07

0.11

HRAS,LRR
C56,PTDSS
2,RNH1

5

171596395

171603750

4

3.47E-07

0.11

STK10

Note: BP = base position; Chr = chromosome number; Min = minimum.
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None
ANO9,AX7483
30,BC031953,
C11orf35,HRA
S,LOC143666,
LRRC56,Metaz
oa_SRP,MIR21
0,MIR210HG,
PHRF1,PTDSS
2,RASSF7,RN
H1,SIGIRR
EFCAB9,STK1
0,UBTD2

Table 18. Annotated top clusters of SNPs for probable posttraumatic stress disorder using results
from meta-analyses.
Chr

Start BP

End BP
153957512
162254016
21250060
190031837
15518328
78098586
18285577

# of
SNPs
2
4
26
1
3
1
2

2
3
4
4
10
10
12

153957506
162247037
21228079
190031837
15513474
78098586
18276779

14
18

102804409
70493335

102804409
70493335

1
1

Min P

Genes

Local genes

1.06E-06
1.98E-07
9.00E-08
1.85E-07
4.01E-07
1.27E-07
5.39E-07

Min
Q
0.43
0.15
0.15
0.15
0.26
0.15
0.29

None
None
KCNIP4
None
None
C10orf11
None

1.19E-06
8.99E-07

0.46
0.38

ZNF839
NETO1

None
None
None
None
ITGA8
None
RERGL
CINP,MOK,T
ECPR2,TRNA
_Ile,ZNF839
None

Note: BP = base position; Chr = chromosome number; Min = minimum.
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Table 19. Annotated top clusters of SNPs for interpersonal violence using results from metaanalyses.
Chr

Start BP

End BP

# of
SNPs

Min P

Min
Q

Genes

Local genes

6

34708901

34724815

6

1.01E-07

0.17

None

C6orf106,SNRP
C,UHRF1BP1

6

34738990

34747409

4

1.08E-07

0.17

SNRPC

6

34777401

34795102

7

1.15E-07

0.17

UHRF1BP1

6

34759502

34763982

2

1.33E-07

0.17

UHRF1BP1

SNRPC,UHRF
1BP1
SNRPC,UHRF
1BP1
SNRPC,UHRF
1BP1

6

34805296

34825662

8

1.69E-07

0.17

UHRF1BP1

ANKS1A,TAF11
,UHRF1BP1

6
2
12
6
6

34689126
6794065
117381060
165895697
165906181

34692474
6794065
117381060
165895697
165906181

2
1
1
1
1

1.92E-07
4.98E-07
5.45E-07
8.26E-07
8.43E-07

0.17
0.29
0.31
0.43
0.43

None
None
FBXW8
PDE10A
PDE10A

12

117425695

117425695

1

9.09E-07

0.44

FBXW8

C6orf106,SNR
PC
None
None
None
None
AK055849,FB
XW8

6

34623905

34623905

1

1.02E-06

0.48

C6orf106

None

Note: BP = base position; Chr = chromosome number; Min = minimum.
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Table 20. Significant SNPs associated with the experimental non-medical use of prescription drugs phenotype, following false
discovery rate correction.
SNP

rs142738451
rs73241778
rs9578774
rs138647543
rs74901044

CHR

A1

A2

INFO

MAF

HWE

z-score

p

Direction

Q_1k

3
20
13
16
11

t
t
a
a
a

c
c
g
g
g

0.612
0.586
0.650
0.929
0.749

0.016
0.021
0.020
0.030
0.101

1
0.436
1
1
1

5.813
-5.788
-5.728
-5.728
-5.658

6.13E-09
7.12E-09
1.02E-08
1.02E-08
1.53E-08

+????
-????
-????
-????
-????

0.033
0.033
0.034
0.034
0.042

Note: CHR = chromosome; A1 = allele 1; A2 = allele 2; INFO = imputation quality; MAF = minor allele frequency; HWE = Hardy Weinberg Equilibrium; p =
p-value; Q_1k = q-value.
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Table 21. Suggestive SNPs associated with the probable posttraumatic stress disorder and interpersonal violence phenotypes.
SNP

CHR

A1

A2

INFO

MAF

HWE

z-score

p

Direction

Q_1k

Probable-PTSD
rs10024355
4
a
g
0.950
0.098
0.822
-5.346
9.00E-08
----0.150
IPV
rs2764203
6
a
g
0.997
0.154
0.888
5.324
1.01E-07
++?++
0.173
Note: Probable-PTSD = probable posttraumatic stress disorder, IPV = interpersonal violence, CHR = chromosome; A1 = allele 1; A2 = allele 2; INFO =
imputation quality; MAF = minor allele frequency; HWE = Hardy Weinberg Equilibrium; p = p-value; Q_1k = q-value.
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Figure 13: Locus Zoom plot for rs142738451 on chromosome 3, associated with experimental
non-medical use of prescription drugs.

Note: Associations for SNPs near rs14273851 (the SNP with the smallest p-value [reference SNP]) are presented in
this plot. The x-axis shows the position of each SNP, while the y-axis reflects the p-value, transformed to –log10(p).
Magnitude of LD for each SNP with the index SNP (r2) is represented by different colors (red being highest and blue
being lowest).
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Figure 14: Locus Zoom plot for rs73241778 on chromosome 20, associated with experimental
nonmedical use of prescription drugs.

Note: Associations for SNPs near rs73241778 (the SNP with the smallest p-value [reference SNP]) are presented in
this plot. The x-axis shows the position of each SNP, while the y-axis reflects the p-value, transformed to –log10(p).
Magnitude of LD for each SNP with the index SNP (r2) is represented by different colors (red being highest and blue
being lowest).
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Figure 15: Locus Zoom plot for rs9578774 on chromosome 13, associated with experimental
non-medical use of prescription drugs.

Note: Associations for SNPs near rs9578774 (the SNP with the smallest p-value [reference SNP]) are presented in
this plot. The x-axis shows the position of each SNP, while the y-axis reflects the p-value, transformed to –log10(p).
Magnitude of LD for each SNP with the index SNP (r2) is represented by different colors (red being highest and blue
being lowest).
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Figure 16: Locus Zoom plot for rs138647543 on chromosome 16, associated with experimental
non-medical use of prescription drugs.

Note: Associations for SNPs near rs138647543 (the SNP with the smallest p-value [reference SNP]) are presented in
this plot. The x-axis shows the position of each SNP, while the y-axis reflects the p-value, transformed to –log10(p).
Magnitude of LD for each SNP (r2) is represented by different colors (red being highest and blue being lowest).
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Figure 17: Locus Zoom plot for rs74901044 on chromosome 11, associated with experimental
non-medical use of prescription drugs.

Note: Associations for SNPs near rs74901044 (the SNP with the smallest p-value [reference SNP]) are presented in
this plot. The x-axis shows the position of each SNP, while the y-axis reflects the p-value, transformed to –log10(p).
Magnitude of LD for each SNP with the index SNP (r2) is represented by different colors (red being highest and blue
being lowest).
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Figure 18: Locus Zoom plot for rs10024355 on chromosome 4, associated with probable
posttraumatic stress disorder.

Note: Associations for SNPs near rs10024355 (the SNP with the smallest p-value [reference SNP]) are presented in
this plot. The x-axis shows the position of each SNP, while the y-axis reflects the p-value, transformed to –log10(p).
Magnitude of LD for each SNP with the index SNP (r2) is represented by different colors (red being highest and blue
being lowest).
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Figure 19: Locus Zoom plot for rs2764203 on chromosome 4, associated with interpersonal
violence.

Note: Associations for SNPs near rs2764203 (the SNP with the smallest p-value [reference SNP]) are presented in
this plot. The x-axis shows the position of each SNP, while the y-axis reflects the p-value, transformed to –log10(p).
Magnitude of LD for each SNP with the index SNP (r2) is represented by different colors (red being highest and blue
being lowest).
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Discussion
The aims of the present study were threefold: 1) examine the longitudinal associations
between NMUPD (-E, -R) and TE, 2) determine the SNP-based heritability of the NMUPD-E,
NMUPD-R, and TE phenotypes via GCTA, and 3) identify specific variants associated with
NMUPD-E, probable-PTSD, and IPV phenotypes by means of GWAS methodologies. Additional
follow-up analyses were also conducted with the potentially more refined phenotypes of probablePTSD and IPV (i.e., greater phenotypic specificity, greater balance between cases and controls).
The present discussion is divided broadly into phenotypic and genotypic sections which each
contain relevant discussion of results, limitation, and clinical implications.
Phenotypic Discussion
Prevalence of NMUPD (-E, -R). Prior to conducting longitudinal analyses, the prevalence of
each phenotype (NMUPD-E, NMUPD-R, TE, and probable-PTSD) was calculated. Both
NMUPD-E and NMUPD-R remained relatively stable across assessment periods with estimates
varying between approximately 16.7%-17.9% and 7.0%-8.8%, respectively. Within the extant
literature, prevalence estimates vary widely across studies due to definitional variability (e.g.,
recreational use vs. DSM-IV-TR criteria [abuse/dependence]) and differences in samples assessed
(Barrett et al., 2008); however, the prevalence identified within the present sample are consistent
with those presented by SAMHSA (2016) for the 18-25-year-old age group (~15% lifetime use,
paralleling the present definition of experimental use). Moreover, studies assessing lifetime use
derive similar prevalence estimates (ranging between approximately 13% and 25%) when focused
specifically on college student samples (McCabe et al., 2016; McCabe et al., 2009; Meisel &
Goodie, 2015). It is critical to note that in addition to definitional variability and differences in
sample characteristics, that the binning of illicit substances with NMUPD in assessment
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measures/analyses also contributes to the variation within rates demonstrated across studies (please
see commentary regarding these concerns by Boyd & McCabe, 2007). The present study also
suffers from this concern which is a significant limitation. Additional research is warranted to
further discern the prevalence rates of NMUPD independent of other forms of substance use.
Comparing the prevalence identified for NMUPD-R in the present study (7.0%-8.8%
depending on year) in relation to rates identified within the literature is also methodologically
challenging. The definition used in the assessment of NMUPD-R in the present study focused on
six or more uses within one’s lifetime (or past 12 months depending on assessment period).
Although this variable may serve as a proxy for potentially problematic use, it is not thorough
enough to adequately capture consequences associated with use or the DSM-5 (APA, 2013) criteria
for a substance use disorder. However, given that adolescents/young adults are likely in the
beginning, yet critical, stages of their potential substance use (Chambers, Taylor, & Potenza,
2003), it may be helpful to identify an index of use that may be predictive of future problematic
NMUPD. Additional examination is warranted to elucidate the potential utility of an intermediate
phenotype that may successfully predict problematic use.
Prevalence of each form of NMUPD (sedatives, stimulants, and opioids). Stimulants were
the most frequently misused substance within this sample, followed by opioids and then sedatives.
A decreasing trend over time for sedatives and opioids (experimental [8.2% prior to college to
5.3% sophomore year, 5.6% prior to college to 4.3% sophomore year, respectively] and repeated
use [2.6% prior to college to 1.9% sophomore year, 1.9% prior to college to 1.5% sophomore year,
respectively]) was present; however, stimulant use (experimental and repeated use [13.5% prior to
college to 15.8% sophomore year, 5.6% prior to college to 7.4% sophomore year, respectively])
increased across time points. Stimulant use has been noted to be a particularly relevant concern
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among college aged students (McCabe, West, Teter, & Boyd, 2014; Ford & Pomykacz, 2016).
Given the potentially competitive nature of academia and pressure to perform, students may resort
to external means of increasing focus/attention in order to improve academic performance (Arria
et al., 2010). Studies explicitly examining stimulant use motives have noted a link between both
interest in enhanced performance and perceptions of undiagnosed attentional difficulties with
stimulant misuse (Judson & Langdon, 2009). Moreover, non-medical stimulant use among
students has also been associated with greater likelihood of skipping classes and poly substance
use (Arria et al., 2008, Arria et al., 2010). Although less common, heightened social pressure
regarding weight and body image within this age range may also contribute to stimulant use as a
weight management tool (Rabiner et al., 2009; Jeffers, Benotsch, & Koester, 2013). Thus, future
studies would benefit from not only assessing specific forms of NMUPD, but motivations behind
such use. Moreover, substance use and motives may show critical patterns by developmental
stage. Specifically, stimulant use is more prevalent among adolescents/young adults. Increased
exposure to other substances (e.g., sedatives and opioids) may occur in later developmental periods
(greater than 30 years of age, Han et al., 2017) potentially given the heightened opportunity to
experience pain and/or stressful life events as a function of time. Additional disaggregated
examination of NMUPD is necessary to further explicate differential associations between specific
forms of prescriptions drug use and environmentally/developmentally influenced motives.
Prevalence of TE and probable-PTSD. Prevalence of TE demonstrated within the present
study are higher than recent prevalence identified in epidemiological studies of TE (~85% in the
present study compared to ~70% in an epidemiological study of adults by Benjet et al., 2015).
However, the rate identified within the present study does fall within the range of prevalence
estimates (52% - 94%) identified in previous studies examining the prevalence of trauma exposure
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among college students specifically (Watson & Haynes, 2007; Vrana & Lauterbach, 1994; Owens
& Chard, 2006; Ford & Arrastia, 2008). The lower prevalence identified in some studies has been
linked to differences regarding what constitutes an event being classified as traumatic (e.g., not
including unexpected/sudden death as a traumatic; Frazier et al., 2009). It is important to note that
the report of natural disaster is likely inflated in the present study due to a mild earthquake that
occurred within the area in 2011, thereby impacting the overall reporting of TE (85.5% including
natural disaster vs. 76.8% excluding natural disaster occurring prior to college). Prevalence of IPV
(approximately 20% across freshman and sophomore year within the present sample) was similar
to rates identified within the extant the literature concerning exposure among college students
(Coker, Follingstad, Bush, & Fisher, 2016). The high prevalence of trauma, particularly IPV,
among college students highlights the need for continued investigation of correlates and efforts
aimed at prevention and intervention post exposure.
The probable-PTSD prevalence identified within the preset study, as assessed by a single item
screener within the present study (39.1% collapsed across all time points), was higher than that
identified within the literature for PTSD diagnosis (13.6% of those reporting symptoms based upon
their self-reported “worst event”; Breslau et al., 2004). Moreover, the screener item used within
the present study merged all of the Primary Care Posttraumatic Stress Disorder Screen (PC-PTSD;
Prins & Ouimette, 2004) items into a single item, thus likely contributing to the inflated rates
identified within the present study vs. those identified when utilizing the four item screener of
probable-PTSD (26.4%; Prins et al., 2016). The Life Experiences and Alcohol Use S4S spin-off
study (P50AA022537 PI Amstadter, F31AA025820 PI Hawn) utilized the full Posttraumatic Stress
Disorder Checklist (Weathers et al., 2013), which mirrors PTSD symptoms specified by the DSM5 (APA, 2013), and derived a probable PTSD prevalence of 15.8%. Thus, there are significant
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concerns associated with specificity of the screener item utilized in the present study in that it may
capture a large proportion of false positives. However, sensitivity to sub clinical distress may
remain useful in identifying those at heightened risk of substance misuse. Future research
endeavors would benefit from a more refined approach in assessing post traumatic symptoms.
Longitudinal Analyses of TE/probable-PTSD and NMUPD (experimental and repeated
use). Given the cross-sectional associations identified within the literature between NMUPD and
TE/probable-PTSD (Walsh et al., 2014; Ham et al., 2016), we aimed to further clarify the
directionality of these relationships by conducting longitudinal comparisons to test multiple
models of comorbidity. Specifically, we compared a saturated model which included all potential
paths (sex and cohort included as covariates) to two Longitudinal Effects models (i.e., selfmedication model and high risk model). Broadly, and contrary to our hypothesis that the selfmedication model (TE/probable-PTSD precedes NMUPD [-E, -R]) would best fit the data, the
longitudinal models consistently yielded results that supported the high risk hypothesis, which
posits that substance use may place an individual at risk for experiencing distress (perhaps via
heightened risk of being exposed to trauma; Cottler et al., 1992). Evidence of the high risk model
has been identified within the literature broader substance use and TE/PTSD literature (Cottler et
al., 1992; Kilpatrick, Acierno, Resnick, Saunders, & Best, 1997; Haller & Chassin, 2014).
However, results from some of the aforementioned studies (Kilpatrick et al., 1997; Haller &
Chassin, 2014) additionally provide support for the self-medication model which posits that
individuals use substances as a method of coping with negative affect (negative reinforcement
model; Keane & Kaloupek, 1997). Thus, the casual pathways between TE/PTSD and substance
use may be multifactorial and warrant further study.
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Although the self-medication model is intuitively appealing (substances provide an escape
from distress and delayed consequences may be discounted in an effort to achieve immediate relief,
resulting in a cycle of sustained use), it is likely problematic to subsume all forms of substance use
post exposure under this umbrella (Khantzian, 1997; Lembke, 2012). Moreover, although the selfmedication framework is frequently considered the prevailing means of conceptualizing
comorbidity, the preponderance of evidence is inconsistent and does not fully support this
hypothesis. This literature is wrought with methodological limitations, including few longitudinal
designs, analyses conducted under the assumption of self-medication (e.g., substance use set as an
outcome in mediator/moderator analyses [Tomaka, Morales-Monks, & Shamaley, 2017; Ullman,
Relyea, Peter-Hagene, and Vasquez, 2013), and lack of consideration of confounding factors (e.g.,
comorbid disorders, trauma type, sociodemographic variables). Similar concerns exist across
various forms of substance use and highlight continued uncertainty with regard to causal
directionality with support existing for multiple pathways (Kessler, 2004; Kassel, Stroud, &
Paronis, 2003; Goldenberg et al., 1995).

Thus, rather than relying on the self-medication

hypothesis, consideration of multiple etiological pathways is necessary to further clarify our
understanding of putative causal associations between TE/PTSD and substance use broadly.
To our knowledge, the present study represents the first study to examine this association
specifically with regard to NMUPD and support was not present for the self-medication
hypothesis. It may be that this causal phenotypic pathway may be associated with the form of
substance use examined (e.g., alcohol; Leeis et al., 2010). However, given the findings of the
present study, greater consideration of the high risk model of comorbidity is warranted. Rather
than framing substance use and TE/PTSD comorbidity within the context of the self-medication
hypothesis, the field would benefit from further conceptualization and longitudinal testing of this
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assumption. It is important to note that the follow-up analyses examining longitudinal associations
between NMUPD-R and IPV provided some support for the self-medication model (significantly
different from the saturated model), however, the fit was superior for the high risk model. Taken
together, the findings highlight the relevance of the high risk model while indicating that
consideration of the self-medication model remains necessary.
Consistently strong and significant autoregressive estimates were identified within each model.
These results suggest that NMUPD (-E, -R) prior to college is a significant predictor of NMUPD
(-E, -R) in the future. This has been demonstrated within the broader substance misuse literature
(Jordan & Andersen, 2017; Schulenberg et al., 2017) and indicates that assessment of prior use
may serve as a method of identifying those at heightened risk of use in the future. Moreover, the
strong path estimates linking prior TE to future TE (a pattern which was also present when
examining IPV and probable-PTSD) supports the extensive revictimization literature (MessmanMoore & Long, 2000; Classen, Palesh, & Aggarwal, 2005). Given the heightened likelihood of
revictimization post exposure, the importance for assessing trauma history is underscored.
Demographic factors were also relevant to risk of TE, probable-PTSD, and both forms of
NMUPD. Associations between cohort and each phenotype were inconsistent across models;
however, sex was consistently associated with all three phenotypes. Specifically, female sex was
positively associated with probable-PTSD while male sex was associated with greater risk of
NMUPD. Differential findings based on sex regarding probable-PTSD are consistent with the
extant literature (Breslau, 2002). The present findings are consistent with some studies regarding
the associations between male sex and NMUPD (McCabe et al., 2014); however, the literature on
this topic is mixed (Simoni-Wastilla et al., 2004). Additional examination of demographic factors
in the association between TE/probable-PTSD and NMUPD are warranted, particularly given that
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consideration of sex in addition to other potential risk factors may serve as a useful means of
identifying vulnerable populations.
Longitudinal Analyses of IPV/natural disaster and NMUPD (-E, -R). Despite the ability
to examine the relationship between TE/probable-PTSD and NMUPD longitudinally, the
assessment of these phenotypes was relatively limited in the present study. Thus, efforts were made
to refine analyses by restricting the trauma exposure phenotype to IPV. The same pattern of
findings was identified as the prior models reviewed. However, the effect sizes within the
autoregressive components of the models were stronger (IPV pre college to IPV in freshman year
and sophomore year) which is consistent with the literature regarding revictimization (Walker et
al., 2019; Breitenbecher, 2001). Additionally, the NMUPD-R and IPV model revealed some
support for the self-medication model (significantly different from the saturated model); however,
similar to the previously described modeling results, the fit was superior for the high risk model.
However, these findings indicate that multiple pathways likely play a role in the comorbidity
between NMUPD and IPV and consideration of the various individual factors that may contribute
to each specific pathway is necessary.
Another potential limitation addressed includes the assessment of TE which may be somewhat
inflated due to higher than usual report of natural disaster associated with a low grade earthquake
experienced within the area in 2011. Although this event was likely not considered traumatic by
most, report of this event inflated TE rates overall which may have obscured the relationship
between TE/probable-PTSD and NMUPD (-E, -R). Given that natural disasters may be considered
more random in nature than other forms of traumatic events, it may be expected that if the
longitudinal examination were restricted to the association between natural disaster and NMUPD
we would either be unable to identify clear support for any specific model or greater support for
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the self-medication model. When these additional analyses were conducted for NMUPD-E, the
pattern of findings was not consistent with previous models such that all paths between NMUPDE and natural disaster. Although this may serve as a form of general model validation, it is critical
to note that prior research suggests that exposure to trauma is not entirely random and that certain
factors (e.g., personality) may increase risk of trauma exposure with underlying genetic factors
influencing environment selection (Jang et al., 2003). Moreover, consistent with this literature,
the model examining the longitudinal association between NMUPD-R (the more refined NMUPD
phenotype) and natural disaster provided further support for the high risk model.
Phenotypic Analyses Limitations. Given the focus on college students, there are numerous
concerns regarding generalizability; however, the sample is generalizable to the home institution
(VCU) as a whole (Dick et al., 2014). It is also critical to note that the analyses within the present
study focused on specific and narrow windows of time. Albeit longitudinal, the timeframe is
truncated and thus introduces limitations in generalizing across longer durations of time.
Additional examination throughout college and into adulthood is warranted. Moreover, the
associations identified within the present study may be less applicable to older individuals. For
example, young adults may be more impulsive and willing to engage in in riskier activities (Romer,
2010; Rolison, Hanoch, Wood, & Liu, 2013) than those in later developmental periods while selfmedication may be more relevant at later developmental periods. It is also important to note
attrition as a limitation, a common issue present in longitudinal research (Barry et al., 2005; Miller
& Wright, 1995). Future research would also benefit from focusing on specific classes of
prescription medications as this may be a key factor in determining the relevant model of
comorbidity. For example, stimulant misuse may be more relevant to the high risk model whereas
the self-medication model may better capture the association between opioid misuse and
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TE/probable-PTSD. More broadly, considering other forms of substance use (e.g., alcohol use) is
necessary as continued efforts are made to determine the relationships between TE/PTSD and
substance use phenotypes. For example, polysubstance use may be driving associations between
these variables, therefore additional research is necessary to control for other forms of substance
use or parse out unique effects related to substance type. Finally, more thorough phenotypic
assessment overall would aid in further understanding of the relationship between NMUPD and
TE/probable-PTSD. Single items aimed at adequately assessing these complex phenotypes
(NMUPD and PTSD) possess a significant concern and additional effort placed on capturing
consequences of misuse (along the substance use disorder continuum) and probable-PTSD
symptoms via multiple items would greatly improve future analyses of these phenotypes.
Phenotypic summary and clinical implications. Overall, the phenotypic analyses further
support literature suggesting that NMUPD, TE, and trauma related symptoms are concerns
relevant to college aged students (McCabe, West, & Wechsler, 2007; Breslau et al., 1998; Read,
Ouimette, White, Colder & Farrow, 2011). Given the high prevalence of these phenotypes,
consistent screening of substance use, specifically NMUPD, and trauma history may aid in
identification of individuals at particularly heightened risk of substance use difficulties and
revictimization. Students may be less inclined to report this form of substance use given
definitional uncertainty (Boyd & McCabe, 2008). Moreover, students with a trauma history may
avoid or delay disclosing their experience particularly if it is interpersonal in nature (Smith et al.,
2000). Thus, direct assessment may prove beneficial in providing early intervention to individuals
that would otherwise not receive it. Results from the longitudinal models support the high risk
hypothesis (although some limited support for the self-medication model was also identified) and
these findings have important clinical implications for prevention and intervention efforts. Given
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the associations noted, inclusion of assessment and psychoeducation regarding TE and PTSD when
an individual presents with a history of NMUPD may aid in the identification of at risk individuals
and serve as a form of risk reduction. Consideration of demographic factors, particularly sex, may
also prove beneficial in identifying those at heightened risk, in light of the sex differences
identified within the present study (i.e., females at heightened risk of probable-PTSD; males
associated with NMUPD).
Although the present study provides support for the high risk hypothesis, the associations
between NMUPD (in addition to substance use more broadly) and TE/PTSD are likely
multifactorial in nature and more emphasis should be placed on understanding the factors that may
contribute to these differential pathways (e.g., personality factors, emotion regulation). NMUPD
and TE/PTSD do not occur within a vacuum, thus conceptual and analytical inclusion of other
variables potentially implicated in the development, maintenance, and interrelations between each
is critical in better understanding the complex relationship between NMUPD and TE/PTSD. As
statistical approaches become more sophisticated, the field is increasingly more equipped to
address these complex empirical questions. One potential method of elucidating the association
between NMUPD and TE/PTSD includes incorporating propensity score matching methodologies
(Rosenbaum & Rubin, 1983), which would control for a multitude of covariates (e.g., personality,
peer deviance), providing a more refined examination of the association between these phenotypes.
Moreover, given that many studies have conducted analyses under the assumption of the selfmedication model, it may prove beneficial to re-analyzed this existing data to compare other
potential models of comorbidity. Support may exist for the high risk model within these datasets;
however, such associations may have been overlooked due to the emphasis on the self-medication
model.
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A multitude of treatment options exist aimed at ameliorating symptoms of substance use (e.g.,
motivational interviewing), distress post trauma exposure (e.g., prolonged exposure) and
comorbidity between the two (Seeking Safety, Najavitz, 2002; Concurrent Treatment of PTSD and
SUDs using Prolonged Exposure [COPE], Back et al., 2014). Greater emphasis over time has
been placed on prevention, particularly with regard to interpersonal violence. Initiatives include
bystander intervention and mandatory education regarding sexual assault (Cares et al., 2014; Zapp,
Buelow, Soutiea, Berkowitz, & Dejong, 2018). Prevention efforts have also been aimed at
reducing substance use among adolescents via parent and teacher interventions (Webster-Stratton
& Taylor, 2001; Kuntsche & Kuntsche, 2016). Given the temporal associations noted within the
present study, increased focus on substance use prevention may aid in reduction of TE and
associated sequelae.
Genotypic Discussion
Another important consideration in the etiology of these phenotypes includes a third factor
that may serve as a potential pathway contributing to the co-occurrence of substance use and
TE/PTSD. For example, Breslau and colleagues (2003) did not find evidence to support the selfmedication hypothesis but suggested that a third factor may be contributing to the comorbidity
between PTSD and substance use. One such factor could include genetic influences, thus, the
present study aimed to determine if NMUPD (-E, -R), TE, and probable-PTSD were heritable via
GCTA methodologies and to identify specific variants that may be associated with each of these
phenotypes of interest.
SNP-based heritability of NMUPD (-E, -R) and TE/probable-PTSD. Univariate GCTAs
were conducted for each phenotype (NMUPD-E, NMUPD-R, TE, probable-PTSD) within each
ancestral group (AFR, AMR, EAS, EUR, and SAS) and then meta-analyzed. GCTA is a SNP
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based method of estimating the heritability of a particular trait among unrelated individuals. This
is accomplished by assigning a code of 0 or 1 based on case status (control or case, respectively)
and creating a genetic relatedness matrix whereby correlations are computed among individuals
and then regressed onto the phenotype of interest (Yang et al., 2011). Similar to other genetic
methods, GCTA has limitations with regard to not accounting for rare variants and being sample
dependent. Moreover, the use of GCTA to examine binary traits (case/control status) is also a
limitation given that this method is better suited for phenotypes more quantitative in nature (Yang
et al., 2011). Use of GCTA for binary traits violates multiple assumptions under the restricted
maximum likelihood method including (a) that the distribution underlying the trait is normally
distributed and (b) that genetic and environmental influences are not correlated. The traits
examined in the present study are not normally distributed and are correlated; therefore, the
estimates derived from GCTA are likely biased. Thus, although the benefit of GCTA lies within
the ability to apply the analyses to non-related individuals (which proves beneficial in obtaining
adequate sample sizes), limitations remain and may remain even when all assumptions have been
met per analyses conducted by Kumar and colleagues (2016). These aforementioned limitations
may contribute to the gap between estimates derived from GCTAs and twin studies. The estimates
identified within the twin literature are typically higher than those identified via GCTA (for
example, 42-58% heritability when utilizing twin methodologies for multiple forms of substance
use vs. 10-30% when GCTA is employed; Vrieze, McGue, Miller, Hicks, & Iacono, 2013). This
has been a topic of ongoing debate within the field and is likely due to some of the limitations
described above and that GCTA only takes into account additive effects, thus excluding effects
associated with dominance, epistasis (genetic interactions), and gene by environment interactions
(Wray et al., 2013).
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Within the present study, meta-analyses revealed significant SNP-based heritability (h2SNP)
estimates for NMUPD-E (h2SNP = .15, SE = .01), NMUPD-R (h2SNP = .22, SE = .01), and IPV (h2SNP
= .05, SE = .01). Moreover, h2SNP estimate identified for NMUPD-E was significantly lower than
that derived for NMUPD-R. However, these estimates should be considered within the context of
limited power as demonstrated by the power calculations. SNP based heritability estimates could
not be derived for the probable-PTSD phenotype, likely due to limited power. Limited power is a
common concern within the field of genetics. Thus, consortia based approaches are on the rise
which include much larger sample sizes (>20,000 participants), greatly improving the ability to
determine the heritability of substance use phenotypes (e.g., alcohol use; Walters et al., 2018) and
trauma related phenotypes (e.g., PTSD; Nievergelt et al., 2018).
GCTAs of substance use more broadly consistently fall within the 25%-36% range (Palmer et
al., 2015).

Moreover, Vrieze and colleagues (2013) identified h2SNP estimates within

approximately the 10-30% range depending on substance use phenotype (21% for alcohol
dependence, 36% nicotine use, and 45% for illicit drug dependence). The SNP based heritability
estimates for NMUPD in the present study fell close the ranges identified within the literature,
particularly as the phenotype became more refined (lifetime use [NMUPD-E] vs. repeated use
[NMUPD-R]). This benefit in refined phenotype can be seen in other GCTAs of substance use
such as cannabis initiation age (Minica et al., 2015) which identified a significant SNP-based
heritability estimate of 25%. Use of more refined assessment methods (e.g., DSM criteria,
problematic use) will likely provide a more nuanced picture of heritability as it relates to this
specific form of substance use. To our knowledge, no h2SNP estimates have been identified for
NMUPD and future research endeavors would benefit from examination in very large samples, in
addition to investigation of the potential overlap between NMUPD and other substances and
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possible overlap between TE/probable-PTSD and NMUPD (bi-variate GCTAs). Bi-variate GCTA
provides an opportunity to not only examine the genetic variance within a specific trait but also
the co-variance between two traits, thereby serving as an index of shared common genetic variance
(Lee, Yang, Goddard, Visscher, & Wray, 2012). Moreover, additional statistical approaches (e.g.,
Cholesky decomposition) could aid in determining whether a latent common factor (e.g., genetic
influences) accounts for the covariance shared between phenotypes (Neale & Cardon, 1992).
Previous GCTAs of interpersonal trauma and PTSD have identified moderate h2SNP estimates
(Duncan et al., 2017; Palmer et al., 2016). Moreover, the recent PGC – PTSD Freeze 2 identified
h2SNP estimates ranging between 10-30% across ancestries; however, significant SNP-based
heritability estimates were only identified for females (female h2SNP = .10, p = 8.03 x 10-11, male
h2SNP = .01, p = .63 [Nievergelt et al., 2018]). Similar to the substance use literature, there is a
discrepancy between estimates identified when utilizing GCTA versus twin modeling
methodologies (with twin studies identifying estimates falling between 23.5% [True et al., 1993]
and 71% [Sartor et al., 2011] relative to the aforementioned ranges identified via GCTAs).
Overall, although significant h2SNP estimates should be interpreted cautiously (due to concerns
regarding power and limitations inherent to GCTAs of case/controls), GWAS remained a
worthwhile venture given the multiple reasons as to why GWAS may identify significant SNPs in
the absence of significant h2SNP estimates derived by GCTA. Aggregate methods, such as GCTA,
do not identify the independent contribution of specific SNPs. Moreover, given the concern of
missing heritability identified within the literature (i.e., twin and GCTA), specific variants may be
captured within GWAS not otherwise subsumed within GCTA estimates (e.g., variants with nonadditive effects, Kumar, Feldman, Rehkopf, & Tuljapurkar, 2016).
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Identifying specific risk variants. A series of GWAS were conducted to identify specific
variants associated with heighten risk of NMUPD-E, IPV, and probable-PTSD. These phenotypes
were selected for GWAS given the greater balance between cases and controls and greater power
to detect an effect relative to NMUPD-R and TE phenotypes which were both underpowered and
lacked case/control balance.
Genetic Variants associated with NMUPD-E. Five genomic bins having at least one SNP
possessing a p-value < 5x10-8 and passing FDR correction for NMUPD-E (rs142738451 [minor
allele ‘t’], rs73241778 [minor allele ‘t’], rs9578774 [minor allele ‘a’], rs74901044 [minor allele
‘a’], and rs138647543 [minor allele ‘a’]) were identified. The direction of effect was similar across
SNPs, with the presence of the minor allele (less frequently occurring allele for a particular SNP)
being negatively associated with NMUPD-E case status, with the exception of rs73241778 which
was positively associated with NMUPD-E case status. Most significant SNPs identified were lone
markers or in weak LD with other SNPs in the region which suggests that the finding is likely
spurious in nature.

The regional association plots show that there are a few SNPs near

rs138647543 that reach significance and are in strong LD with each other, which is suggestive of
other potential SNPs that may be associated with the NMUPD-E phenotype.
The present study represents the first GWAS of NMUPD. Significant SNPs on the PAK7 (a
protein coding gene [SNP rs73241778]) and LINC00922 (a noncoding RNA gene [SNP
rs138647543]) genes emerged following GWAS of NMUPD-E. The regional association plot for
rs73241778 revealed that it is a lone SNP, in weak LD with surrounding markers. However,
rs138647543 was in high LD with surrounding markers per the regional association plot,
suggesting that multiple SNPs within the region may be linked with NMUPD-E or that the
identified SNP is not the casual variant but may be in high LD with the true casual variant. Of
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these identified SNPs, rs73241778 (minor allele ‘t’) was a common variant (MAF = .10) positively
associated with NMUPD-E case status, while rs138647543 (minor allele ‘t’) was a rare variant
(MAF > .05) negatively associated with case status.
Although the PAK7 gene has been linked with physical concerns including cancer (pancreatic
cancer [Giroux, Iovanna, Garcia, & Dagorn, 2009], melanoma [LaPak et al., 2016], breast cancer
[Li et al., 2018]), the literature with regard to mental health is limited. However, Morris and
colleagues (2014) identified an association between a PAK7 duplication and psychosis (bipolar
disorder and schizophrenia) in an Irish discovery sample and replicated in the International
Schizophrenia Consortium (ISC, 2008). The LINC00922 gene has also been implicated in cancer
risk (Drak Alsibai & Meseure, 2018); however, to our knowledge, an association between the gene
and any metal health phenotype has not been identified within the literature. Given the limited
literature, both replication and additional GWAS of the NMUPD phenotype are necessary to
further explicate specific variants associated with case status.
The present study did not find genome wide significant SNPs in genes that have been
previously identified in the literature. Although a paucity of genetic association studies exists with
regard to NMUPD, multiple GWAS have been conducted for other substance use phenotypes
including illicit substance use which frequently includes NMUPD (multiple forms of illicit
substance use, including NMUPD, aggregated into a single binary or symptom count variable).
Additionally, multiple GWAS have focused on opioid use phenotypes (e.g., dependence, symptom
count) and have identified several genome-wide markers present within the following genes:
NCK2 [Liu et al., 2013], KCNG2, KCNC1, APBB2, PARVA [Gelertner et al., 2014], and CNIH3
[Nelson et al., 2016]. Genome wide significant SNPs have also been identified within the FAM53B
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for cocaine dependence (Gelernter et al., 2014) and Uhl and colleagues (2008) identified SNPs in
genes CDH13 and CSMD1 that almost reached genome-wide significance.
Genetic Variants associated with probable-PTSD and IPV. GWAS were also conducted
for probable-PTSD and IPV; however, no genome wide significant markers emerged. Although
no SNPs reached genome wide significance, strong signals were identified for each phenotype
meeting a less conservative threshold of p < 5x10-5 and are considered suggestive SNPs of interest.
As discussed in the results, KCNIP4 (SNP rs100243550 [minor allele ‘a’]) emerged as a gene
associated with probable-PTSD and has been associated with personality disorders and ADHD.
SNRPC and UHRF1BP1 (SNP rs2764203 [minor allele ‘a’]) protein coding genes were associated
with IPV case status.

SNRPC has been linked with certain forms of cancer (myeloma;

Shaughnessy et al., 2011) while UHRF1BP1 has been associated with systemic lupus
erythematosus (Gateva et al., 2013). The SNP with the lowest p-value for probable-PTSD was
negatively associated with the phenotype and is considered common variant. The SNP with
the lowest p-value for IPV was positively associated with the phenotype and is also
considered a common variant.
Although more extensive than the NMUPD molecular literature, only twelve GWAS to
date have focused on PTSD; however, multiple genes with genome wide significant SNPs have
been identified. These genes include RORA (Logue et al., 2013), lincRNA AC068718.1 (Guffanti
et al., 2013), ANKRD55, ZNF626 (Stein et al., 2016), PRTFDC1 (Nievergelt et al., 2015), IL2RA
(Powers et al., 2016), NLGN1 (Kilaru et al., 2016), and KLHL1 (Duncan et al., 2018). Novel loci
have also been identified on chromosome 7p12 (Xie et al., 2013) and 4p15 (Almli et al., 2015).
Additionally, a nominally significant finding was identified by Xie and collogues (2013) in the
Tolloid-Like 1 gene. However, two studies (Wolf et al., 2014; Ashley-Koch et al., 2015) were
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unable to find genome-wide significant SNPs (likely due to low sample size). Results from Freezes
1 and 2 of the PGC – PTSD have also identified potential variants of interest. Duncan and
colleagues (2011) identified a variant in the KLHL1 gene among the African ancestral group during
Freeze 1; however, cautioned that the finding may be spurious due to the decreased significance
when meta-analyzed. Upon examination of Freeze 2 data, which included approximately ten-fold
the number of participants than Freeze 1), multiple genes were identified including ZDHHC14,
PARK2, KAZN, TMRM51-AS1, SH3RF3, PODXL, and ZNF813 within the European ancestral
group and LINC02335, MIR5007, TUC338, LINC02571, and HLA-B within the African ancestral
group (Nievergelt et al., 2018). The present study identified several genes with suggestive p-values
that may be associated with probable-PTSD and IPV.
Despite identifying strong signals above the p < 5x10-5 threshold, these effects did not reach
genome-wide significance (p < 5x10-8). The lack a genome-wide significant results could be
attributable to lack of true effect, in addition to several other factors associated with power and
phenotypic assessment. For GWAS, multiple factors effect power including sample size, effect
size, and minor allele frequency. With small sample sizes, it becomes more difficult to identify
less common variants and/or variants with smaller effects. Thus, obtaining large samples improves
the ability to detect affects. Aspects of the phenotype are also relevant to power, as those with
relatively lower heritability estimates will need larger sample sizes to detect effects (Visscher et
al., 2017). Only probable-PTSD and IPV phenotypes were adequately powered to identify an
effect and the NMUPD-E phenotype was underpowered but better powered relative to the
phenotypes of NMUPD-R and TE. Both NMUPD-R and TE lacked balance as far as proportion
of cases and controls were concerned, thus, no attempt to complete a GWAS was made given the
heightened likelihood of questionable results. Given these concerns, additional examination in a
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large balanced dataset (cases/controls) would be beneficial.
Genotypic analyses limitations. The present study represents a novel contribution to the
field with regard to genetic influences on NMUPD and associated phenotypes. However, it is not
without many notable limitations that will be discussed in turn.
Phenotypic assessment. There are multiple concerns associated with the assessment of
each of the phenotypes which impact the analyses/results. NMUPD-E provides a broad assessment
of the phenotype; however, the degree to which any use represents a form of problematic use
remains uncertain and likely lacks the nuance necessary to identify specific environmental
correlates and genetic factors that may be contributing to use. NMUPD-R may serve as a proxy
for more problematic use; however, additional examination is necessary to determine whether it
provides a sufficiently refined phenotype. Probable-PTSD also suffers from the same assessment
concerns. The four items of the PC-PTSD were merged into a single item thereby reducing
specificity in identifying those with potential PTSD at a diagnostic level (probable-PTSD in
present sample was 39.1% vs. data using a national sample of U.S. adults suggesting a lifetime
prevalence of 8.3% based on DSM 5 criteria; Kilpatrick et al., 2013). Thus, this item likely serves
as a crude screener of a heterogeneous disorder. Finally, TE was assessed in a much more thorough
manner with five separate trauma types being queried (natural disaster, physical assault, sexual
assault, any other unwanted and/or uncomfortable sexual experience, and motor vehicle accident).
Although assessment of these phenotype was an improvement relative to the other phenotypes, the
binning of each separate form of trauma into a single dichotomous TE variable introduced
significant heterogeneity. However, by implementing a more refined IPV variable, a more
homogeneous group was created. Yet, it is certainly worth noting that a significant degree of event
variability remains even within the IPV variable. Given these assessment concerns, a more
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thorough approach to phenotypic assessment should be applied. Large-scale genetic studies are
frequently confronted with finding the balance between adequate assessment and feasibility.
Given that researchers are often interested in assessing thousands of participants (to increase power
to detect effects), reducing both researcher and participant burden by simplifying assessment
makes this task more manageable. However, multiple approaches are being taken to tackle this
issue including “deep” phenotyping (more nuanced phenotypic assessment) and the rise of
consortia which provide the opportunity to merge data across multiple datasets for genetic analyses
and address concerns regarding heterogeneous sample populations (by increasing power).
Power. Many of the genetic analyses in the present study were underpowered. This is a
large issue within the field of behavioral genetics and as studies become better powered (via the
aforementioned consortia) the ability to detect the small effects across an array of different SNPs
associated with mental health phenotypes will continue to improve. Given that the field works
under the hypothesis of polygenetic risk (Vissher et al., 2017), many common variants likely have
small effects and thousands (upon thousands) of participants will be needed to detect such small
effects. The use of larger samples improves the ability to identify variants with smaller effect sized
and also increases the ability to detect less common variants. For example, with each successive
inclusion of large numbers of participants in the Schizophrenia Working Group of the Psychiatric
Genomics Consortia, the ability to detect small effect among many genes increases (Ripke et al.,
2014). As presented within the GWAS power calculations of the present study, the ability to detect
variants with lower MAFs and genotype relative risks was limited (for example, MAF > .25%,
genotype relative risk > 1.20, for NMUPD-E).
Method. Limitations regarding method employed encompass multiple concerns. First,
the use of binary variables creates limitations both statistically and conceptually.
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Use of

quantitative variables aid in the performance of models and provide a more nuanced view of the
phenotype (diagnoses are indeed dichotomous yet concerns exist regarding the view of mental
health in binary terms, please see Timimi, 2014 for additional details). Moreover, the field of
behavioral genetics is rapidly changing and the use of methods such as polygenic risk scores (PRS;
aggregates the effects across risk alleles into a single risk score) may better capture the effects of
many variants when under the constraints of limited power. PRS has been successfully used to
examine associations between PTSD and other mental health conditions (e.g., major depressive
disorder; Duncan et al., 2018) and the relationships between substance use related phenotypes
including alcohol use (Taylor et al., 2016; Mies et al., 2018) and cannabis initiation (Vink et al.,
2014). However, it is important to note that these emerging techniques also present challenges
similar to those described for GCTA regarding assumptions of normal distribution and
independence of markers (Dudbridge, 2013; Lewis & Vassos, 2017).
Genotypic summary and clinical implications. In an effort to examine the genetic
liability contributing to the etiology of comorbid NMUPD and TE/probable-PTSD, genetic
methods (GCTAs and GWAS) were utilized to determine the h2SNP of these phenotypes and
putative variants associated with case status. Meta-analyses revealed significant SNP-based
heritability (h2SNP) estimates for NMUPD-E and IPV. Although significant molecular heritability
estimates were not identified for probable-PTSD, GWAS were conducted for NMUPD-E,
probable-PTSD, and IPV. Given power concerns and imbalance with regard to cases and controls,
GWAS were not conducted for the NMUPD-R and TE phenotypes; however, GWAS were
performed for the phenotypes of NMUPD-E, probable-PTSD, and IPV. Following the GWAS of
NMUPD-E, five genomic bins with SNPs reaching genome wide significance and passing FDR
correction (method of controlling for Type 1 errors while maximizing power compared to standard

120

Bonferroni type corrections; Benjamini & Hochberg, 1995) threshold of .05 were identified.
Genes associated with genome wide significant SNPs for NMUPD-E included PAK7 and
LINC00922. Suggestive SNPs within the KCNIP4 gene for probable-PTSD and SNRPC and
UHRF1BP1 genes (other surrounding genes included C6orf106, 1BP, ANKS1A, and TAF1) for
IPV were identified; however, these SNPs did not reach genome wide significance. Despite
finding genome wide significant or suggestive hits, the SNPs/genes did not overlap across
phenotypes. Additional investigation is needed to better understand the potential unique and
overlapping influence of genes on NMUPD, probable-PTSD, and IPV.
These findings may have important clinical implications as the field continues to strive
towards personalized medicine. The aim of personalized medicine is to take into consideration the
various factors (environmental and genetic) that may account for individual differences in physical
and mental health (Ginsberg & Willard, 2009).

In doing so, more targeted therapeutic

interventions may be undertaken, ranging from identification of individuals at heightened risk to
determining the most appropriate psychopharmacological method of treatment.

Although

personalized medicine would be ideal, there is a significant amount of work that needs to be
completed prior to this aspiration becoming a reality within the realm of mental health. Although
personalized medicine with regard to genetics has seen success, particularly single gene, single
disorder phenotypes (e.g., Huntington disease), it is far more difficult to take this approach with
mental health phenotypes due to their polygenetic and multifactorial etiology (Chatterjee, Shi, &
Garcia-Closas).

However, recent research has made significant strides in determining the

predictive utility of genetic information (particularly via polygenic risk scores [PRS]) in the
identification of vulnerable populations (Khera et al., 2018). The focus of the aforementioned
work involved medical concerns (e.g., diabetes, cardiovascular disease) yet application of PRS to
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other polygenic disorders (e.g., mental health concerns) is promising. Particularly promising is
that PRS could be used for targeted intervention. Khera and colleagues (2018) noted the benefits
of encouraging lifestyle interventions among those identified to be at-risk through PRS, given the
previous success noted with the implementation of such intervention for common diseases
(Knowler et al., 2002; Khera et al., 2016). Similarly, use of PRS could be helpful in the promotion
of certain interventions among individuals at heightened risk of developing psychiatric symptoms.
Given the complicated nature of psychiatric phenotypes, additional genetic research,
replication, and use of multifactorial models is warranted and consideration must be placed in how
this information is disseminated to both clinicians and the general population. Concerns regarding
potential fatalistic views associated with genetic risk (i.e., if an individual possesses a specific risk
variant, they may believe they have limited control with regard to prevention/intervention [Claasen
et al., 2010) need to be considered in the ways in which genetic information is disseminated to
patients in the future. Moreover, additional psychoeducation for the public regarding the role of
genes in mental health is needed to address misperceptions and cultivate better understanding of
biological influences.
Conclusions. The present study aimed to examine the multiple etiological pathways (selfmedication, high risk, and third factor [genetic influences]) hypothesized to contribute to the
comorbidity and/or etiology of NMUPD and TE/probable-PTSD. Although the self-medication
model is frequently assumed to be the model best explaining the substance use TE/PTSD
comorbidity, the present study lends support to the extant literature suggesting that the high risk
model plays an important role. The present study also identified significant heritability estimates
for NMUPD (-E, -R) and IPV although caution is warranted when attempting to interpret the
estimates given power concerns. Moreover, genetic variants associated with NMUPD-E and
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suggestive variants for probable-PTSD and IPV were also identified; however, the SNPs/genes
identified were specific to each phenotype (not overlapping). Although the self-medication model
and shared liability model received limited support within the present study, it is critical to note
that each of these pathways is likely important yet partially dependent on a multitude of other
factors including developmental period and class of NMUPD substance. Moreover, limited power
greatly restricted the ability to adequately examine these phenotypes from a genetic perspective.
Although additional examination is needed to better take into consideration nuances
associated with context and reduce issues associated with power and assessment, the present study
addresses a significant gap within the extant literature. To our knowledge, the present study is the
first to 1) longitudinally examine NMUPD and TE/probable-PTSD longitudinally, 2) attempt to
determine h2SNP estimates for NMUPD, and 3) conduct GWAS for the phenotype of NMUPD.
These novel contributions mark the next step in the growing empirical literature addressing
etiological factors (environmental and genetic) contributing to NMUPD, trauma exposure, and
traumatic stress.
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Appendix I
NMUPD (Fall Freshman Year)
Have you ever used any of the following drugs for non-medical use? Non-medical use means
on your own, without a doctor's prescription, in greater amounts than prescribed, or for
reasons other than your doctor recommended. Remember that all your responses are
completely confidential.
Sedatives: Ativan, Dalmane, Halcion, Klonopin, Rivotril, Librium, Serax, Valium, Xanax,
Lunesta, other? ( ) Yes ( ) No [program: if no, skip all other sedatives questions] ( ) I choose not
to answer [program: if choose not to answer, skip all other sedatives questions]
Stimulants: ecstasy, amphetamines, crystal meth, Dexedrine, Ritalin, Adderall, Provigil, other? (
) Yes ( ) No [program: if no, skip all other stimulants questions] ( ) I choose not to answer
[program: if choose not to answer, skip all other opioids questions]
Opioids: heroin, opium, morphine, codeine, other? ( ) Yes ( ) No [program: if no, skip all other
opioids questions] ( ) I choose not to answer [program: if choose not to answer, skip all other
opioids questions]
Have you used the following drugs 6 or more times in your life?
Sedatives: Ativan, Dalmane, Halcion, Klonopin, Rivotril, Librium, Serax, Valium, Xanax,
Lunesta, other? ( ) Yes ( ) No ( ) I choose not to answer
Stimulants: ecstasy, amphetamines, crystal meth, Dexedrine, Ritalin, Adderall, Provigil, other? (
) Yes ( ) No ( ) I choose not to answer
Opioids: heroin, opium, morphine, codeine, other? ( ) Yes ( ) No ( ) I choose not to answer

STRESSFUL EVENTS (Fall Freshman Year)
Listed below are a number of difficult or stressful things that sometimes happen to people.
For each event check one or more of the boxes to indicate if the event happened to you ever
in your lifetime, and if it happened to you in the past 12 months.
Natural disaster (for example, flood, hurricane, tornado, earthquake, fire or explosion) ( ) Ever ( )
Past 12 months ( ) Never happened to me ( ) I choose not to answer
Physical assault (for example, being attacked, hit, slapped, kicked, beaten up, shot, stabbed) ( )
Ever ( ) Past 12 months ( ) Never happened to me ( ) I choose not to answer
Sexual assault (rape, attempted rape, made to perform any type of sexual act through force or threat
of harm) ( ) Ever ( ) Past 12 months ( ) Never happened to me ( ) I choose not to answer
Other unwanted or uncomfortable sexual experience ( ) Ever ( ) Past 12 months ( ) Never
happened to me ( ) I choose not to answer
Transportation accident (for example, car accident, boat accident, train wreck, plane crash) ( )
Ever ( ) Past 12 months ( ) Never happened to me ( ) I choose not to answer
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PTSD (Fall Freshman Year)
Have any of these experiences resulted in any of the following symptoms: Nightmares about
it, tried hard not to think about it or went out of your way to avoid situations that reminded
you of it, constantly on guard, watchful, or easily startled, or felt numb or detached from
others, activities, or your surroundings?
( ) Yes ( ) No ( ) I choose not to answer
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Appendix II
NMUPD (Spring Freshman Follow-up)
Since you started at VCU, have you used any of the following drugs for non-medical use?
Non- medical use means on your own, without a doctor's prescription, in greater amounts
than prescribed, or for reasons other than your doctor recommended. Remember that all
your responses are completely confidential.
Sedatives: Ativan, Dalmane, Halcion, Klonopin, Rivotril, Librium, Serax, Valium, Xanax,
Lunesta, other? ( ) Yes [program: if yes, ask b.1] ( ) No [program: if no, skip all other sedatives
questions] ( ) I choose not to answer [program: if choose not to answer, skip all other sedatives
questions]
Have you used sedatives 6 or more times? ( ) Yes ( ) No ( ) I choose not to answer
Stimulants: ecstasy, amphetamines, crystal meth, Dexedrine, Ritalin, Adderall, Provigil, other? (
) Yes [program: if yes, ask c.1] ( ) No [program: if no, skip all other stimulants questions] ( ) I
choose not to answer [program: if choose not to answer, skip all other stimulants questions]
Have you used stimulants 6 or more times? ( ) Yes ( ) No ( ) I choose not to answer
Opioids: heroin, opium, morphine, codeine, other? ( ) Yes [program: if yes, ask e.1] ( ) No
[program: if no, skip all other opioids questions] ( ) I choose not to answer [program: if choose
not to answer, skip all other opioids questions]
Have you used opioids 6 or more times? ( ) Yes ( ) No ( ) I choose not to answer

STRESSFUL EVENTS (Spring Freshman Follow-up)
Listed below are a number of difficult or stressful things that sometimes happen to people.
Please indicate whether you have experienced the following events since coming to VCU.
Natural disaster (for example, flood, hurricane, tornado, earthquake, fire or explosion) ( ) Yes ( )
No ( ) I choose not to answer
Physical assault (for example, being attacked, hit, slapped, kicked, beaten up, shot, stabbed) ( )
Yes ( ) No ( ) I choose not to answer
Sexual assault (rape, attempted rape, made to perform any type of sexual act through force or threat
of harm) ( ) Yes ( ) No ( ) I choose not to answer
Other unwanted or uncomfortable sexual experience ( ) Yes ( ) No ( ) I choose not to answer
Transportation accident (for example, car accident, boat accident, train wreck, plane crash) ( )
Yes ( ) No ( ) I choose not to answer

PTSD (Spring Freshman Follow-up)
Have any of these experiences resulted in any of the following symptoms: Nightmares about
it, tried hard not to think about it or went out of your way to avoid situations that reminded
you of it, constantly on guard, watchful, or easily startled, or felt numb or detached from
others, activities, or your surroundings?
( ) Yes ( ) No ( ) I choose not to answer
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NMUPD (Spring Freshman NEW)
Have you ever used any of the following drugs for non-medical use? Non-medical use means
on your own, without a doctor's prescription, in greater amounts than prescribed, or for
reasons other than your doctor recommended. Remember that all your responses are
completely confidential. If you have used a particular drug both before and after starting
school at VCU, please mark both boxes.
Sedatives: Ativan, Dalmane, Halcion, Klonopin, Rivotril, Librium, Serax, Valium, Xanax,
Lunesta, other? ( ) Yes, before coming to VCU ( ) Yes, since coming to VCU ( ) No [program: if
no, skip all other sedatives questions] ( ) I choose not to answer [program: if choose not to
answer, skip all other sedatives questions]
Stimulants: ecstasy, amphetamines, crystal meth, Dexedrine, Ritalin, Adderall, Provigil, other? (
) Yes, before coming to VCU ( ) Yes, since coming to VCU ( ) No [program: if no, skip all other
stimulants questions] ( ) I choose not to answer [program: if choose not to answer, skip all other
stimulants questions]
Opioids: heroin, opium, morphine, codeine, other? ( ) Yes, before coming to VCU ( ) Yes, since
coming to VCU ( ) No [program: if no, skip all other opioids questions] ( ) I choose not to answer
[program: if choose not to answer, skip all other opioids questions]
Have you used the following drugs 6 or more times in your life?
Sedatives: Ativan, Dalmane, Halcion, Klonopin, Rivotril, Librium, Serax, Valium, Xanax,
Lunesta, other? ( ) Yes ( ) No ( ) I choose not to answer
Stimulants: ecstasy, amphetamines, crystal meth, Dexedrine, Ritalin, Adderall, Provigil, other? (
) Yes ( ) No ( ) I choose not to answer
Opioids: heroin, opium, morphine, codeine, other? ( ) Yes ( ) No ( ) I choose not to answer

STRESSFUL EVENTS (Spring Freshman NEW)
Listed below are a number of difficult or stressful things that sometimes happen to people.
For each event check one or more of the boxes to indicate if the event happened to you.
Natural disaster (for example, flood, hurricane, tornado, earthquake, fire or explosion) ( ) Yes,
before starting at VCU ( ) Yes, since starting at VCU ( ) No ( ) I choose not to answer
Physical assault (for example, being attacked, hit, slapped, kicked, beaten up, shot, stabbed) ( )
Yes, before starting at VCU ( ) Yes, since starting at VCU ( ) No ( ) I choose not to answer
Sexual assault (rape, attempted rape, made to perform any type of sexual act through force or threat
of harm) ( ) Yes, before starting at VCU ( ) Yes, since starting at VCU ( ) No ( ) I choose not to
answer
Other unwanted or uncomfortable sexual experience ( ) Yes, before starting at VCU ( ) Yes, since
starting at VCU ( ) No ( ) I choose not to answer
Transportation accident (for example, car accident, boat accident, train wreck, plane crash) ( ) Yes,
before starting at VCU ( ) Yes, since starting at VCU ( ) No ( ) I choose not to answer
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PTSD (Spring Freshman Follow-up NEW)
Have any of these experiences resulted in any of the following symptoms: Nightmares about
it, tried hard not to think about it or went out of your way to avoid situations that reminded
you of it, constantly on guard, watchful, or easily startled, or felt numb or detached from
others, activities, or your surroundings?
( ) Yes ( ) No ( ) I choose not to answer
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Appendix III
NMUPD (Spring Sophomore Follow-up)
Have you used any of the following drugs for non-medical use? Non-medical use means on
your own, without a doctor's prescription, in greater amounts than prescribed, or for reasons
other than your doctor recommended. Remember that all your responses are completely
confidential.
Sedatives: Ativan, Dalmane, Halcion, Klonopin, Rivotril, Librium, Serax, Valium, Xanax,
Lunesta, other? ( ) Yes ( ) No [program: if no, skip all other sedatives questions] ( ) I choose not
to answer [program: if choose not to answer, skip all other sedatives questions]
Stimulants: ecstasy, amphetamines, crystal meth, Dexedrine, Ritalin, Adderall, Provigil, other? (
) Yes ( ) No [program: if no, skip all other stimulants questions] ( ) I choose not to answer
[program: if choose not to answer, skip all other stimulants questions]
Opioids: heroin, opium, morphine, codeine, other? ( ) Yes ( ) No [program: if no, skip all other
opioids questions] ( ) I choose not to answer [program: if choose not to answer, skip all other
opioids questions]
Have you used any of the following drugs in the last 12 months?
Sedatives: Ativan, Dalmane, Halcion, Klonopin, Rivotril, Librium, Serax, Valium, Xanax,
Lunesta, other? ( ) Yes ( ) No [program: if no, skip question 98b]
Stimulants: ecstasy, amphetamines, crystal meth, Dexedrine, Ritalin, Adderall, Provigil, other? (
) Yes ( ) No [program: if no, skip question 98c] ( ) I choose not to answer [program: if choose not
to answer, skip question 98c]
Opioids: heroin, opium, morphine, codeine, other? ( ) Yes ( ) No [program: if no, skip question
98e] ( ) I choose not to answer [program: if choose not to answer, skip question 98e]
Have you used the following drugs 6 or more times in the past 12 months?
Sedatives: Ativan, Dalmane, Halcion, Klonopin, Rivotril, Librium, Serax, Valium, Xanax,
Lunesta, other? ( ) Yes ( ) No ( ) I choose not to answer
Stimulants: ecstasy, amphetamines, crystal meth, Dexedrine, Ritalin, Adderall, Provigil, other? (
) Yes ( ) No ( ) I choose not to answer
Opioids: heroin, opium, morphine, codeine, other? ( ) Yes ( ) No ( ) I choose not to answer

STRESSFUL EVENTS (Spring Sophomore Follow-up)
Listed below are a number of difficult or stressful things that sometimes happen to people.
Please indicate whether you have experienced the following events over the past 12 months.
Natural disaster (for example, flood, hurricane, tornado, earthquake, fire or explosion) ( ) Yes ( )
No ( ) I choose not to answer
Physical assault (for example, being attacked, hit, slapped, kicked, beaten up, shot, stabbed) ( )
Yes ( ) No ( ) I choose not to answer
Sexual assault (rape, attempted rape, made to perform any type of sexual act through force or threat
of harm) ( ) Yes ( ) No ( ) I choose not to answer
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Other unwanted or uncomfortable sexual experience ( ) Yes ( ) No ( ) I choose not to answer
Transportation accident (for example, car accident, boat accident, train wreck, plane crash) ( )
Yes ( ) No ( ) I choose not to answer

PTSD (Spring Sophomore Follow-up)
Have any of these experiences resulted in any of the following symptoms: Nightmares about
it, tried hard not to think about it or went out of your way to avoid situations that reminded
you of it, constantly on guard, watchful, or easily startled, or felt numb or detached from
others, activities, or your surroundings?
( ) Yes ( ) No ( ) I choose not to answer
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Appendix IV
Longitudinal associations between IPV and NMUPD-E. To examine the longitudinal
associations between IPV (i.e., sexual assault, physical assault, any other unwanted and/or
uncomfortable sexual experiences) and NMUPD-E, autoregressive cross lag models were
conducted with sex and cohort included as covariates. The first (saturated) model, serving as the
basis for comparison, included all potential paths (Figure 1 [see page 36).
Model comparisons: IPV and NMUPD-E. Next, a series of sub-models were fitted by
constraining paths. The fit statistics (AIC and change in -2 log likelihood) from each sub-model
were compared to the saturated model (Model 1.5, Table 22). Two models examining the selfmedication and the high risk hypotheses (i.e., Longitudinal Effects Models in Table 22) were
compared to the saturated model. In Model 2.5 (Table 22), cross lag paths from IPV to NMUPDE across time points (h, k, and l paths) were constrained to zero to test the self-medication model
across time. This model was not significantly different from the saturated model (p = .59)
indicating that these paths could be dropped without significantly effecting the fit. In Model 3.5
(Table 22), cross lag paths from NMUPD-E to IPV across time points (i, j, and m paths) were
constrained to zero to test the high risk model across time. This model was significantly different
from the saturated model (p < .001) suggesting that dropping these paths would result in worse fit
with the data. In short, the results of the model fitting procedures provide support for the high risk
hypothesis (i.e., prior NMUPD-E is associated with heightened risk for IPV).
IPV and NMUPD-E best fitting model results. Following comparisons between the
Longitudinal Effects Models (Table 22, Models 2.5 [self-medication model] and 3.5 [high risk
model]) to the saturated model (Table 22, Model 1.5), the fit indices from Model 2.5 indicate that
paths from IPV to NMUPD-E across time can be constrained to zero. Path estimates with these
paths dropped are located in Table 23.
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Regarding covariates, sex was significantly associated with IPV and NMUPD-E at all three
time points (ps<.05), with female sex being associated with greater report of IPV but lower report
of NMUPD-E, with the exception of NMUPD-E sophomore year. Cohort was inconsistently
associated with IPV and NMUPD-E, with significant associations only being identified at baseline
and between cohort and NMUPD-E sophomore year. Being a part of a later cohort was associated
with lower report of IPV; however, cohort was positively associated with NMUPD-E at baseline
but lower NMUPD-E sophomore year. When examining IPV and NMUPD-E, prior IPV and
NMUPD-E were significant predictors of future IPV and NMUPD-E, respectively. Specifically,
IPV prior to college was associated with IPV freshman year (B = .34, p < .001 [path a]) and IPV
in freshman year was significantly associated with IPV sophomore year (B = .39, p < .001 [path
b]). NMUPD-E prior to college was associated with freshman year NMUPD-E (B = 1.17, p < .001
[path c]) and freshman year NMUPD-E was also significantly associated with sophomore year
NMUPD-E (B = .56, p < .001 [path d]).

Potential long term associations between IPV and

NMUPD-E occurring prior to college and IPV and NMUPD-E, respectively, occurring in
sophomore year were also examined. IPV prior to college was associated with IPV sophomore
year (B = .27, p = .001 [path n]) and NMUPD-E prior to college was also significantly associated
with NMUPD-E sophomore year (B = .53, p = .001 [path o]).
Given that model fitting results suggested that IPV was not a significant predictor or
NMUPD-E across time, these paths were not included in the final model and thus only the cross
paths between NMUPD-E and IPV across time are presented. NMUPD-E prior to college served
as a significant predictor of IPV freshman year (B = .17, p = <.001 [path i]); however, NMUPD-E
during freshman year did not serve as a significant predictor of IPV sophomore year (B = .08, p =
.001 [path j]). NMUPD-E prior to college did not serve as a significant predictor of IPV
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sophomore year (B = .05, p = .21 [path m]).

To summarize, the results of the model fitting

procedures provide support for the high risk hypothesis (i.e., prior NMUPD-E is associated with
heightened risk for IPV).
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Table 22. Model fitting results of autoregressive cross lag models between interpersonal violence and experimental non-medical use of
prescription drugs.

Model

Changes

-2LL

df

AIC

-2LL

df

p

--

--

--

Saturated Model
1.5

a

56581.07

47462

-38342.93

Longitudinal Effects Models
2.5

b

56583.01

47465

-38346.99

1.93

3

0.59

3.5

c

56624.24

47465

-38305.76

43.17

3

< .001

Note: a = model includes all paths; b = paths ‘pre college IPV to freshman NMUPD-E’, ‘freshman IPV to sophomore NMUPD-E’, and ‘pre college IPV to
sophomore NMUPD-E’ constrained to zero; c = paths ‘pre college NMUPD-E to freshman IPV’, ‘freshman NMUPD-E to sophomore IPV’, and ‘pre college
NMUPD-E to sophomore IPV’ constrained to zero.
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Figure 20. Visual representation of path significance for the best-fitting cross lag autoregressive
model examining the longitudinal associations between interpersonal violence and experimental
non-medical use of prescription drugs.
n
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Note: Significant paths are represented with black lines while grey lines represent non significant estimates. TE =
trauma exposure, NMUPD = non-medical use of prescription drugs, Y1F = prior to college, Y1S = freshman year,
Y2S = sophomore year.
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Table 23. Path estimates, p values, standard errors, and confidence intervals for the interpersonal
violence and experimental non-medical use of prescription drugs longitudinal model.

Path
Correlations
IPV Y1F
NMUPD-E Y1F (e)
IPV Y1S
NMUPD-E Y1S (f)
IPV Y2S
NMUPD-E Y2S (g)
Sex
IPV Y1F
Sex
NMUPD-E Y1F
Cohort
IPV Y1F
Cohort
NMUPD-E Y1F
Regressions
Controlling for sex and cohort
Sex
IPV Y1S
Sex
NMUPD-E Y1S
Sex
NMUPD-E Y2S
Sex
IPV Y2S
Cohort
IPV Y1S
Cohort
NMUPD-E Y1S
Cohort
NMUPD-E Y2S
Cohort
IPV Y2S
Autoregressive paths 1
IPV Y1F
IPV Y1S (a)
IPV Y1S
IPV Y2S (b)
NMUPD-E Y1F
NMUPD-E Y1S (c)
NMUPD-E Y1S
NMUPD-E Y2S (d)
Autoregressive paths 2
IPV Y1F
IPV Y2S (n)
NMUPD-E Y1F
NMUPD-E Y2S (o)
Cross lag paths 1
IPV Y1F
NMUPD-E Y1S (h)
IPV Y1S
NMUPD-E Y2S (k)
NMUPD-E Y1F
IPV Y1S (i)
NMUPD-E Y1S
IPV Y2S (j)
Cross lag paths 2
IPV Y1F
NMUPD-E Y2S (l)
NMUPD-E Y1F
IPV Y2S (m)

Estimate p value

SE

.30
.21
.10
.08
-.11
-.12
.08

<.001
<.001
.05
<.001
<.001
.04
<.001

.02
.04
.05
.02
.02
.02
.02

.15
-.09
-.05
.10
-.02
-.03
-.11
.02

<.001
.006
.21
.008
.34
.41
.005
.56

.03
.04
.04
.04
.02
.03
.04
.03

.34
.39
1.17
.56

<.001
<.001
<.001
<.001

.03
.05
.05
.06

.27
.53

<.001
<.001

.04
.06

.17
.08

<.001
.001

.03
.06

.05

.21

.08

Note: IPV = interpersonal violence, NMUPD = non-medical use of prescription drugs, Y1F = prior to college, Y1S =
freshman year, Y2S = sophomore year. - = best fitting model (Table X) indicated that these paths could be dropped.
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Longitudinal Associations between IPV and NMUPD-R. To examine the longitudinal
associations between IPV and NMUPD-R, a similar set of autoregressive cross lag models as
described above for NMUPD-E were also conducted with sex and cohort as covariates. The first
(saturated) model, serving as the basis for comparison, is presented in Figure 1 (Model 1.6 in Table
24).
Model comparisons: IPV and NMUPD-R. A series of sub-models were fitted by
constraining paths. The fit statistics (AIC and change in -2 log likelihood) from each sub-model
were compared to the saturated model (Model 1.6, Table 24). Two models examining the selfmedication and the high risk hypotheses (i.e., Longitudinal Effects Models in Table 24) were
compared to the saturated model. In Model 2.6 (Table 24), cross lag paths from IPV to NMUPDR across time points (h, k, and l paths) were constrained to zero to test the self-medication model
across time. This model was significantly different from the saturated model (p = .01) indicating
that these paths could not be dropped without significantly effecting the fit. In Model 3.6 (Table
24), cross lag paths from NMUPD-R to IPV across time points (i, j, and m paths) were constrained
to zero to test the high risk model across time. This model was significantly different from the
saturated model (p < .001) suggesting that dropping these paths would result in worse fit with the
data. The results of model fitting procedures suggest that dropping paths associated with the selfmedication and high-risk hypothesis resulted in worse model fit; however, Model 2.6 remained
the worst fitting model between the two Longitudinal Effects Models, providing further support
for the high risk hypothesis.
IPV and NMUPD-R best fitting model results. Following comparisons between the
Longitudinal Effects Models (Table 24, Models 2.6 [self-medication model] and 3.6 [high risk
model]) to the saturated model (Table 24, Model 1.6), the fit indices from Model 2.6 indicate that
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paths from IPV to NMUPD-R across time can be constrained to zero. Path estimates with these
paths dropped are located in Table 25.
Regarding covariates, sex was significantly associated with IPV and NMUPD-R at all three
time points (ps<.05), with female sex being associated with greater report of IPV but lower report
of NMUPD-E, with the exception of NMUPD-R sophomore year. Cohort was inconsistently
associated with IPV and NMUPD-R, with significant associations only being identified at baseline
and between cohort and NMUPD-R sophomore year. Being a part of a later cohort was associated
with heightened report of IPV freshman year while cohort was negatively associated with
NMUPD-E at baseline and sophomore year.

When examining IPV and NMUPD-R, prior IPV

and NMUPD-R were significant predictors of future IPV and NMUPD-R, respectively.
Specifically, IPV prior to college was associated with IPV freshman year (B = .34, p < .001 [path
a]) and IPV in freshman year was significantly associated with IPV sophomore year (B = .39, p <
.001 [path b]). Repeated use NMUPD-R prior to college was associated with freshman year
NMUPD-R (B = 1.13, p < .001 [path c]) and freshman year NMUPD-R was also significantly
associated with sophomore year NMUPD-R (B = .43, p < .001 [path d]).

Potential long term

associations between IPV and NMUPD-R occurring prior to college and IPV and NMUPD-R,
respectively, occurring in sophomore year were also examined.

IPV prior to college was

associated with IPV sophomore year (B = .29, p < .001 [path n) and NMUPD-R prior to college
was also significantly associated with NMUPD sophomore year (B = .59, p < .001 [path o]).
Given that model fitting results suggested that Model 2 (constraining paths between prior
IPV to future NMUPD-R) was the worst fitting, these paths were not included in the final model
and thus only the cross paths between NMUPD-R and IPV across time are presented. Repeated
use NMUPD prior to college served as a significant predictor of IPV freshman year (B = .25, p =
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<.001 [path i]) and NMUPD-R during freshman year also served as a significant predictor of IPV
sophomore year (B = .19, p = .01 [path j]). Repeated use NMUPD prior to college did not serve
as a significant predictor of IPV sophomore year (B = -.12, p = .27 [path m]. In summary, the
results of the model fitting procedures provide support for the high risk hypothesis (i.e., prior
NMUPD-R heightens risk for IPV).
The high risk hypothesis was found to be the best fitting model across both forms of
NMUPD (-E, -R) when comparing the Longitudinal Effects Models to the saturated model. When
examining the best-fitting model for each form of NMUPD, NMUPD (-E, -R) prior to college was
significantly associated with IPV freshman year. However, significant associations between
NMUPD freshman year and IPV sophomore year were only identified when examining NMUPDR. This path was not significant when examining the association between NMUPD-E freshman
year and IPV sophomore year. Thus, although the high risk model best fits the data in both models
examining IPV and NMUPD-E/NMUPD-R, NMUPD serving as a significant predictor across
each time point is not consistent. Interestingly, this is the same pattern that was noted when
examining the associations between NMUPD-E/NMUPD-R and the primary phenotypes of
interest (TE and probable-PTSD). However, it is critical to note that dropping the paths from prior
IPV to future NMUPD-R resulted in model fit significantly different from the saturated model and
thus should be viewed as important paths to consider when investigating the longitudinal
associations between IPV and NMUPD-R.
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Table 24. Model fitting results of autoregressive cross lag models between interpersonal trauma and repeated use non-medical
use of prescription drugs.
Model

Changes

-2LL

df

AIC
Saturated Model

1.6

a

51448.55

47473

-2LL

df

p

--

--

--

-43497.45

Longitudinal Effects Models
2.6

b

51459.71

47476

-43492.29

11.16

3

0.01

3.6

c

51497.27

47476

-43454.73

48.73

3

< .001

Note: a = model includes all paths; b = paths ‘pre college IPV to freshman NMUPD-R’, ‘freshman IPV to sophomore NMUPD-R’, and
‘pre college IPV to sophomore NMUPD-R’ constrained to zero; c = paths ‘pre college NMUPD-R to freshman IPV’, ‘freshman NMUPDR to sophomore IPV’, and ‘pre college NMUPD-R to sophomore IPV’ constrained to zero.
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Figure 21. Visual representation of path significance for the best-fitting cross lag autoregressive
model examining the longitudinal associations between interpersonal trauma and repeated use nonmedical use of prescription drugs.
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Note: Significant paths are represented with black lines while grey lines represent non significant estimates. TE =
trauma exposure, NMUPD = non-medical use of prescription drugs, Y1F = prior to college, Y1S = freshman year,
Y2S = sophomore year.
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Table 25. Path estimates, p values, and standard errors for the best-fitting interpersonal trauma and
repeated use non-medical use of prescription drugs autoregressive cross lag model.

Path
Correlations
IPV Y1F
NMUPD-R Y1F (e)
IPV Y1S
NMUPD-R Y1S (f)
TE Y2S
NMUPD-R Y2S (g)
Sex
IPV Y1F
Sex
NMUPD-R Y1F
Cohort
IPV Y1F
Cohort
NMUPD-R Y1F
Regressions
Controlling for sex and cohort
Sex
IPV Y1S
Sex
NMUPD-R Y1S
Sex
NMUPD-R Y2S
Sex
IPV Y2S
Cohort
IPV Y1S
Cohort
NMUPD-R Y1S
Cohort
NMUPD-R Y2S
Cohort
IPV Y2S
Autoregressive paths 1
IPV Y1F
IPV Y1S (a)
IPV Y1S
IPV Y2S (b)
NMUPD-R Y1F
NMUPD-R Y1S (c)
NMUPD-R Y1S
NMUPD-R Y2S (d)
Autoregressive paths 2
IPV Y1F
IPV Y2S (n)
NMUPD-R Y1F NMUPD-R Y2S (o)
Cross lag paths 1
IPV Y1F
NMUPD-R Y1S (h)
TE Y1S
NMUPD-R Y2S (k)
NMUPD-R Y1F
IPV Y1S (i)
NMUPD-R Y1S
IPV Y2S (j)
Cross lag paths 2
IPV Y1F
NMUPD-R Y2S (l)
NMUPD-R Y1F
IPV Y2S (m)

Estimate

p value

SE

.27
.13
.04
.08
-.12
.05
-.12

<.001
.01
.46
<.001
<.001
<.001
<.001

.03
.05
.06
.02
.03
.02
.02

.17
-.11
-.02
.11
-.53
.05
-.13
.02

<.001
.01
.68
.01
.41
.25
.01
.58

.03
.05
.07
.05
.02
.04
.05
.043

.34
.39
1.13
.43

<.001
<.001
<.001
<.001

.04
.05
.10
.08

.29
.59

<.001
<.001

.04
.11

.25
.19

<.001
.01

.04
.04

-.12

.27

.07

Note: IPV = interpersonal victimization, NMUPD = non-medical use of prescription drugs, Y1F = prior to college,
Y1S = freshman year, Y2S = sophomore year. - = best fitting model (Table 5) indicated that these paths could be
dropped.
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Appendix V
Longitudinal associations between natural disaster and NMUPD (-E, -R). As a
potential proof of concept, exploratory models were also conducted examining the longitudinal
associations between natural disaster, a form of trauma exposure considered potentially less
influenced by substance use, including NMUPD (-E, -R). Given that many participants may have
reported natural disaster due to a small earthquake that occurred in the area in 2011, it was
hypothesized that the high risk model (dropping all paths from TE to NMUPD [-E, -R]) would not
fit the data better than the self-medication model as was found in the previous analyses. Given the
exploratory nature of these models, only broad comparisons across models were conducted and
thus, path estimates for the best-fitting models are not presented.
Natural Disaster and NMUPD-E best fitting model results. Following comparisons
between the Longitudinal Effects Models (Table 26, Models 2.7 [self-medication model] and 3.7
[high risk model]) to the saturated model (Table 26, Model 1.7), the results indicate that all paths
with prior NMUPD-E predicting natural disaster could be dropped, as well as, all paths with prior
natural disaster predicting NMUPD-E.
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Table 26. Model fitting results of autoregressive cross lag models between natural disaster and experimental non-medical use of
prescription drugs.
Model

Changes

-2LL

df

AIC

-2LL

df

p

--

--

--

Saturated Model
1.7

a

57783.41

47995

-38206.59

Longitudinal Effects Models
2.7

b

57790.73

47998

-38205.27

7.31

3

.06

3.7

c

57790.92

47998

-38205.08

7.50

3

.06

Note: a = model includes all paths; b = paths ‘pre college TE to freshman NMUPD-E’, ‘freshman TE to sophomore NMUPD-E’, and ‘pre college TE to
sophomore NMUPD-E’ constrained to zero; c = paths ‘pre college NMUPD-E to freshman TE’, ‘freshman NMUPD-E to sophomore TE’, and ‘pre college
NMUPD-E to sophomore TE’ constrained to zero.
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Natural Disaster and NMUPD-R best fitting model results. Following comparisons
between the Longitudinal Effects Models (Table 27, Models 2.8 [self-medication model] and 3.8
[high risk model]) to the saturated model (Table 27, Model 1.8), the best fitting model was Model
2.8 which constrained the paths from natural disaster to NMUPD-R across time to zero. In short,
the results of the model fitting procedures provide support for the high risk hypothesis (i.e., prior
NMUPD-R is associated with heightened risk for natural disaster).
The findings from these models were inconsistent, with the NMUPD-E model suggesting
that all longitudinal paths could be dropped without significantly impacting model fit while the
NMUPD-R model followed the same patterns identified in the analyses conducted for the primary
phenotypes of interest (TE and probable-PTSD).

These findings, which is counter to the

hypothesis that significant differences would not be identified across models, may lend additional
support for the high risk model given that one would expect that prior NMUPD-E would not serve
as a significant predictor of natural disaster, as it is perceived to be a “random” trauma type (with
little influence from the individual exposed). Overall, paths from NMUPD-E to natural disaster
could be dropped without significantly effecting model fit. However, the same pattern was not
present when examining NMUPD-R, which demonstrated findings consistent with the high risk
hypothesis.
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Table 27. Results of autoregressive cross lag models for natural disaster and repeated use non-medical use of prescription drugs.

Model

Changes

-2LL

df

AIC

-2LL

df

p

--

--

--

Saturated Model
1.8

a

52506.44

48006

-43505.56

Longitudinal Effects Models
2.8

b

52510.52

48009

-43507.48

4.09

3

.25

3.8

c

52516.96

48009

-43501.04

10.53

3

.02

Note: a = model includes all paths; b = paths ‘pre college natural disaster to freshman NMUPD-R’, ‘freshman natural disaster to sophomore NMUPD-R’, and
‘pre college natural disaster to sophomore NMUPD-R’ constrained to zero; c = paths ‘pre college NMUPD-R to freshman natural disaster’, ‘freshman NMUPDR to sophomore natural disaster’, and ‘pre college NMUPD-R to sophomore natural disaster’ constrained to zero.
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Appendix VI
Determining the SNP-based heritability of IPV. Given the lack of significant findings
with regard to the univariate GCTAs conducted for NMUPD (-E, -R), TE, and probable-PTSD,
GCTAs were also conducted for IPV within each ancestral group in an effort to derive molecular
heritability estimates for a potentially more refined phenotype. Prior to these analyses, power
calculations were conducted for IPV within each ancestral group (Table 28). Power analyses
suggest that there is limited power to detect effects (with the exception of GCTAs within the EUR
ancestry group for the IPV phenotype with high heritability [h2SNP = 0.50]).
When univariate GCTAs were conducted, no significant findings were identified and
standard errors for estimates frequently included 0 (Table 29). In accordance with standard
practice set forth by the PGC (https://github.com/Nealelab/ricopili), the results were metaanalyzed across ancestry groups. The h2SNP estimate derived from the meta-analysis for IPV was
.05 (SE = .01).
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Table 28. Power calculations for interpersonal violence phenotype by ancestral group.

Phenotypic
Outcome

IPV

Ancestry
Group
N
Prevalence
AFR
1314
39%
AMR
568
43%
EAS
542
32%
EUR
2949
42%
SAS
441
32%

2

Controls
691
295
341
1518
296

Cases
623
273
201
1431
145

h SNP
= 0.50
.26
.09
.08
.84
.07

Power
h2SNP h2SNP =
= 0.20
0.10
.08
.06
.06
.05
.05
.05
.22
.09
.05
.05

Note: NMUPD = non-medical use of prescription drugs, TE = trauma exposure, probable-PTSD = posttraumatic stress
disorder, h2 = SNP-based heritability estimate, h2SNP = SNP based heritability estimate.

Table 29. Estimates of SNP-based heritability for interpersonal violence (controlling for
population stratification, sex, cohort) phenotype generated from genome-wide complex trait
analyses.

Super population

AFR
AMR
EAS
EUR
SAS

Covariates

PCs, cohort,
sex
PCs, cohort,
sex
PCs, cohort,
sex
PCs, cohort,
sex
PCs, cohort,
sex

Sample prevalence

h2SNP

SE

p-value

IPV
47%

.07

.27

.40

48%

.53

.42

.10

37%

.15

.63

.40

49%

<.001

.13

.50

33%

< .001

.73

.50

Note: Ca = cases, Co = controls, PCs = principle components, AMF = African ancestry, AMR = Americas ancestry,
EAS = East Asian ancestry, EUR = European ancestry, AMF = South Asian ancestry, and h2SNP = SNP based
heritability estimate.

178

Appendix VII
In an additional effort to potentially refine the analyses, TE and probable-PTSD were
included as covariates in a series of univariate GCTAs (in addition to PCs, sex, and cohort) of
NMUPD (-E, -R). These analyses were conducted only among the European ancestral group given
the greater power of detecting an effect (larger sample size relative to the other ancestral groups).
Results are shown in Table 30. No significant SNP-based heritability estimates of NMUPD (-E,R) was identified.
Overall, the findings from the additional GCTAs (IPV and NMUPD-E with inclusion of
TE and probable-PTSD as covariates) did not identify significant h2SNP estimates. Similar concerns
as those discussed within the molecular portion of the results section, lack of significant results is
likely attributable to limited statistical power to detect effects and limitations associated with
phenotypic assessment.
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Table 30. Estimates of SNP-based heritability for nonmedical use of prescription drug use ([-E, R] while controlling for trauma exposure, probable posttraumatic stress disorder, population
stratification, cohort, and sex) phenotypes generated from genome-wide complex trait analyses
only among the European ancestral group.

Super population

N (Ca/Co)

EUR

988/1952

EUR

892/1640

EUR

528/2413

EUR

480/2053

Covariates

NMUPD-E
PCs, cohort,
sex, TE
PCs, cohort,
sex, TE,
probable-PTSD
NMUPD-R
PCs, cohort,
sex, TE
PCs, cohort,
sex, TE,
probable-PTSD

Sample
prevalence

h2SNP

SE

pvalue

34%

.13

.13

.20

35%

.16

.15

.10

18%

.07

.13

.30

19%

.04

.15

.40

Note: NMUPD-E = experimental non-medical use of prescription drugs, NMUPD-R = repeated non-medical use of
prescription drugs, Ca = cases, Co = controls, PCs = principle components, TE = trauma exposure, probable-PTSD =
probable posttraumatic stress disorder, h2SNP = SNP based heritability estimate.
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